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Abstract 
 
 
Application of Centrifugal Microfluidics and Fluorescence-based Detection  
for Rapid Biological Analysis 
Xin Zhang 
 
The goal of this research was to develop and optimise microfluidic systems and assays 
for rapid detection of selected targets such as marine toxins and human IgG. The 
measurement of IgG, as the major format of therapeutic antibodies, was used as a 
prototype to develop a centrifugal-based microfluidic system for effectively monitoring 
biopharmaceutical production. To achieve this, a sandwich immunoassay for human 
IgG detection was developed and used to study the implementation of a new 
microfluidic CD-based cartridge. The centrifugal-based microfluidic CD adopted a 
serial siphon technique for implementation of automated sequential delivery of the 
assay reagents. Surface-confined supercritical angel fluorescence (SAF)-based detection 
was designed to sensitively measure the fluorescence signal from the microfluidic CD-
based immunoassay. The CD substrate was functionalized with 
aminopropyltriethoxysilane (APTES) using plasma enhanced chemical vapour 
deposition (PECVD) for the immobilization of analyte capture protein. The developed 
prototype microfluidic system could automatically run a microfluidic assay in less than 
30 min, and accurately measure industrial bioprocess samples that contained 10 mg mL-
1 of human IgG. Additionally, computational simulations were performed to 
fundamentally understand the kinetics of immunoassays in a microfluidic system. The 
effects of varying assay parameters on the capture of analytes in microfluidic-based 
heterogeneous immunoassays under real-world operating conditions, was examined by 
using theoretical modeling and experimental binding assay results. A marine toxin, 
saxitoxins (STX), was another potential target for analysis using the developed 
centrifugal-based microfluidic CD. Work was carried out to generate recombinant 
antibodies (scFv) to saxitoxin and its derivatives. After successful immunization of the 
host animal with different STX-conjugates, an scFv antibody phage library against anti-
STX was constructed by PCR amplification of scFv genes, cloning the genes library 
into phagemid vector and transforming into E. coli cells. The phages expressing high 
affinity antibody gene were isolated by “bio-panning”.  
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1.1 Introduction 
 
This thesis mainly focuses on the development of a microfluidic ‘lab-on-chip’ system, 
which is able to be used for the analysis of hIgG or marine toxins. In addition, studies  
on the  development of a recombinant antibody for marine toxin detection were carried 
out. 
   
This chapter will initially introduce the immune system, which includes innate and 
adaptive immunity.  Innate immunity describes a general non-specific first line of 
defence of the body to an infection or a foreign substance, while adaptive immunity is a 
highly directed response which involves specific cells (cellular response) and antibody 
generation (humoral response). These concepts will be discussed to provide a basis for 
the understanding and need for the generation of recombinant antibodies. A successful 
and specific immune response to a small-molecular weight marine shellfish toxin is 
necessary for the generation of a recombinant antibody with high affinity. Phage 
display, one of the most important tools used in the isolation and engineering of 
recombinant antibodies, will also be outlined. 
 
Immunoassay and its applications will then be introduced. Immunoassay is one of the 
most widely used analytical tools in medicine and fundamental life-science research. 
Immunoassays can be classified into several formats, which meet various requirements. 
However, the core of immunoassay systems is the interaction between the antibody and 
the antigen, which significantly impacts the sensitivity and specificity of immunoassays. 
In order to enhance the performance of immunoassays, amplification strategies, such as 
the use of the avidin-biotin system, are also widely applied. These concepts and 
applications are introduced to provide a background for the design and development of 
the specific immunoassay used in the research described in this thesis. 
 
Additionally, advanced microfluidic immunoassay systems and the associated 
applications are introduced. Microfluidics is an emerging technology that presents 
significant benefits for miniaturizing immunoassays due to its capacity for parallel 
analysis of multiple analytes with significantly reduced assay time and sample 
consumption. The major components required for development of a microfluidic system 
are propulsion, fluid valving, substrate materials, surface modification strategies, and 
the requisite detection method. The details of these factors will be discussed to provide 
	 3 
an overview for the development of a novel microfluidic assay system. The concept of 
computational simulation will be introduced to model key parameters (e.g. reagent flow 
speed, kinetics etc.) that impact on our understanding of immunoassay in low volume 
environments. This approach will be applied to define the importance of analyte 
molecule transport factors including convection and diffusion, binding kinetics, flow 
velocity and channel height in microfluidic systems. Furthermore, this model will be 
applied to provide a strategy to optimize microfluidic assays for maximal sensitivity, 
minimal sample volume requirements and fast performance.  
 
1.2 The immune system 
 
The immune system protects the body against the invasion of foreign bodies and 
pathogens and maintains an individual’s well-being. It consists of two major parts, the 
innate immune system and the acquired immune system, which interact at several levels 
to develop a complete defence against invading pathogens (Agarwal, 2010). 
   
1.2.1 Innate immunity 
 
Innate immunity describes the initial defences required to prevent infectious agents 
from entering the body. As shown in Table 1.2.2, innate immunity is a non-specific but 
immediate response to foreign bodies, the efficiency of which is not enhanced through 
repeated exposure to the same foreign object. In addition, innate immunity lacks 
immunological memory and the response time is short (Agarwal, 2010). The functional 
components of innate immunity can be divided into anatomical, physiological, and 
chemical barriers (Turvey & Broide, 2010). Among these barriers the anatomical and 
physiological barriers are the primary defences against pathogens. These defences 
include: intact skin, mucosal clearance mechanisms, low stomach pH, and bacteriolytic 
lysozyme secretions (Turvey & Broide, 2010). If a pathogen penetrates the epithelial 
surface it can be destroyed by the neutrophils, macrophages and NK cells, and defence 
elements such as the complement system and interferons (Gomez et al., 2005). 
Moreover, innate immunity plays a critical role in activating the subsequent adaptive 
immune response (Akira et al., 2001; Shanker, 2010). 
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1.2.2 Adaptive immunity 
 
The adaptive immunity consists of cell-mediated immunity and humoral immunity. It 
defends against the pathogens, which have evolved to resist innate immunity. 
Additionally, it is involved in the generation of immunological memory. The adaptive 
immune system is highly specific against a wide range of pathogens due to the 
participation of extremely diverse types of lymphocytes and other white blood cells. 
Moreover the extent of the immune response is enhanced through repeated pathogen 
exposure over days/weeks or even years (Yuan et al., 2012). An overview of the 
adaptive immunity is illustrated in Fig. 1.2.2. The two types of adaptive immunity, 
humoral immunity and cell-mediated immunity, involve different cells and molecules. 
Humoral immunity is mediated by antibodies, which are produced by B lymphocytes. 
Antibodies neutralize and eliminate microbes and microbial toxins that are present 
generally outside of host cells. Cell-mediated immunity can defends against intracellular 
microbes. For example, T lymphocytes destroy microbes by activating phagocytes or 
directly killing infected cells (Abbas et al., 2012). 
 
Table 1.2.2 Features of innate and adoptive immunity (adapted from Agarwal, 2010). 
 
 Innate Adaptive 
Level of defence First line Second line 
Antigen specificity Not specific to antigen Highly specific 
Time to respond Minutes to hours Days to weeks 
Response on 
repeated exposure 
to the antigen 
Extent of response remains 
the same on repeated 
exposure to the antigen 
Improves with repeated 
exposures 
Memory No memory Memory 
Types of immune 
Cells 
Granulocytes, 
macrophages, natural killer 
cells, natural killer T cells 
T lymphocytes, 
B lymphocytes 
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Figure 1.2.2 An overview of adaptive immunity. In humoral immunity, activated B-
cells secrete antibodies that eliminate extracellular microbes. In cell-mediated 
immunity, activated T-cells either activate macrophages to destroy phagocytosed 
microbes or kill infected cells (adapted from Abbas et al., 2012).  
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1.2.2.1 Cell-mediated immunity 
 
Cell-mediated immunity has evolved to deal with infections that cannot be reached 
through humoral antibodies, like intracellular pathogens, such as viruses. T-
lymphocytes (T-cells) are the key components of cell-mediated immunity. They 
originate in the thymus circulate permanently between the blood and lymphatic system 
(Pancer & Cooper, 2006). The activation of naive T-cells mainly depends on 
interactions of T- cell receptor (TCR) with major histocompatibility complex (MHC)-
associated peptide antigens displayed on antigen-presenting cells (APCs). However, the 
initiation of T-cell responses for antigens requires participation of some accessory 
molecules on the T-cells, including CD3, CD4, CD8, CD28, CTLA-4, LFA-1, VLA-4 
and ζ. The APCs can be phagocytes containing surviving microbe or microbe-infected 
non-phagocytic cells (e.g. epithelial cells). The MHC molecules that display peptides to 
T-cells include class I MHC expressed by all nucleated cells in the body and class II 
MHC produced mainly by specialised APCs, including dendritic cells, macrophages and 
B lymphocytes (Reinhardt and Jenkins, 2003; Abbas et al., 2012).  
 
The TCR and CD4 or CD8 co-receptor together recognize the MHC molecules on 
APCs, providing the initiating signal for T-cell activation. The naïve cytotoxic T-cells 
(TC) recognise an antigen in association with a class I MHC. If an infected cell is 
recognised by a Tc cell, it induces the infected cell to become apoptotic and commit 
suicide, thus killing that cell along with any intracellular pathogens. In addition, the Tc 
cells can release interferon-γ to reduce the spread of pathogens in adjacent cells. The 
The naïve helper T-cells (TH) activated by class II MHCs, differentiate into subsets of 
effector cells (TH1, TH2 and TH17 cells) which produced distinct cytokines. The 
cytokines perform different functions during adaptive immunity. They can activate 
macrophages and kill phagocytosed microbes. Additionally, they can activate B-cells to 
produce antibodies in humoral immune responses (Alberts, 2012).   
 
1.2.2.2 Humoral immunity 
 
Humoral immunity relates mainly to the generation of antibodies by B cells. The 
humoral immunity defends the microbes presenting in the extracellular spaces. As 
APCs, B-cells can express MHC II proteins on their surface, which are recognised by 
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TH2 cells (Zhu et al., 2012).  TH2 cells release interleukin-4, 5, 10 and 13, which results 
in the activation, proliferation and differentiation of B-cells. The B-cell displays a 
membrane bound immunoglobulin on its surface that acts as an antigen receptor. 
Subsequently, antibody-secreting plasma cells, derived from B cells, are produced. 
These antibodies serve to neutralised the pathogen and promote its elimination before it 
can establish a significant infection.  
 
Generally, the B-cell mediated immune response involves the activation of multiple B-
cells recognizing an antigen with single or multiple identical antigenic determinants 
(epitopes). Hence, a large number of antibodies are produced with distinct specificity 
and affinity. Polyclonal immunoglobulins are a heterogeneous mixture of antibodies, 
which has many different antigen specificities and epitope affinities (Ofek et al., 2010). 
They are harvested from the serum of immunised animals. Polyclonal antibodies are 
widely used in antibody-based methods. In contrast, monoclonal antibodies are derived 
from a single B cell clone and bind to a single epitope. In general monoclonal 
antibodies have high specificity and low cross-reactivity. The structure and 
classification of antibodies are discussed in the following section. 
 
1.3 Antibodies 
 
Antibodies, also known as immunoglobulins (Ig), are soluble glycoproteins secreted by 
B-lymphocytes in response to foreign antigens. Immunoglobulins are the first molecules 
involved in specific immune recognition and are widely used in clinical and medical 
applications. They bind specifically to their respective antigen with a high degree of 
affinity (Murphy, 2011). According to their physical characteristics and biological 
properties, mammalian immunoglobulins are often grouped into 5 distinct classes: IgA, 
IgD, IgE, IgG and IgM (Table 1.3). IgG is the smallest antibody and is widely used in 
assay development and antibody-based therapeutics. In addition, IgG is the major 
antibody component (80%) of blood; IgG can bind to viruses, bacterial and fungi, and 
protects the body by activating the complement system to neutralise pathogens (Lee & 
Andrew, 2009). In contrast, IgM is produced in the early stages of infection (Li, Woo et 
al., 2004; Muto et al., 2004). Whereas, IgE is present in small amounts in the serum and 
is responsible for Type I hypersensitivity reactions (e.g. allergy, asthma and 
anaphylaxis), IgE levels are also greatly increased in response to helminth parasite 
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infections (Abbas et al., 2012).  
 
IgA is most abundant and most active in secretions at mucosal surfaces where it 
provides the primary defence. IgA is also abundant in saliva, tears and breast milk, 
especially colostrum. IgD is found on the surface of B-lymphocytes. However, its exact 
function still unclear, although it appears that it acts as an antigen receptor and that it is 
needed for B cell activation (Lee & Andrew, 2009). 
 
Table 1.3 Characteristics and functions of mammalian antibodies.  
 
 
Characteristics 
 
IgA 
 
IgD 
 
IgE 
 
IgG 
 
IgM 
Heavy Chain α δ ε γ µ 
Light Chain κ or λ κ or λ κ or λ κ or λ κ or λ 
Molecule 
Weight (KDa) 
 
150-500 
 
180 
 
190 
 
150 
 
950 
 
Molecular 
formula 
 
(α2κ2)1-2 or 
(α2λ2)1-2 
 
δ2κ2 or 
δ2λ2 
 
 
ε2κ2 or 
ε2λ2 
 
 
γ2κ2 or 
γ2λ2 
 
(µ2κ2)5 or 
(µ2λ2)5 
 
In vivo serum 
half-life (d) 
 
6 
 
3 
 
2.5 
 
16-36 
 
5 
Concentration 
in serum 
1-4  
mg/ml 
10-400 
ng/ml 
0-0.4 
mg/ml 
8-16  
mg/ml 
0.5-2 
mg/ml 
 
Functions 
 
Protect the 
respiratory and 
gastrointestinal 
tracts from 
infection 
 
Binds to the 
surface of B-
lymphocytes 
 
Triggers 
the 
allergic 
response 
 
Neutralise, 
opsonise 
and 
indirectly 
lyses the 
pathogen 
 
Neutralise, 
opsonise 
and 
indirectly 
lyses the 
pathogen 
(Adapted from Abbas et al., 2012).  
 
Although the structure of each specific immunoglobulin is unique, antibodies are built 
using the same basic structural plan. Typically an antibody molecule consists of two 
identical heavy chains (50-70 kD) and two identical light chains (23 kD) ( David, 2001). 
Both heavy and light chains contain constant (C) and variable (V) domains based on 
differences in amino acid sequence. Unlike the C domains, the V domains show great 
variability in amino acid sequence composition. The two heavy chains are linked to 
each other by disulphide bonds and each heavy chain is linked to a light chain by a 
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disulphide bond. Furthermore, the four chains are assembled into a Y-shape molecule 
(Fig. 1.3). Each variable region contains three hypervariable regions (HR) or 
complementarity determining regions (CDRs), which are surrounded by a framework 
region (FR). The CDR regions are located in loops between the anti-parallel -sheets 
(Elgert, 2009). The CDR loops of the light and heavy chains form the antigen-binding 
surface. An additional domain that lies between the constant heavy chain CH1 and CH2 
domains is the hinge region. This area allows flexibility and some degree of freedom for 
the movement of the two arms of the antibody molecule. Functionally, an antibody can 
be divided into a Fab region (fragment antigen binding), and a Fc region (fragment 
crystallisable). In addition, it is possible to create a scFv (single chain fragment variable) 
by genetic engineering. The Fab region is composed of two constant and variable 
domains of both light and heavy chains. In contrast, the Fc region contains heavy chain 
constant domains. This region has a numbers of important biological functions that 
include, binding complement and binding to cell receptors. The scFv fragment contains 
both antigen-binding VL and VH domains, connected with a short linker peptide of 10-
25 amino acids. Generally, this linker can either connect the N-terminus of the VH with 
the C-terminus of the VL or vice versa in a scFv fragment (Elgert, 2009). Additonaly, a 
longer linker can help to increase affinity and decrease the formation of aggregates 
(Whitlow et al., 2003). Compared to a Fab, an scFv fragment with a small size of 
approximately 26-27 kDa allows it to be produced efficiently in bacterial expression 
systems. 
  
The significance of antibodies as diagnostic and analytical reagents has been known and 
exploited for almost a century. In recent years, antibodies have become increasingly 
accepted as therapeutic reagents. Recombinant DNA technology has allowed for the 
creation of new and improved antibody molecules. The following section describes the 
use of phage display for the selection of recombinant antibody fragments.  
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Figure 1.3 The basic structure of an antibody (IgG) molecule, Fab and scFv antibody 
fragments. Heavy chains are shown in blue and light chains are shown in orange, 
whereas, the variable regions are outlined with a dashed pattern. The N-terminal end of 
the antibody molecule is characterised by sequence variability in both the heavy and 
light chains, which are referred to as the VH and VL regions, respectively. The constant 
portion of the light chains and heavy chains are referred as the CL and CH, respectively. 
Unlike CL, the constant portion of the heavy chain consists of three structurally discrete 
regions: CH1, CH2 and CH3. The hinge is a flexible region of the antibody and sits 
between the CH1 and CH2 domains.  
scFv 
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VH 
VL 
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VL 
CL 
Disulphide Bridge 
Hinge Region 
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1.4 The development of recombinant antibodies using phage display 
 
In contrast to polyclonal antibodies (pAb), recombinant monoclonal antibodies (rAb) 
have many advantages. These include high specificity and sensitivity, relative short 
production time, and no variation between antibody batches (Moutel et al., 2009). In 
addition, unlike pAbs, the affinity and sensitivity of rAbs can be further improved using 
techniques such as affinity maturation, chain shuffling and error-prone PCR 
(Hoogenbom, 2002). Recombinant antibody technology involves the amplification of 
antibody variable genes from the host cDNA by PCR and pairing them at random, 
creating a library of the antibody genes with different combinations of variable heavy 
and light chains (Kontermann et al., 2010). This library of antibody genes can be further 
cloned into an appropriate vector system for expression. 
 
Phage display is one of the most important tools in the isolation and engineering of 
recombinant antibodies ( Rockberg et al., 2008; Tiller et al., 2008; Pansri et al., 2009). 
This technique involves the use of filamentous bacteriophage for coupling proteins with 
the genetic information that encodes them and selection of genotypes whose phenotypes 
interact specifically with the antigen (Pande et al., 2010). This is achieved by cloning 
the antibody genes into the single stranded phage genome, and coding for surface capsid 
or coat proteins used for displaying the antibodies as fusion products for target selection 
on the surface of encapsulated phage particles (Qi et al., 2012). The cloned library is 
then transformed into E. coli cells and grown. This results in the propagation of phage 
particles in the presence of helper phage. Helper phage provides the necessary proteins 
for packaging the phage particle (Bradbury et al., 2004). On assembly the phage 
particles are released from the bacteria and this library of phage particles are selected 
against the target antigen. Those phage particles with affinity for the antigen bind, 
whereas, those with no or low affinity are washed away. The selected phage are eluted 
from the bound antigen, re-infected, re-amplified and reprocessed several times thus 
enriching for the specific phenotype along with the coding genotype (Hust et al., 2008). 
This cyclic process of alternating selection and enrichment of phage particles against a 
specific target is termed “biopanning” (Fig. 1.4). In this thesis the use of this approach 
for the selection of anti-saxitoxin scFv is described. 
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Figure 1.4 Selection of antibodies from antibody libraries (panning) by phage display. 
Total mRNA was extracted from lymphocytes and then used to synthesise cDNA. Gene 
fragments encoding for the heavy and the light variable regions of antibodies (VH, VL) 
were amplified and assembled by PCR. The assembled genes are inserted in a phagemid 
vector in frame with the gene encoding the coat protein pIII. The vector is introduced 
into E. coli. After rescue with helper phage, the library of antibody fragments is 
displayed on phage (adapted from Hust et al., 2008).  
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1.5 The antigen-antibody interaction 
 
The antigen-antibody interaction is a typical reversible process with both forward and 
backward rate constants. This reaction depends on several factors, which includes the 
concentration of antigen and antibody, temperature, pH, ionic strength (Reverberi et al, 
2007). The antigen–antibody complex [!" − !"] formation can be described by the 
Law of Mass Action (Absolom & Van Oss, 1986). 
  
                               [!"]= antigen concentration 
                               [!"] = antibody concentration                                    [!" − !"] = antigen-antibody complex 
                               !! = association rate constant 
                               !! = dissociation rate constant 
 
The ratio of the two rate constants gives the equilibrium constant (Keq), which 
represents the ratio of bound to unbound analyte and antibody. 
 !!"  =  [!" − !"]/[!"][!"] 
 
Principally, the range of !!"  is 106 L/mol – 1012 L/mol. However, !!"less than 108 
L/mol are not useful in immunoassays. In order to improve antibody detection, the ratio 
between antigen-antibody complex [!" − !"]  and free antigen [!"]  should be 
increased. This can be obtained in two ways: 1) increasing the equilibrium constant; 2) 
increasing the antibody concentration (Reverberi et al., 2007). 
   
1.5.1   Heidelberger-Kendall curve 
 
The Heidelberger-Kendall curve was used to describe the formation of 
immunocomplexes in the antigen and antibody reaction (Liu and Huo, 2009; 
Vercammen et al., 2011). It demonstrated that when an increasing amount of an antigen 
is added to a fixed amount of corresponding antibody, the amount of formed 
immunocomplex is described by a bell shaped curve. The Heidelberger-Kendall curve is 
generated by plotting the amount of antigen against the amount of antibody-antigen 
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complex formed (Fig. 1.5.1). It is divided into three phases as described in Table 1.5.1. 
The first phase (A) expresses the type of calibration curve found in an immunometric 
noncompetitive, excess reagent assay. The following phase (B) describes the reaction 
when at equilibrium. In the last phase (C), the reaction describes the calibration curve 
found in a competitive, limited reagent assay (Durner, 2010).  
 
 
   
 
Figure 1.5.1 Representation of the relationship between the amounts of 
immunocomplex formed when a variable amount of antigen reacts with a constant 
amount of antibody. The blue curve is known as the Heidelberger-Kendall curve, which 
is divided into three zones according to immunocomplex formation (modified from 
Dodig, 2009).   
 
 
 
 
 
 
Table 1.5.1 The properties of the Heidelberger-Kendall curve. 
 
A                             B                      C 
A
m
ou
nt
 o
f a
nt
ig
en
-a
nt
ib
od
y 
co
m
pl
ex
 fo
rm
ed
  
Amount of antigen present  
A-antibody excess;     B-equilibrium;       C-antigen excess 
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Phase Characteristics Diagrams 
Antibody excess  
 
A large amount of unbound antibody 
exists. 
 
Antigen binding sites tend to be saturated 
by antibody.  
 
Signal increases proportionally to the 
amount of antigen.  
 
 
Equivalence Cross-linking results in the formation of 
large immunocomplexes.  
 
The binding sites are fully occupied and 
the reaction has reached saturation. 
 
Signal increases with antigen concentration 
but not proportionally. 
 
 
Antigen excess Most of the binding sites are occupied thus 
hindering the formation of precipitate due 
to the high concentration of antigen. 
 
Signal decreases with an increasing 
amount of antigen. This phenomenon is 
called the Hook effect. 
 
 
 
1.5.2 The Hook effect in an immunoassay  
 
The Hook effect refers to the sharply decreasing signal in the immunoassay even with 
the addition of more antigens (Buedia et al., 2010) (zone C of Heidelberger-Kendall 
curve in Fig. 1.5.1). This was reported in many immunoassay formats (Garber, 2008; 
Liu and Huo, 2009; AI- Mahdili and Jones, 2010) The Hook effect occurs when the 
amount of antibody in an assay system is not sufficient to bind to excess free antigens. 
Consequently, excess free antigen can compete for antibody-binding sites with bound 
antigen. As a result, the readout signal is lower than expected with higher antigen 
concentrations (Miller, 2004). In this case, the Hook effect leads to an incorrect signal at 
high concentrations of analyte. The Hook effect can be overcome through the following 
strategies:   
       (1) Adding excess capture antibody into the analyte matrix. 
       (2) Removing the excess analyte by a wash step before adding the secondary   
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antibody. 
       (3) Use of a different assay format, such as the sandwich immunoassay. 
 
1.6 Immunoassays 
 
In the last 50 years, the immunoassay technique has made significant contributions to 
medicine and fundamental life-science research (Ganz et al., 2008; Hachem et al., 2009; 
Lindsley et al., 2011; Johnson et al., 2013). An immunoassay can be defined as a 
sensitive analytical assay that employ antibodies to quantitatively and qualitatively 
measure target analytes in complex biological mixtures (David, 2013). The interaction 
between the antibody and the antigen is the key point for every immunoassay system, 
and the level of sensitivity and specificity for antibody determination is at the heart of 
the immunoassay. Hence, it is critical to select proper immune reagents and assay 
formats (Bonwick & Smith, 2004; Knopp, 2006). 
 
1.6.1 Historical perspective of immunoassays 
 
In 1959, R.S. Yalow and S.A. Berson developed a new technique, radioimmunoassay 
(RIA), and used this method to measure insulin in human plasma. This method had a 
very significant impact on the clinical chemistry laboratory (Yalow, 1959). In 1968, G. 
Charles Oliver presented the first RIA for the measurement of a drug compound 
(digitoxin) (Oliver, 1968). Enzyme-labeled immunoassays were first developed in the 
early 1970s, and this eliminated some of the drawbacks of the RIA method, such as, 
limited isotope stability, health hazards, and the high equipment costs. Subsequently, the 
idea of using an enzyme label in an immunoassay was presented. Immunoassay research 
moved into the area of immunochemical modification, specifically, research focused on 
how to couple a bulky enzyme molecule to an antibody or antigen without sterically 
hindering the immunochemical reaction. In 1971, Engvall and Perlmann published their 
first paper on enzyme-linked immunosorbent assay (ELISA) and demonstrated 
quantitative measurement of IgG in rabbit serum using alkaline phosphatase as the 
reporter label (Engvall et al., 1971). In the same year, the first paper on enzyme 
immunoassay (EIA) was published by van Weemen and Schuurs. In this research work, 
human chorionic gonadotropin in urine was quantified using an enzyme-coupled to 
glutaraldehyde as the reporter label (van Weemen et al., 1971). In the following years, 
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this technology moved from the clinical research laboratory to the mainstream 
analytical laboratory, where it gradually became a very widely used analytical tool. 
Examples of different immunoassay applications are listed in the table below.  
 
Table 1.6.1 Immunoassay applications. 
 
 
1.6.2 Principles of immunoassays 
 
Field Measuring Authors and Date 
Environmental 
Contamination 
Explosives in ground water and soil Keuchel et al., 1992 
Herbicides in drinking and river water McConnell et al., 
1993 
Gibberellin hormones in plant tissue Yang et al., 1993 
Determination of mycotoxins in grain Casale et al., 1998 
Clinical 
Medicine 
Insulin levels in human serum Hales et al., 1963 
Detection of cancer biomarkers Liu et al., 2008 
 
Detection of early HIV infection  McFarland et al., 
1999 
Detection of Chlamydia trachomatis 
infection in human urine sample 
Jensen et al., 2003 
Detection of Helicobacter pylori infection in 
human body materials 
Kabir, 2003 
Human 
Biomonitoring 
Human growth hormone in plasma Schalch et al., 1964 
Determination of benzene in human blood as 
an indicator of environmental exposure to 
volatile aromatic compounds 
Angerer et al., 1991 
Biological monitoring and biochemical 
effect monitoring of exposure to polycyclic 
aromatic hydrocarbons 
Angerer et al., 1997 
Monitoring urinary excretion of 
cannabinoids 
Fraser et al., 2002 
Environmental pollutants in blood of the 
German population. 
Becker et al., 2002 
Food Safety Determination of the species of origin of 
milk 
Perez et al., 1992 
Fungicides in potatoes and apples Brandon et al., 
1993 
Identification of lung tissue in processed 
meat products 
Smith, 1992 
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Immunoassays can measure the concentration of a large number of different compounds 
or analytes (David, 2013). For example these can include: large polymeric proteins, 
antibodies, nucleic acids or even small molecular-weight haptens, which reside in a 
complex matrix. This is based on three unique features of antibodies (Zourob et al., 
2008): 
a. Antibodies are able to bind to a wide range of antigens. This is because of 
their unique hypervariable regions at the antigen binding sites. 
b. Antibodies are capable of exceptional specificity, and they can recognise 
the antigens in the presence of structurally similar compounds. Moreover, 
antibodies can detect antigen routinely in the picomolar range.  
c. The strong non-covalent bond between an antibody and its target does not 
breakdown during immunoassay processing. 
 
1.6.3 Immunoassay Classifications 
 
Immunoassays can roughly be divided into two categories distinguished by the use of a 
label i.e., labelled or ‘label-free’ (unlabelled) methods. In terms of the labelled 
immunoassays, they can be classified into several groups as shown in Fig. 1.6.3. 
Labelled immunoassays can be classified into radioimmunoassay, enzyme 
immunoassay, fluoroimmunoassay or others according to the type of label. Depending 
on the requirement for physical separation of antibody-bound antigen from remaining 
free antigen, labelled immunoassays can be further subdivided into homogeneous and 
heterogeneous immunoassays. Additionally, labelled immunoassays can be divided into 
competitive or non-competitive immunoassays formats.  
 
1.6.3.1 ‘Label-free’ immunoassays 
 
In ‘label-free’ immunoassays, neither antigen nor antibody is labelled. This 
immunoassay format has many advantages, which includes, direct measurement of 
antibody-antigen complexes; study of unlabelled and, therefore, unmodified molecules 
and simple assay setup. ‘Label-free’ methods include immunonephelometry and 
immunoturbidimetry. In addition, commercial instruments such as surface plasmon 
resonance (SPR) and quartz crystal microbalance (QCM) transducers are also used.  
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1.6.3.2 Labelled immunoassays 
 
In a labelled immunoassay, a molecule is included that will produce a measureable 
signal, once the antigen-antibody complex is formed. Labelled immunoassays can be 
classified into many groups as shown in Fig. 1.6.3.2. Examples of immunoassay labels 
include radioactive compounds, enzymes and fluorescence molecules. Immunoassays 
are also classified by the different formats used to distinguish the bound antigen-
antibody complex from the free unbound label; these formats can be described as 
competitive and non-competitive. In addition, a further classification is based on the 
separation of bound antigen-antibody complex. These formats can be described as 
homogeneous and heterogeneous (Bonwick & Smith, 2004). 
 
 
 
Figure 1.6.3.2 The sub-classification of labelled immunoassays. 
 
1.6.3.3 Radioimmunoassay (RIA) 
 
RIA was first developed by R. S. Yalow, as discussed previously (Section 1.5.1). In this 
technique a radioactive label is used as the tracer. Although this method has high 
sensitivity and precision it also has a number of drawbacks. For example, the 
Labelled 
immunoassay 
Type of label 
Radioimmunoassay 
Enzyme immunoassay 
Fluoroimmunoassay 
Others 
Number of phases 
Homogeneous immunoassay 
Heterogeneous immunoassay 
Procedure 
Competitive immunoassay 
Non-competitive immunoassay 
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radioactive label has limited stability. Furthermore, there are disposal and safety issues 
which surround the use of radioactive materials. Moreover, there are high costs 
associated with the detection instrumentation (Gómez-Hens, 2010). 
 
1.6.3.4 Enzyme-based immunoassays (EIA/ELISA) 
 
Enzyme immunoassay, also called enzyme-linked immunosorbent assay (ELISA), has 
been widely adopted for applications such as diagnostics, quality control, food safety 
assurance and environmental monitoring. Generally, ELISA can often provide greater 
versatility in assay designs, higher sensitivity and reproducibility than equivalent RIA 
methods (Jachson et al, 1983; Porstmann et al, 1992). Additionally, ELISA is safer as 
non-toxic enzymes are used as labels instead of harmful radioactive substances. Often 
enzymes used to label the antigen or antibody in ELISA can convert a colourless 
substrate to a coloured product. This coloured product can be easily detected using a 
plate reader and a specific wavelength of light (Gong, 1994). Some of the most 
commonly used ELISA enzymes are listed below. 
 
Table 1.6.3.4 Enzymes and their substrates commonly used in immunoassays 
 
Enzymes Substrates Detection 
λm (nm) 
Horseradish peroxidase (HRP) 3,3ʹ,5,5ʹ-Tetramethylbenzidine (TMB) 450 
Alkaline phosphatase (AP) p-Nitrophenyl Phosphate (pNPP) 405 
β-Galactosidase o-nitrophenyl-β-D-galactoside (ONPG) 420 
 
1.6.3.5 Fluorescence-based immunoassays (FIA) 
 
Fluorescent molecules are capable of absorbing radiation and emitting it as photons. 
Instead of an enzyme label, FIA utilises fluorescent labels as the tracer molecule. 
Importantly, fluorescence-based immunoassays may provide superior performance in 
terms of assay sensitivity. For example, the utilisation of a fluorophore may increase 
assay sensitivity by upwards of 10 to 1,000 fold. However, a number of different 
parameters may affect the performance of the fluorescent complex, such as excitation 
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and emission wavelengths, fluorescence lifetime, temperature, pH, and concentration. 
The principle of fluorescence measurement is shown in Fig. 1.6.3.5 (Quentin et al, 
1984). The fluorophore absorbs light at a specific wavelength and subsequently emits 
light at a longer wavelength. The application of an appropriate wavelength of light 
induces the excitation of fluorophores and subsequently, the fluorophores return to the 
ground state with light emitted at a lower energy (a longer wavelength and slower 
frequency). The difference between the excitation and emission wavelengths can be 
described in terms of a Stokes shift. The larger Stokes shift, the easier it is to measure 
the emitted light without interference from the incident light (Hemmilä, 1985; 
Diamandis et al., 1996). In addition, an important property of fluorescence is the so 
called, quantum efficiency, also known as the quantum yield. This fluorescence property 
is defined as the ratio of the number of photons emitted to the number of photons 
absorbed (Lakowicz, 1999). It can directly affect the measured fluorescence intensity 
(Christopoulos et al., 1996). Commonly used immunoassay fluorescent dyes include: 
Fluorescein, Rhodamine, Alexa, DyLight and ATTO dyes. 
 
 
Figure 1.6.3.5 Illustration of the principle of fluorescence measurement (adapted from 
Demchenko, 2009). The Stokes’ shift is the distance between the excitation and 
detection wavelengths, induced by excitation and emission of the fluorophores. The 
larger Stokes’ shift contributed to a precise detection result without the interference 
from the emission light. 
Theoretically, fluorescence-based methods have upwards of 1,000-fold better sensitivity 
than absorption-based methods. However, assay sensitivity is often reduced due to the 
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high background that is often present in the materials and samples used for fluorometric 
analysis. Specifically, 1) light scattering: scattering of excitation light from solvent 
molecules or from small particles result in high background signal (Valeur et al., 2012); 
2) background fluorescence: the fluorescent components inherent in the assay reagents 
give rise to background (Tan et al., 2010; Akbari et al., 2014); 3) quenching: the 
molecules in the antigen matrix (e.g. serum) can often absorb light and thus cause 
fluorescent quenching (Ramakrishna et al., 2011). 
 
1.6.3.6 Homogeneous immunoassays 
 
Homogeneous immunoassays allow the coexistence of the un-bound and antibody-
bound complex of the analyte in the measurement step. Generally, homogenous 
immunoassays are faster to perform, as they have no wash steps and a reduced amount 
of incubation steps (Table 1.6.3.6).  The simple experimental setup of a homogeneous 
immunoassay also allows a robust analysis even when performed by non-laboratory-
trained personnel (Kreisig et al., 2011). However, this method has the drawback of low 
sensitivity and limited dynamic range. One of the major applications of this method is 
the determination of small molecules (e.g. toxins, pollutants, drugs) using the 
competitive immunoassay format. For example, Mayilo et al reported on a competitive, 
homogeneous immunoassay for the successful detection of the hapten digoxigenin 
(Mayilo et al., 2009). 
 
Table 1.6.3.6 Properties of homogeneous and heterogeneous immunoassays. 
 
Properties Homogeneous Heterogeneous 
Assay time Short Long 
Detected limitation High Low 
Target Small molecules Small molecules or proteins 
Signal background High Low 
Sensitivity Generally low Generally high 
 
 
1.6.3.7 Heterogeneous immunoassays 
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If the antigen–antibody complex is separated from the unbound reactants before 
measurement, this is referred to as a heterogeneous assay. Heterogeneous assays are 
wildly used to determine the presence of not only small molecules but also 
macromolecular analytes such as antibodies and proteins, and generally have superior 
sensitivity and selectivity. The use of either immobilised antibody or antigen has given 
rise to a wide range of immunoassays, which are implemented using microplates, 
microbeads (Wheeler et al., 2010), magnetic micro-particles (Ng et al., 2012), or ﬂow-
through techniques (Hartwell et al., 2010). 
 
1.6.3.8 Competitive immunoassays 
 
In competitive immunoassay, labelled analyte (usually antigen) and unlabelled analyte 
present simultaneously compete for the limited number of specific antibody binding 
sites (Liu et al., 2012; Wang et al., 2014). Generally, the ‘unlabelled’ analyte, or free 
analyte as the target of quantification, is prepared with the increasing concentrations in 
order to generate a standard curve, whereas the labelled analyte as the tracer has a 
constant concentration. After reaching equilibrium unbound analyte is removed by 
washing with a mild detergent solution. The labelled analyte competes with the free 
analyte for the antibody binding sites. Thus, an inverse relationship exists between the 
signal obtained from the tracer and the concentration of the target molecules in the 
sample, i.e. the more target molecules in the analytical sample the lower the signal. 
Figure 7A presents the principle of competitive immunoassay. The capture antibodies 
immobilised on a solid surface, provide a consistent amount of antigen binding sites. 
Enzyme-labelled antigen and antigen of interest are exposed to the immobilised 
antibodies and compete for the binding sites. The unbound antigens were removed by a 
washing step. A substrate solution (e.g. TMB) is added and reacts with the enzyme 
linked to the antigen, leading to colour generation. The measurement of this change can 
indicate the amount of free antigen in the sample. Typically the competitive assay is 
used to detect small molecules, such as haptens, which have only one discrete epitope 
(Wang et al., 2011; Parra et al., 2012). This assay can provide high specificity.  
 
 
1.6.3.9 Non-competitive immunoassays 
 
	 24 
As the name implies, non-competitive immunoassays represent a group of assays, in 
which the analyte binds to antibody without competition (Bigalke et al., 2011; 
Mukundan et al., 2012; Liu et al., 2014). The sandwich immunoassay format is one of 
the widely used non-competitive assay formats, and is illustrated in Fig. 1.6.3.9b.  In the 
sandwich immunoassay, two different antibodies are used for binding the analyte. 
Generally, one of these two antibodies is immobilised on a solid surface to capture the 
analyte. The other antibody, with a probe/label added binds to the captured analyte. 
Therefore, the sandwich assay usually is used to detect relatively large analytes, which 
allow simultaneous binding of two antibodies with different specificities. In Fig. 
1.6.3.9a, the capture antibody is specific to the analyte and will selectively absorb 
analyte presenting in a sample. After equilibrium is reached, the unbound analyte is 
removed by washing steps. A second antibody, linked to enzyme, is applied to recognize 
and bind to a different epitope on the analyte. On application of a substrate solution, the 
enzyme linked to the second antibody is activated, leading to a color change. The 
detected signal derived from the color change is directly proportional to the analyte 
concentration in the sample. Generally, non-competitive immunoassays have high 
sensitivity and specificity. Typically they are employed in the clinic to measure 
important disease biomarkers such as Human Immunodeficiency Virus (HIV)  (Tang 
and Hewlett, 2010) and cardiac troponins (Stein et al., 2011).  
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Figure 1.6.3.9 Illustration of competitive immunoassay and non-competitive 
immunoassay formats. (a) enzyme-labelled and unlabelled analytes competed for 
binding with surface-immobilised anti-analyte capture antibodies. After the binding 
reaction reaches equilibrium, the unbound analytes are removed by washing. The signal 
is generated from measurement of the absorbance, following the reaction between the 
substrate and the enzyme label, and is indirectly proportional to the amount of free 
antigen. (b) For the non-competitive immunoassay, antigen is sandwiched between the 
surface-immobilised capture and the detection antibodies (labelled with enzyme). The 
absorbance generated is directly proportional to the amount of captured analyte.  
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1.7 Signal amplification strategies for immunoassays 
 
The sensitivity of an immunoassay can be dramatically enhanced by using a signal 
amplification system. Immunoassay signal amplification can be achieved by many 
different methods. However, a widely used method is the biotin-avidin system.  
 
1.7.1 The Avidin-Biotin system 
 
Biotin, also known as vitamin H, is a small and water-soluble molecule that is found in 
living cells. The biotin molecule contains a valeric acid chain, which reacts with various 
biotin-affinity proteins through derivatization. Biotin has a high affinity constant 
(kd=10-15 M) for the egg-white protein – Avidin (Lesch et al., 2010). The avidin – biotin 
interaction is the strongest known non-covalent bond and is, therefore, employed in the 
purification of biotin-bonded molecules from complex matrices such as serum 
(Tomizaki et al., 2010).  
 
Avidin is a basic glycoprotein found in the egg white and tissues of birds, reptiles and 
amphibians. It is a tetrameric protein having four identical binding sites. The basic 
isoelectric point of avidin (10-10.5) confers structural stability in a wide range of pH 
and temperature values.  However, disadvantages of avidin is its high nonspecific 
binding properties due to its high carbohydrate content (10%) and its high charge at 
neutral pH, due to its isoelectric point (Almonte et al., 2014). 
 
A second biotin binding protein is streptavidin found in Streptomyces avidinii. Similar 
to avidin, streptavidin contains four identical subunits each having one binding site. 
However, streptavidin has no carbohydrate and has a pI of 5.5 (Chiver et al., 2010). 
Another biotin binding protein is the commericially available NeutrAvidin™. This 
protein is also a deglycosylated version of avidin and has a high binding affinity for 
biotin. Its development was based on research that proved that the carbohydrate portion 
was not necessary for the biotin-avidin reaction (Wang and Kaplan, 2011). Unlike 
avidin and streptavidin, NeutrAvidin™ lacks the Arg-Tyr-Asp sequence which can 
cause non-specific binding particularly in immunohistochemical methods (Nguyen et al., 
2011). NeutrAvidin™ has a l pI of 6.3 and is widely used to detect biotinylated 
molecules (Table 1.7.1).  
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Table 1.7.1 Characteristics of different biotin-binding proteins (adapted from Thermo 
Scientific avidin-biotin technical Handbook, last accessed on 20th Aug 2014; retrieved 
from http://www.piercenet.com/files/1601675_AvBi_HB_INTL.pdf.). 
 
 
Characteristics 
 
   Avidin 
 
Streptavidin 
 
NeutrAvidin 
Molecular 
Weight 
 
  67KDa 
 
53KDa 
 
60KDa 
Biotin-binding 
Sites 
 
     4 
 
4 
 
4 
Isoelectric Point  
10-10.5 
 
5.5 
 
6.3 
Affinity for 
Biotin (M) 
 
   10-15 
 
10-15 
 
10-15 
Non-specific 
Binding 
 
  High 
 
Low 
 
Very Low 
 
Source 
 
Egg-white, 
oviducts of birds, 
etc. 
 
 
Bacteria 
e.g. Streptomyces 
avidinii 
 
In vitro 
production of 
genetically 
modified avidin 
 
Applications 
 
Purification of 
proteins from 
complex mixtures 
 
 
Purification of cell-
surface glycoproteins 
and membrane antigens 
 
Immunoprecipit
ation 
capturing 
biotinylated 
cell-surface 
proteins and 
peptides 
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The use of the biotin-avidin system in immunoassays can be divided into two main 
categories (Colburn, 2005). These are: (1) avidin can be used to mediate the interaction 
between the detector molecule and the primary antibody or antigen (Han et al., 2011), 
and (2) avidin/biotin can be immobilised onto the solid phase in order to improve the 
characteristics of the capture system (Liu et al., 2014).  
 
An example of the biotin-amplified detection system (1) using either a sandwich 
immunoassay format or a competitive immunoassay format is shown in Fig 1.7.1. In the 
sandwich format (Fig. 1.7.1a), the antigen is bound to the solid phase via a capture 
antibody and then bound by a biotinylated primary antibody. Once biotin is present in 
the system, an avidin-conjugated detector can be used to quantify the amount of antigen. 
In this approach, the avidin molecules are incorporated into the biotin-containing 
system such that additional free binding sites are available for subsequent interaction 
with the detector. In contrast, in the competitive format (Fig. 1.7.1b), the biotinylated 
and non-biotinylated antigen molecules compete for the combining sites of an 
immobilised capture antibody. The biotinylated antigen, which is bound to the capture 
antibody, is then determined by the avidin-detector conjugate.  
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Figure 1.7.1 Application of the biotin-avidin complex in sandwich and competitive 
immunoassays. (a) The sandwich immunoassay format, in which an antigen from a 
complex mixture of molecules is selectively bound to solid phase via a capture 
antibody, and detected subsequently via a biotinylated primary antibody and avidin-
conjugated detector. (b) The competitive immunoassay format, wherein a biotinylated 
antigen competes with the native from of the antigen, prior to quantification by the 
avidin-conjugated detector. 
 
The major formats of immunoassays were introduced previously. Currently, the format 
most often applied to perform these various immunoassays is a 96-well microtiter plate, 
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which possesses a few inherent shortcomings. Firstly, several hours of incubation time 
are required under static conditions. This is because analyte molecules in the bulk 
solution must diffuse across a long distances to encounter and interact with antibodies 
on the surface. Generally, the process of molecular diffusion takes hours. For example, a 
large protein like IgG (150 kDa) needs more than 3 hours to diffuse 1mm (Lionello et 
al., 2004). Secondly, large amounts of several assay reagents are required. Generally, a 
volume of 100 µL of each reagent is used to perform the microtiter plate-based 
immunoassay. Additionally, the microtiter plate-based immunoassay involves a labour-
intensive protocol, which may lead to large operator errors. After each reagent 
incubation step, a wash step is carried out manually by pipetting washing solutions 
in/out. To improve throughput and reproducibility of these processes, robotic systems, 
such as a microtiter plate washer, can be used for wash solution handling. However, this 
approach requires high costs for purchase and maintenance. Another solution to 
circumvent these issues is miniaturization and automation of immunoassays in 
microfluidic systems. This will be introduced in the following section.   
  
1.8 Microfluidics 
 
Reducing the level of immunoassay reagents to a microscale and the handling of these 
fluids in a network of microchannels, is called microfluidics. The reduction in scale 
results in a number of unique features (Fig. 1.8):  
 
a. Laminar flow. Typically, the fluid flow in microchannel falls into the category of 
laminar flow, which shows parallel flow layers with no disruption between the 
layers. For laminar flow the velocity profile in the channel obeys the Hagen-
Poiseuille law, with maximum velocity at the geometric center and zero velocity 
at the walls of the microchannel (Berthier et al., 2010). This laminar flow can 
contribute to an easily controllable fluid.  
b. Diffusion. Molecules can be transported across layers by diffusion in a typical 
laminar flow. Different fluids containing miscible fluids and molecules can flow 
next to each other in a microchannel without any mixing other than by diffusion. 
Small molecules diffuse faster than larger ones, which facilitate separation of 
molecules by size (Gossett et al., 2010; Lenshof and Laurell, 2010). It is 
possible to design microchips to detect small analytes in complex samples such 
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as blood (Tachi et al., 2009).  
c. Surface tension. Due to scaling down effects, the surface–to-volume ratio 
dramatically increases. Therefore, surface tension dominates over gravitation 
forces in the microchannel. For a passive microfluidic system, controlling this 
force to handle the fluid by simply designing a series of microchannel, can 
enable a cheap, portable platform (Galusinski and Vigneaux, 2008; Nwankire et 
al., 2013).			 
 
 
 
 
Figure 1.8 Illustration of laminar flow in a microchannel. The fluid with analytes enters 
the microchannel at the inlet on the left side and flows through the microchannel under 
laminar conditions with a parabolic flow profile. The analyte molecules can diffuse 
perpendicularly to the flow direction whenever a concentration gradient exists. 
(Modified from Zimmermann et al., 2005)    
 
 
On the basis of these features microfluidics-based technologies have revolutionized the 
potential for new assay format development and implementation. Compared to 
conventional immunoassay formats, microfluidic platforms provide remarkable new 
features. A high ‘surface-to-volume’ ratio with microchannels, for instance, is capable 
of dramatically influencing interfacial reaction kinetics in solid-phase-based 
immunoassays and the handling of reagents in the micro and nano-litre range (Bange et 
al., 2005). Consequently, these features allow a ‘sample-to-answer’ test to be generated 
with short analysis times, minimal reagent consumption, integration, automation and 
parallel processing, leading to in-line, at-line and in-situ processing of samples. 
Furthermore, centrifugal microfluidic platforms inherently possess additional 
advantages when compared to other ‘lab-on-a-chip’ systems, due to the absence of 
expensive syringe pumps. Thus, disc platforms enable full integration of multiple liquid 
Inflow 
Analyte 
Diffusion 
Outflow 
Parabolic flow profile Microchannel 
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handling and assay processes including pumping, metering, mixing, reagent storage and 
sequential reagent delivery. To this end, several multi-step and multiplex assays can be 
integrated onto the platforms, and with further development, they can facilitate the 
integration of optical sensors on other detections strategies.  
 
1.8.1 Microfluidic platform 
 
Simple microfluidic devices include the capability of automation, miniaturisation, 
enclosed reactions, cost effectiveness, lower reagent consumption and shortened 
operation time (Haeberle & Zengerle, 2007; Dungchai et al., 2011; Guo et al., 2012). 
Details on some of the problems related to immunoassays and how they can be 
addressed through microfluidics are now presented and discussed. 
 
 
a. Reduced amounts of reagent and sample: Most reagents, such as fluorescent 
labels and enzymes, are integral to immunoassays but are expensive. Therefore, 
minimisation of both reagent and sample amounts is an effective way to reduce 
the cost in an immunoassay. Microfabrication technology can be applied to the 
generation of multiple fluid-handling components, and these can be networked 
within one simple microfluidic device. Such integrated micro-devices can 
substantially reduce reagent consumption (Lai et al., 2004). 
b. Decreased analysis time: The widely applied heterogeneous immunoassay 
requires many incubation and washing steps. The requisite long incubation times 
are caused by inefficient mass transport of antigen/antibody from solution to the 
solid surface. If the analysis time can be reduced from days to minutes or even 
seconds, the immunoassay system would be capable of fast and continuous real-
time monitoring. Recent reports from the literature show that, this problem also 
could be solved by the application of microfluidic devices as it could enhance 
the reaction efficiency and reduce the incubation times ( Miller et al., 2012; 
Kantak et al., 2012; Xiao et al., 2013; Kim et al., 2014). 
c. Automation. In classical immunoassay procedures, a loss of precision and 
accuracy can occur due to operator error. In contrast, integrated microfluidic 
devices reduce the operational errors, and provide automated functions such as: 
delivery, pumping, valving and mixing of reagents, washing as well as ‘on-chip’ 
detection (Gorkin, 2010). Automation of the experimented process can often 
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increase speed, precision, and accuracy. 
d. Integration and portability. Miniaturization has more advantages than the simple 
‘scale-down’ of chamber dimensions and volumes. For trace chemical 
interactions based on surface and solution phases, the ratio of surface area to 
volume is higher, and, therefore, results in faster interaction time and better 
molecule transportability. A portable device is necessary to eliminate delay for 
the delivery in the application of clinical diagnostics. A further benefit of 
portable microfluidic devices is a reduction in power consumption. Moreover, 
portability is a key factor for ‘point-of -care’ applications (Bhagat et al., 2011). 
 
1.8.2 The development of microfluidic platforms 
 
Initially, microfluidic devices often had simple channel geometries that allowed for a 
few chemical reactions on a glass or polymer chip (Haraldsson, 2005). The first and 
most successful application of microfluidics was the inkjet print head, and it provides 
the basics for ink-jet technology (Le, 1998). At the end of 1980s, micro-valves and 
micro-pumps were produced by silicon micromachining. On this premise automation of 
liquid handling protocols based on microfluidic integration became a reality.  A new 
field of “lab-on-a-chip” (LOC) or “micro total analysis systems” (µTAS) then emerged 
(Mark et al., 2010). Current microfluidic devices are far more complex with entire 
laboratory protocols shrunk down to only a few cm. The dramatic increasing number of 
publications in these areas demonstrate that microfluidic technology is now firmly 
established in academia, where it provides a new toolbox for the development of new 
methods and products in life sciences (Mark et al., 2010).   
 
1.9 Application of microfluidic platforms in immunoassay 
 
In order to transfer an immunoassay to a microfluidic platform, there are some 
fundamental properties of microchip fabrication and design that need to be considered 
(Bange et al., 2005). These include:  
 
a. Materials. The characteristics of the materials are critical for the application of a 
microfluidic system in immunoassay due to the performances of chemical and 
physical operations inside the microchip. The ideal material used to fabricate 
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microfluidic systems possesses chemical resistance, optical transparency, ease of 
microfabrication and low cost (Henares et al., 2008).   
b. Fluid force. Capillary phenomena are important in micro-channels as adhesion 
to the walls is stronger than the cohesive forces between the water molecules 
(Haeberle & Zengerle, 2007). This causes an increase in the flow resistance for a 
pumped liquid. Thus, both pump and capillary force control the flow of liquid. 
c. Valving. Valve performance is a critical component in microfluidic platforms. It 
contributes to precise control of the flow of liquid at multiple points throughout 
the assay process.  
d. Microfluidic design. Design is important with regard to the device performance, 
specifically, in the case of handling the fluid in micro-scale. An ideal 
microfluidic system should be portable, self-contained and able to integrate 
multiple functions, such as reagent preparation, sequential delivery.  
e. Surface modification. Modification of the surface is often essential in order to 
provide the proper surface chemistry for specific antibody immobilisation. In 
order to remove the excess reagents and block the unused immobilisation sites, 
generally, washing and well defined blocking processes are required.  
f. Detection. The detection method can directly affect the sensitivity and accuracy 
of a microfluidic-based immunoassay. With regard to the micro-scale detection 
area, however, the conventional detection methods such as a plate-reader or 
fluorescent microscope are not suited. Therefore, a novel detection method with 
significantly high sensitivity needs to be considered.  
 
These challenges have been addressed in many publications (Whiteside, 2006; Henares 
et al., 2008; Mark et al., 2010; Tabeling, 2010; Lee et al., 2011, Giordano et al., 2012). 
A short review of some techniques and developments are described below. 
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1.9.1 Microfluidic propulsion  
 
Microfluidic platforms can be classified into different groups according to various 
principles of liquid propulsion, such as capillary, centrifugal, pressure-driven, 
electrokinetic, acoustic microfluidic-based, magnetic-driven and syringe systems 
(Madou et al., 2006). In this section, centrifugal microfluidics is discussed and 
compared with two other popular fluid propulsion methods, which are syringe pumping 
and electrophoresis.  
 
A pressure driven flow platform is characterized by liquid transport mechanisms based 
on pressure gradients. Typically this leads to hydrodynamically stable laminar flow 
profiles in microchannels. There is a broad range of different implementation strategies 
in terms of using external or internal pressure sources such as using syringes, pumps or 
micropumps, gas expansion principles or pneumatic displacement of membranes. In 
Fig. 1.9.1a, a syringe-driven flow is illustrated for example. The external syringe pump 
is coupled to microfluidic channel. The samples and reagents are processed by injecting 
them into the chip inlets either batch-wise or in a continuous mode ( Henares et al., 
2008; Mark et al., 2010 ). A pressure driven approach can be used for a wide range of 
solutions because of the relative ease and insensitivity to surface contamination, ionic 
strength and pH.  It even allows non-electrically conductive fluid flows. However, the 
flow behaviour using peristaltic pumps is usually non-linear which may cause problems 
in miniaturisation and multiplexing.  
 
Electrokinetic pumping in microfluidic channels is performed by employing and 
housing planar microelectrodes on to one or more sides of the microchannel structures 
(Yang & Kwok, 2004). This method can be principally used for the controlled 
manipulation, isolation, concentration, separation and characterisation of electrically 
polarisable particles, such as intact cells, proteins, viruses, bacteria, and micro-
organisms (Dalton & Kaler, 2007). In Fig. 1.9.1b, an electrokinetic platform is 
illustrated. In this system, a pair of coplanar meandering electrodes with an alternating 
current (ac) voltage is configured in parallel with the channel. The electrically charged 
particles or molecules in this electric field are attracted by the electrodes. This effect can 
be used for chromatographic separation (Haeberle & Zengerle, 2007). The 
electrokinetic system does not require any moving parts and is easily implemented. 
However, some disadvantages of this method include: (1) the requirement of a high 
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voltage (1-30 kV) power supply; (2) high sensitivity of the flow rate to the ionic 
strength and the pH of the solution; and (3) difficulty in valving liquids (Madou et al., 
2006).  
 
Centrifugal force is typically performed on ‘compact-disc (CD)-like’ structures 
containing channels and micro-chambers. Centrifugal force is produced by spinning the 
CDs using a rotor, as shown in Fig. 10c. The volumetric flow rate is dependent on the 
speed at which the disc spins, the distance from the centre of the disc, the geometry of 
the fluidic channels, and the fluidic properties (density, viscosity, and surface tension). 
The centrifugal approach provides several benefits over the other pumping methods. 
Firstly, centrifugal forces only need a low-power rotary motor. In addition, fluid flow is 
dependent upon the intensity and liquid viscosity rather than pH or ionic strength. 
Furthermore, centrifugal propulsion can work through the entire length of the fluid 
body. This allows smooth, controlled, and reproducible flow, but reduces the influence 
of bubbles, as well as enabling transfer of liquid with a high efficiency. Finally, many 
parallel units can be placed on an individual platform, and this is beneficial for the 
simplification of multiple operation steps in immunoassays (Siegrist et al., 2009). 
Currently, a whole range of fluidic functions, including decanting, mixing, metering, 
and separation, have been implemented with the centrifugal microfluidic platform 
(Gorkin et al., 2010). In addition, analytical measurements in a centrifugal microfluidic 
platform can be made by electrochemical (Kim et al., 2013), fluorescence (Chang et al., 
2013) or light absorption-based methods (Czugala et al., 2012). 
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Table 1.9.1  Comparison of microfluidic propulsion techniques (adapted from Madou et 
al., 2006). 
 
  
Centrifuge 
 
Pressure 
 
Electrokinetic 
Valving for 
liquids 
 
Available  
 
Available 
 
Available 
 
Maturity 
 
Products available 
 
Products available 
 
Products available 
Influence 
for 
propulsion 
 
Density and viscosity 
 
Geometry of channel 
 
pH and ionic strength 
 
Power 
source 
 
Rotary motor 
 
Pump and mechanical 
roller 
 
Metal electrode 
 
Materials 
 
Plastic, paper 
 
Plastic, glass, paper 
 
Glass, plastic 
 
Flow rate 
From less than  
1nl s-1 to greater than 
100 µl s-1 
Very wide range  
(less than nl s-1 to  
Liter s-1) 
 
0.001 – 1 µl sec-1 
General 
remarks 
Inexpensive CD drive; 
mixing is easy; 
most solutions 
possible (serum and 
cells);  
better for diagnostic 
platform 
Standard technique; 
difficult to miniaturize 
and multiplex 
Mixing difficult;  
high voltage source is 
dangerous and many 
parameters influence 
propulsion;  
better for smallest 
samples 
 
 
	 38 
 
Figure 1.9.1 Illustration of three fluid propulsion methods. (a) Syringe pump. A syringe 
is coupled to microfluidic channel. The samples in the syringe are injected into the 
channel by an external force on the syringe. (b) Electrophoresis. A pair of coplanar 
meandering electrodes with an AC voltage provides a steady electric field to the 
electrically charged particles or molecules, which can be separated according to charge 
and size.  (c) Centrifugal pump. A rotor is applied to provide a controllable centrifugal 
pumping force, which depend on the speed at which the disc spins, the distance from the 
centre of the disc, the geometry of the fluidic channels, and the fluidic properties 
(density, viscosity, and surface tension). 
Syringe 
Microchannel 
Microfluidic chip 
+   _   ν   
Electrode 
Positively charged molecules  
+ + 
+ - - 
- 
+ - 
Negatively charged molecules  
F 
F 
Electrode 
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and Reservoirs 
Nut and Washer 
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(b) 
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1.9.2 Valving in centrifugal microfluidics  
 
The most important determining factor in choosing a fluidic system is the ease of 
implementing valves. In the case of the centrifugal microfluidic CDs, valving is 
accomplished by varying rotation speed and capillary diameter. A selection of valving 
formats that can be applied in a centrifugal microfluidic CD is discussed in the 
following sections. 
 
1.9.2.1 Capillary valve (hydrophilic valve) 
 
The capillary valve is most often used in centrifugal microfluidic systems. This passive 
valve operates in hydrophilic channels and the movement of fluid is aided by centrifugal 
force generated by the rotation of the microfluidic disc. However, when a fluid has 
reached a sudden widening in the microchannel, a large surface tension force will 
develop. In Fig. 1.9.2a, a schematic operation of a capillary valve is shown. When the 
surface tension force is higher than that of the centrifugal force, the flow of fluid stops, 
despite the continued rotation of the CD. However, when a critical burst frequency is 
reached, the centrifugal forces overpower the surface tension forces, and the fluid will 
then move down the microchannel. 
 
1.9.2.2 Hydrophobic valve 
 
Two distinct strategies have been used to produce hydrophobic valves:  (1) extension in 
channel geometry, and (2) modification of the local surface property, such as surface 
tension. Both schemes are illustrated in Fig. 11b. In the channel geometry approach, 
when fluid experiences a quick change from a wide to narrow channel, the flow of 
liquid (right) can be blocked. Alternatively, hydrophobic functionalisation of the 
channel downstream has the same effect (Fig. 1.9.2b, left). In both cases, fluid can be 
forced past the hydrophobic valve by means of increasing the spin frequency to a 
threshold value. The most significant disadvantage associated with hydrophobic valving 
is that the effectiveness of passive fluid control is reduced when surfactant or some 
organic solvents are present in the solution (Haeberie and Zengerie, 2007; Tsougeni et 
al., 2010). 
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1.9.2.3 Siphon valve  
 
The siphon valve relies on a hydrophilic environment and surface tension acts as a 
pump in this model while centrifugal force acts as resistance. When the cross section of 
the channel is small enough to provide sufficient surface tension, the liquid in the 
chamber is able to flow along the channel (Siegrist et al., 2009). In Fig. 1.9.2c, the fluid 
is pumped out from a loading reservoir into a microchannel and then is stopped in one 
position under a condition of high-speed rotation. When the rotation speed is reduced to 
a certain level, capillary forces can pump fluid over the siphon channel crest. Therefore, 
the functional siphon valve is based on well-controlled rotational speed. Siphons are 
extremely useful on microfluidic CD platforms where they can serve several functions, 
often times in combination, such as valving, pumping, metering, and volume definition 
(Ducrée et al. 2007; Kido et al. 2007; Gorkin et al., 2012).  
 
Passive valves are controlled by varying the rotational speed of the CD, and require 
only deliberate geometry designs or surface modifications without extra moving parts. 
In order to obtain a great accuracy level and avoid errant release of the fluid, the 
material, position, and dimensions of passive valves must be designed carefully. 
 
 
 
 
Figure 1.9.2 Illustration of three forms of passive valving in a centrifugal microfluidic 
platform (modified from Siegrist et al., 2009). 
 
 
(a) Capillary Valve (b) Hydrophobic Valve (c) Siphon Valve 
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Constriction 
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1.9.3 Substrate materials for microfluidic immunoassays 
 
The most wildly used materials for fabrication of microfluidic platforms are silicon, 
glass and polymers (Henares et al., 2008). A comparison of these materials is 
summarised in Table 1.9.3. 
 
Table 1.9.3 Comparing characteristics of various type of material for fabrication of 
microfluidic platforms (adapted from Henares et al., 2008) 
 
Materials Silicon Glass Polymers 
Cost of raw 
materials 
Expensive 
(~ 1 dollar cm-2) 
Less expensive 
(20~40 cents cm-2) 
Cheap 
(~ 1 cent cm-2) 
 
Ease in 
fabrication 
Available in the 
integrated circuit 
industry; involved 
in a series of 
processes and 
chemicals 
 
Geometry limitation 
due to the isotropicity 
(shallow, semicircular 
cross-section) 
 
 
High processibility 
 
Mass  
production 
 
Yes, slow process; 
high cost 
 
Yes, slow process; 
high cost 
 
Yes (not well-
developed); fast 
process; low cost 
 
 
Optical 
 
Opaque 
 
Transparent 
 
Transparent; may 
absorb the ultraviolet 
light 
 
Thermal 
conductivity 
 
1.4 W mK-1 
 
~ 1 W mK-1 
 
~ 0.1 W mK-1 
 
Biocompatibility 
 
Usually need 
surface 
modification 
 
 
Good 
 
Depends on polymers 
and applications 
High temperature 
sterilisation 
 
Feasible 
 
Feasible 
 
Tend to deform 
Electric 
conductive 
 
Semiconductor 
 
 
Electric insulator 
 
Electric insulator 
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Silicon has great thermal conductivity, stable chemical and physical properties.  
However, silicon is not optically transparent in the UV/visible region, which is normally 
the detection wavelength range for most bioanalyses (Osterbroek, 2003). Also, 
microchip construction using silicon requires costly fabrication facilities and this 
therefore limits the implementation of this material in a commercial environment.  Glass 
substrates possess good chemical resistance and offer excellent optical properties for 
biomolecular detection. However, microfabrication with glass using a common method 
of isotropic wet etching is also expensive (Fiorini & Chiu, 2005). Currently, polymers 
are attracting far more attention for use in microfluidic devices due to the ease of 
microfabrication. Physical and chemical properties like good chemical resistance, 
optical transparency, low autofluorescence and absence of UV absorption. The 
availabilities of various surface chemistries contributing to many choices of 
immobilisation techniques for different antibodies or antigens are additional advantages 
(Attia and Marson, 2009). The most typically used polymers include polystyrene, 
polypropylene, polyvinvyl chloride (PVC), polycarbonate, polymethyl methacrylate 
(PMMA) and polydimethylsiloxane (PDMS). Among these, PMMA and PDMS show 
unique potential for microfluidic immunoassay systems because of low cost, high 
transparency and excellent dielectric and mechanical properties. 
  
1.9.4 Surface modification 
 
An ideal substrate for microfluidic immunoassay should have a high binding capacity 
but also should show outstanding adhesion, stability and resistance against harsh 
washing and regeneration conditions. For covalent attachment of biomolecules, the 
polymer surface needs to be functionalised. Many methods for surface modification 
have been used for enhanced antibody immobilisation and reduction of non-specific 
binding. Non-specific binding of molecules in a heterogeneous assay impacts the 
accuracy and precision of the immunoassay. Surface modifications can generate both 
covalent and non-covalent antibody-substrate interactions by alterations in surface 
chemistry (Zhou et al., 2010). Many methods for surface modification of PMMA 
surfaces are available (Brown et al., 2006; Tennico et al., 2010; Chehimi et al., 2014). 
A description of three widely used surface modification methods follows. 
 
 
	 43 
1.9.4.1 Plasma treatment  
 
A plasma refers to a partially ionised state of matter (Flamm and Auciello, 2012). In this 
state a proportion of electrons and ions are free instead of being bound to an atom or 
molecule (Zhou & Voelcker, 2010). Plasma surface modification relies on gases (i.e. 
oxygen, nitrogen and hydrogen), which react with the substrate surface and 
subsequently create chemical functional groups. 
 
1.9.4.2  Chemical vapour deposition (CVD) 
 
CVD refers to a chemical process used to generate a thin film on a substrate surface by 
the deposition of gaseous molecules, which chemically react on the surface (Gubala et 
al., 2010; Zhou et al., 2010).The sequence of events in CVD includes sublimation, 
pyrolysis and deposition. Chen and Lahann have deposited poly (4-benzoyl-p-xylylene-
co-p-xylylene) on PDMS via CVD and, subsequently, wet-chemically patterned the 
resulting reactive coating of a microchannel with poly (ethylene oxide) (Chen et al., 
2005). Chen et al., have demonstrated CVD polymerization of a range of functionalised 
poly (p-xylylenes) within PDMS microchannels with complete coating of the entire 
channel length (Chen et al., 2006). In these previous studies, it was demonstrated that 
the CVD technique could overcome the challenges caused by the conventional liquid-
phase technique, which were the requirement of manual intervention to introduce the 
precursors (e.g. APTES), and poor uniformity of surface coating.  
 
1.9.4.3 Combination of plasma treatment and silanisation 
 
In contrast to the multi-step complexity of the methods described above, a fast and 
simple route to versatile amine-functionalised surfaces on plastics was demonstrated by 
Gubala’s group (Gubala et al., 2010). In this method oxygen plasma activation was 
combined with plasma enhanced chemical vapour deposition (PECVD) using an 
aminated precursor. This technique has a number of advantages over the multistep, wet 
chemical methods or even CVD. It can be used to coat a large number of substrates in a 
single batch, it avoids direct contact with the solvent, and thus reduces chemical waste. 
In addition, the process can be performed at room temperature (Volcke et al., 2010). 
Moreover, no major limitations have been observed in terms of preparation of 
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homogeneous coatings on curved or patterned surface and microfluidics channels 
(Angelini et al., 2006). 
 
1.9.4.4 Silanisation 
 
Surface silanisation can be implemented on different substrates if they have surface 
hydroxyl groups, which are capable of reacting with alkoxysilanes to form covalent Si-
O-Si bonds with the underlying substrate (Howarter & Youngblood, 2006; Raj et al., 
2009).  (3-Aminopropyl)-triethoxysilane (APTES) is a commonly used aminosilane in 
the process of silanization. This agent contains an amine terminal and a silane terminal, 
which can be introduced onto the oxidative surfaces and provides amine-groups for 
reaction with biomolecules. Additionally, the application of APTES for the 
immobilization of antibodies on the microchannel surface, has been extensively 
reported in the literature (Lee, 2006; Lee et al., 2010; Chen et al., 2010).  
 
1.9.5 Detection methods in microfluidic immunoassays 
 
To develop fast, sensitive and portable point-of-care device, it is crucial to choose an 
appropriate detection method with high sensitivity and portability.  The most commonly 
used detection methodology in microfluidic systems is fluorescence, in which a specific 
fluorophore is labelled fluorescently. Typically, fluorescence detection system consists 
of the following components: a light source for emitting light at a suitable wavelength 
range, an excitation filter to eliminate unwanted light, a dichroic mirror for the optical 
separation of excitation and emission channels, an emission filter, and a detector with 
electronics for signal processing (Lin et al., 2011). Integration of fluorescent labels with 
microfluidics can offer several benefits. The reduction in the sample volume can 
mitigate background signal noise and improve the sensitivity as well as signal-to-noise 
ratio (Irawan et al., 2007). However, challenges still exist in using fluorescent labels 
with microfluidics. Firstly, the chip material needs to be microscopy-compatible, e.g. 
low auto-fluorescence. Secondly, traditional fluorescent signal acquisition is bulky, 
which does not facilitate development of fully integrated and portable systems in point-
of-care microfluidic systems.   
 
A new polymeric material, cyclic olefin polymer (COP) demonstrated itself to be an 
	 45 
ideal substrate for fluorescence detection in microfluidic system. Outstanding features 
of COPs, such as high chemical resistance, good optical transparency and low 
autofluorescence, have been reported (Roy et al., 2010; Jena et al., 2011; Ait-Ali et al., 
2012). In addition, COPs present excellent properties for fabrication, allowing 
integration of optical components on-chip (Skinner et al., 2014). Furthermore, COPs are 
cost efficient (Nunes et al., 2010). 
 
In recent years, more and more research has focused on improvement of detection 
technology for lab-on-a-chip systems. Several ‘lab-made’ fluorescence detection 
systems have been developed with advanced features, such as miniaturization, low 
background signal and low costs. For example, Yang et al. developed a scanning laser 
induced fluorescence detection system by using optical fibers, which was compatible, 
low cost and stable (Yang et al., 2012). Tan et al. designed and fabricated a microfluidic 
system, where fluorescence intensity was enhanced by twenty times using a photonic 
crystal surface embedded in the microfluidic chip (Cunningham, 2015). All of these 
fluorescence detection technologies can facilitate point-of-care device portability. 
 
Today, although there are numerous novel microfluidic systems generated and widely 
used, the majority of research still focuses on the stage of demonstrations rather than 
quick commercialization, as many hurdles exist. Firstly, high initial investment for 
market entry is required; secondly, the fabrication technologies are too expensive; and 
finally, application of immunoassays on a chip requires a lot of research for 
development and optimization. 
 
1.10 Simulation of an immunoassay in microchannels  
 
Microfluidic systems can enhance the kinetics of an immunoassay in comparison with 
that performed in a microtitre plate. This microfluidic paradigm strongly relies on the 
micro-dimensional channel. At these small scales fluids exhibit laminar flow, i.e. fluidic 
streams that flow parallel to each other, and mixing occurs only by diffusion. However, 
the enhancement effect on the kinetics of microfluidic immunoassay also can be 
influenced by many other conditions such as the design of microchannel geometry, the 
flow velocity of reagents in the microchannel and the size of the sensing area. In order 
to understand how changes in these conditions affect the immunoassay, the technique of 
computational simulation can be used to predict the trends in assay performance 
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resulting under different modelled conditions. Furthermore, the predicted data can 
provide very useful information for the design and optimization of microfluidic systems 
and assays. 
 
1.11 Thesis Aims  
 
The main purpose of the thesis is the development and optimization of microfluidic 
system for use with immunoassays for selected targets such as marine toxins and human 
IgG. 
 
Firstly, Saxitoxins (STX) are potent cyanobacterial neurotoxins that accumulate in 
water, fish and shellfish which feed upon marine algae. These toxins can cause paralytic 
shellfish poisoning, blockage of Na+ ion channels in nerve membranes, and may result 
in paralysis and respiratory failure. To meet the urgent requirement for reliable detection 
methods and to reduce the risk of human exposure to potent marine biotoxins, the 
generation of an anti-STX antibody with high affinity and specificity to a range of 
saxitoxin derivatives such as neosaxitoxin, gonyuatoxin, decarbamoyl and saxitoxin 
itself was envisioned. 
 
Secondly, the thesis research aims to develop a prototype microfluidic system for the 
performance of rapid and sensitive immunoassays. The microfluidic platform should 
include well-designed microchannel networks, which incorporates sample loading, 
valving, and sequential delivery. In order to perform the heterogeneous immunoassay in 
the microfluidic platform, the functionalised substrate should have uniformly deposited 
amine groups. Additionally, an optical detection method should be developed to meet 
the requirement of quick, sensitive and accurate measurement. Moreover, this 
microfluidic immunoassay should detect selected samples in the nanomolar range and 
the assay time should be significantly shorter than conventional methods (e.g. ELISA 
based on microtitre plates) and should ideally have potential for automation. 
 
Finally, the developed microfluidic-based immunoassay should be analysed and 
evaluated by computational simulation. The kinetics of microfluidic-based 
immunoassay should be studied; furthermore, the effect of varying assay parameters 
should be verified.  
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2.1 Materials 
 
2.1.1 Reagents 
 
All reagents used were of analytical grade and purchased from Sigma-Aldrich Ireland 
Ltd (Dublin, Ireland), unless otherwise specified. 
 
Reagent Supplier 
Bacteriological Agar 
Yeast extract 
Tryptone 
Cruinn Diagnostics Ltd.,  
Hume Centre,  
Parkwest Business Park,  
Nangor Road,  
Dublin 12,  
Ireland. 
DNA Ligase 
Helper phage 
Restriction enzymes 
Phusion High-Fidelity DNA polymerase 
Antarctic Phosphatase 
ISIS Ltd., 
Unit 1 & 2, Ballywaltrim Business 
Centre,  
Boghall Road,  
Bray, Co. Wicklow,  
Ireland. 
dNTPs 
GoTaq® DNA Polymerase 
 
Medical Supply Company Ltd, 
Damastown,  
Mulhuddart,  
Dublin 15,  
Ireland. 
PageRuler™ Plus Prestained Protein 
Ladder 
 
AGB Scientific Limited –  
A VWR International Company, 
Orion Business Campus,  
Northwest Business Park,  
Ballycoolin, Dublin 15,  
Ireland. 
PCR primers Eurofins MWG Operon,  
318 Worple Road,  
Raynes Park, London, 
SW20 8QU,  
UK. 
Platinum® Taq DNA Polymerase High 
Fidelity 
Trizol 
Bio-sciences,  
Crofton Road,  
Dun Laoghaire,  
Dublin,  
Ireland. 
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RNaseZap™     
RNAlater™   
Glycogen (5 mg/mL)  
3M Sodium acetate   
Applied Biosystems/Ambion, 
2130 Woodward St., 
Austin,  
TX 78744-1832,  
USA. 
Protein A  
Neutravidin-Dylight 650 
Thermo Fisher Scientific Inc., 
3747 N Meridian Rd, 
Rockford, IL.,  
USA.  
IgG-free bovine serum albumin (BSA)  
 
Jackson ImmunoResearch Laboratories 
Inc., 
872 West Baltimore Pike,  
West Grove, PA 19390,  
USA. 
A biotinylated, secondary anti-human-IgG 
antibody  
Gallus Immunotech Inc., 
6570 First Line of Westgarafraxa, 
FERGUS, 
Ontario N1M 2W4,  
USA. 
Micro-90 concentrated cleaning solution VWR International LLC. 
100 Matsonford Road, 
Radnor,  
PA 19087-8660, 
USA. 
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2.1.2 Equipment 
The equipment used and the suppliers are listed below. 
 
Equipment Name Supplier 
Biometra T-Gradient PCR machine 
 
LABREPCO, 
101 Witmer Road, Suite 700, 
Horsham, PA19044,  
USA. 
Eppendorf™ Centrifuge 5810 R with 
swing-bucket rotor (A-4-62) and 
fixed-angle rotor (F-45-30-11) 
 
AGB Scientific Limited –  
A VWR International Company, 
Orion Business Campus,  
Northwest Business Park,  
Ballycoolin, Dublin 15,  
Ireland. 
Gene Pulser Xcell™ electroporator, 
Biorad Gel electrophoresis system 
 
Bio-Rad Laboratories, Inc.,  
2000 Alfred Nobel Drive,  
Hercules, California 94547,  
USA. 
MSC-Advantage Laminar Flow 
Cabinet 
PX2 thermal cycler  
Thermo Electron Corporation,  
81 Wyman Street, Waltham,  
Massachusetts (MA),  
02454, USA. 
Nanodrop™ ND-1000  
  
NanoDrop Technologies, Inc., 
3411 Silverside Rd 100BC,  
Wilmington, DE19810-4803,  
USA. 
Roller mixer SRT1    Science lab, Inc., 
14025 Smith Rd, 
Houston, Texas 77396, 
USA. 
Safire™ 2 plate reader    Tecan™ Group Ltd. 
Seestrasse 103, 
CH-8708 Männedorf,  
Switzerland. 
Vibra Cell™ sonicator   Sonics and Materials Inc., 
53 Church Hill Road, 
Newtown,  
CT 06470-1614,  
USA. 
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ANDOR iXon 885 camera  
 
Andor Technology plc., 
425 Sullivan Avenue, 
Suite #3, 
South Windsor, 
CT 06074, 
USA. 
Epilog Zing Laser cutter Epilog Laser, 
16371 Table Mountain Parkway, 
Golden,  
CO 80403,  
USA.  
Roland MDX-40A Benchtop Milling 
Machine 
Roland DG Corporation, 
1-6-4 Shinmiyakoda,  
Kita-ku,  
Hamamatsu-shi,  
Shizuoka-ken,  
431-2103, 
Japan. 
 
Computer-numerical control (CNC) 
machine (T-Tech, GA, USA- 
QuickCircuit 5000) 
 
RoutOut CNC Ltd., 
Unit D5, 
Capel Hendre Industrial Estate, 
Ammanford, 
SA18 3SJ, 
USA. 
Cutter-plotter (Graphtec, Japan- 
Graphtec CE-2000) 
 
Graphtec America Inc. 
17462 Armstrong Avenue Irvine,  
CA 92614-5724, 
USA. 
Hot Roll Laminator  ChemInstruments International Inc., 
9079 Tyler Blvd, 
Mentor, 
Ohio 44060, 
USA. 
Harrick Plasma Cleaner PDC-002 
Mass flow controller (PDC-FMG) 
 
Henniker Plasma, 
Cavendish House, 
Birchwood Park, 
Warrington, WA3 6BU, 
England. 
 
Scroll pump (Edwards XDS-5)  
 
Mason Technology, 
228 South Circular Road, 
Dublin 8, 
Ireland. 
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Oxford Plasmalab System100 PECVD 
reactor 
 
Oxford Instruments, 
Abingdon, Oxfordshire,  
OX13 5QX, 
United Kingdom. 
 
 
 
 
 
2.1.3 Culture media formulations 
All the reagents were prepared in distilled water and autoclaved at 120oC for 20 
minutes. 
 
Media  Components 
2x Tryptone Yeast extract (2xTY) 
 
Tryptone (16 g/L) 
Yeast extract (10 g/L) 
NaCl (5 g/L) 
 
Super Broth (SB) MOPS (10 g/L) 
Tryptone (30 g/L) 
Yeast extract (20 g/L)          
 
Super Optimal Catabolite (SOC) 
 
Tryptone (20 g/L) 
Yeast extract (5 g/L) 
NaCl (0.5 g/L) 
KCl (2.5 mM) 
MgCl2 (20 mM) 
Glucose (20 mM) 
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2.1.4 Buffer preparation 
 
2.1.4.1 General buffers 
 
All the reagents were prepared in distilled water and autoclaved at 120oC for 20 
minutes. 
 
 
Buffer Name Components 
Phosphate-buffered saline (PBS)  
150 mM (pH 7.4) 
NaCl (5.84 g/L) 
Na2HPO4 (4.72 g/L) 
NaH2PO4 (2.64 g/L)  
 
PBS Tween 20 (PBST) NaCl (5.84 g/L) 
Na2HPO4 (4.72 g/L) 
NaH2PO4 (2.64 g/L) 
Tween 20 (0.05 %,v/v) 
 
2.1.4.2 Buffers for Western blotting 
 
Transfer Buffer Volume (1 L) 
Tris 3.03 g 
Glycine 14.4 g 
Methanol 200 mL 
 Adjust to 1L with dH20 
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2.1.4.3 Buffers for sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
Preparation of 12.5 % Separation Gel 1 gel/ 6 mL 
1 M TrisHCl (pH 8.8)     1.5 mL 
30 % (w/v) acrylamide (AcrylaGel) 2.5 mL 
2 % (w/v) methylamine bisacrylamide (Bis-AcrylaGel) 1.0 mL 
Water  934 µL 
10 % (w/v) sodium dodecyl sulfate (SDS)    30 µL 
10 % (w/v) Ammonium persulfate (APS) (Fresh)   30 µL 
N,N,N',N'-Tetramethylethylenediamine (TEMED)   6 µL 
 
 
Preparation of 4.5 % Stacking Gel 1 gel/ 2.5 mL 
1 M TrisHCl (pH 6.8)     300 µL 
30 % (w/v) acrylamide (Acrylagel) 375 µL 
2 % (w/v) methylamine bisacrylamide (Bis-Acrylagel) 150 µL 
Water  1.625 mL 
10 % (w/v) SDS      24 µL 
10 % (w/v) APS 24 µL 
TEMED        2 µL 
 
10X Electrophoresis Buffer Volume (1 L) 
196 mM Glycine   144 g 
50 mM Tris (pH 8.3)  30 g 
0.1 % (w/v) SDS  10 g 
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4X Loading Dye Volume (10 mL) 
Tris 0.5M (pH 6.8)  2.5 mL 
Glycerol      2 mL 
2-mercaptoethanol  0.5 mL 
20 % (w/v) SDS  2.5 mL 
Bromophenol blue   0.01 g 
Water    2.5 mL 
 
Coomassie Stain   Volume  
(500  mL) 
0.2 % (w/v) Coomassie blue R-250         1 g 
45 % (v/v) Methanol        225 mL 
Water  225 mL 
10 % (v/v) Acetic acid    50 mL 
 
Coomassie Destain Volume (1 L) 
10 % (v/v) Acetic acid  100 mL 
25 % (v/v) Methanol  250 mL 
 Water  650 mL 
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2.1.5 Commercial antibodies and antigens 
 
Reagent Supplier 
Horseradish peroxidase-conjugated goat 
anti-rabbit pAb  
Horseradish peroxidase-conjugated rabbit 
anti-mouse pAb 
Sigma Aldrich,  
3050 Spruce Street, 
St. Louis, MO 63103,  
USA. 
Mouse anti-haemagglutinin (HA) mAb
  
Cambridge Bioscience,  
24-25 Signet Court,   
Newmarket Road,   
Cambridge CB5 8LA,  
UK. 
Horseradish peroxidase-conjugated 
mouse anti-M13 antibody  
GE Healthcare Bio-Sciences AB,  
SE-751 84 Uppsala,  
Sweden. 
 
2.1.6 Commercial kits 
 
Reagent Supplier 
Superscript III reverse transcriptase kit Invitrogen Corporation, 
5791 Van Allen Way, 
Carlsbad, CA 92008,  
USA. 
Wizard Plus SV Miniprep™ kit Promega, 2800 Woods Hollow 
Road, Madison, WI 53711,  
USA. 
QIAquick gel extraction Kit Qiagen, 
28159 Avenue Stanford, 
Valencia, CA 91355, 
USA. 
NucleoSpin® Xtra Midi Plasmid Purification 
Kit 
Macherey-Nagel, 
Fisher Scientific Ireland Ltd., 
Suite 3, Plaza 212, 
Blanchardstown Corporate Park 
2, 
Ballycoolin, 
Dublin 15. 
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2.1.7 Bacterial strains 
 
All strains were purchased from Stratagene, La Jolla, Calfornia, USA. 
 
E. coli TOP10Fʹ strain: {lacIq, Tn10(TetR)} mcrA (mrr-hsdRMS-mcrBC) 
Φ80lacZ M15 lacX74 recA1 araD139 (ara-leu)7697 galU galK rpsL (StrR) 
endA1 nupG. 
 
E. coli XL1-Blue strain: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F′ proAB lacIqZ∆M15 Tn10 (TetR)]. 
 
 
2.1.8 Material for fabrication of  microfluidic plaforms 
 
Material Supplier  
 
Zeonor™ slide 
Zeonor™ SAF chip 
Zeon Corporation, 
Shin Marunouchi Center Building,  
1-6-2 Marunouchi,  
Chiyoda-ku, Tokyo 100-8246, 
Japan. 
 
Poly(methyl methacrylate) 
 
Radionics Ltd.,  
Glenview Industrial Estate,  
Herberton Road, Rialto,  
Dublin 12,  
Ireland. 
 
Pressure-sensitive adhesive  
  
Adhesives Research Ireland Ltd., 
Raheen Business Park, 
Limerick,  
Ireland. 
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2.2 Methods 
 
2.2.1 Production of scFv antibody library 
 
The approach for recombinant antibody generation is based on a standard protocol 
(Barbas et al., 2004). The novelty of the work undertaken was to attempt to generate 
unique scFv antibody fragments against PSP toxins, which have a number of potentially 
different side-groups and would act as different epitopes. In addition, these fragments 
would have His and other tags which would be highly valuable for immobilisation and 
correct orientation of the antibodies to ensure excellent functionality for binding on any 
sensor surface developed.  
                                                                                                                               
Immunisation of a New Zealand white rabbit with paralytic shellfish poisoning (PSP) 
toxin conjugates (NeoSTX-KLH) was successfully performed by Queen’s University 
Belfast (QUB). Serum samples, bone marrow and spleen were also obtained and 
transferred to DCU. In order to determine an immune response against NeoSTX-KLH, 
serum titre analysis was carried out. A NUNC™ 96 well plate was coated with 10 
µg/mL NeoSTX-KLH conjugate and 10 µg/mL KLH overnight at 4oC. The antigen 
solution was flicked out from the overnight plate, wells were blocked with 3 % (w/v) 
milk powder (Marvel) /PBS (150 mM, pH 7.4) solution, 200 µL per well, at 37˚C for 1 
hour. Following blocking, the plate was washed three times with PBST (150 mM, pH 
7.4) and three times with PBS (150 mM, pH 7.4). The immune serum was serially 
diluted from 10-2 to 10-7 in 1 % (w/v) milk powder (Marvel)/0.01 % (v/v) Tween-
20/PBS (150 mM, pH 7.4) and added to the plate. This was incubated for 1 hour at 
37oC; following this it was washed as above. HRP-labelled anti-rabbit polyclonal 
antibody (Sigma Aldrich, Ireland), 100 µL, at a 1/2,000 dilution in a 1 % (w/v) milk 
powder (Marvel) /PBS (150 mM, pH 7.4) solution was added to each well. The plate 
was incubated at 37˚C for 1 hour. Following incubation, the plate was washed as above 
and 100 µL 3, 3', 5, 5' tetramethylbenzidine (TMB) substrate solution (Sigma Aldrich, 
Ireland) prepared in 0.05 M phosphate-citrate buffer, pH 5.0, was added to each well. 
The plate was then incubated for approximately 20 minutes under tinfoil to allow for 
colour development after which the reaction was stopped by addition of 50 µL of 10 % 
(v/v) HCl. The absorbance was then determined at 450 nm with a Tecan™ Safire II 
plate reader (Tecan™, UK). 
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2.2.1.1 Phenol-chloroform extraction of RNA 
 
All tubes and equipment were ‘RNase-free’ or treated with Presept and RNase Zap in 
order to remove all contamination resulting from RNAse. All of the manipulations were 
carried out in a laminar flow cabinet. Both the spleen and the bone marrow were stored 
in RNALater®. Then the RNALater® was normally centrifuged at 2,500 g (Eppendorf 
5810R, bucket rotor A-4-62) for 10 minutes. After removal of RNALater®, 10mL of 
cold Trizol™ was immediately added to the sample and homogenized using a sterile 
homogeniser (autoclaved and baked O/N at 180°C) at 50% output for 45 seconds 
followed by 100% output for 15 seconds. A further 20mL of Trizol™ reagent was added 
and incubated for 5 minutes at room temperature in order to dissociate nucleoprotein 
complexes. Subsequently, the samples were centrifuged at 2,500 g (Eppendorf 5810R 
Rotot A-4-62) for 20 minutes at 4°C. The supernatant containing the genetic material 
was transferred to a polypropylene Oakridge tube and mixed with 6mL of MG-
chloroform by manually shaking for 15 seconds, followed by 15 minutes incubation at 
room temperature. The centrifugation was carried out at 12,000 g using a SS34 rotor for 
25 minutes at 4°C. The RNA solution was concentrated into the upper aqueous layer. 
This layer was carefully transferred to a polycarbonate tube and mixed with 15mL of 
MG-isopropanol by manually shaking for 15 seconds. The sample was incubated at 
room temperature for 10minutes and was centrifuged at 17,000 g (fixed angle, pre-
cooled Sorval SS34 rotor) for 25 minutes at 4°C. An RNA pellet was formed in the 
bottom of the tube. After carefully removing the supernatant and adding 30mL of cold 
75% (v/v) MG ethanol, the final centrifugation was performed at 17,000 g for 20 
minutes at 4°C. The supernatant was removed and the air-dried pellet was gently re-
suspended in 500uL of MG-water. The RNA solution was quantified using the 
NanoDrop™ spectrophotometer ND-1000.  
 
2.2.1.2 cDNA synthesis by reverse transcription PCR 
 
Reverse transcription was carried out using a Superscript III First Strand Synthesis 
System RT-PCR kit. In this protocol, two mixtures were prepared and each of them 
contained a 20X reaction mixture. The details are outlined in Table 2.2.1.2a. Mixture 1 
was dispensed into 8 X 25 µL aliquots and centrifuged before step 1 of the PCR (Table 
2.2.1.2b). The tubes were placed on ice for 1 minute and 25 µL of mixture 2 was added 
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to each tube before step 2 of the PCR program. The contents of four of the tubes were 
pooled together and 20 µL of RNase H was added into each tube (1 µL of RNase H into 
10 µL of reaction mixture).  RNase H was used to digest template RNA from the RNA-
cDNA hybrid. This was then followed by step 3 of the PCR program i.e. the synthesis of 
cDNA. The cDNA obtained was stored at -80 oC. 
 
Table  2.2.1.2a Reverse transcription of PCR. 
 
Mixture 1 1x 20x 
RNA X µL (to give 5 µg) 20X µL 
Oligo-(dT)20 (50 µM) 1 µL 20 µL 
dNTPs (10 mM) 1 µL 20 µL 
MG Water Y µL (to give final volume of 
200µL) 
20X Y µL 
 
Mixture 2 1x 20x 
10X RT Buffer 2 µL 40 µL 
MgCl2 (25mM) 4 µL 80 µL 
DTT (0.1 M) 2 µL 40 µL 
RNase OUT (40 U/µL) 1 µL 20 µL 
Superscript III RT (200 
U/µL) 
1 µL 20 µL 
  
Table 2.2.1.2b PCR program to synthesize cDNA using thermal cycling. 
 
Step Temperature (oC) Time (minutes) 
1 65 5  
2 50 
85 
50  
5  
3 37 20  
 4 Hold 
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2.2.1.3 PCR amplification of antibody light and heavy chain genes 
 
Polymerase chain reaction (PCR) was used to amplify the variable heavy and variable 
light chain antibody genes from the synthesised cDNA. The pComb3XSS series primer 
sequences were obtained from Barbas et al. (2001) and primers were synthesised by 
Eurofins-MWG-Operon. The various primer combinations used for the heavy and light 
variable chains were as follows: 
 
Table 2.2.1.3a Primer combinations for amplification of antibody variable genes. 
  
 
Item Abbreviation Forward Reverse 
 
 
 
Variable light 
chain kappa 
VK1 RSCVK1 RKB9J10-BL 
VK2 RSCVK1 RKB9J0-BL 
VK3 RSCVK1 RKB42J0-BL 
VK4 RSCVK2 RKB9J10-BL 
VK5 RSCVK2 RKB9J0-BL 
VK6 RSCVK2 RKB42J0-BL 
VK7 RSCVK3 RKB9J10-BL 
VK8 RSCVK3 RKB9J0-BL 
VK9 RSCVK3 RKB42J0-BL 
 
Variable light 
chain lambda 
 
VLλ 
 
RSCλ1 
 
RJλo-BL 
 
Variable heavy 
chain 
VH1 RSCVH1 RSCG-B 
VH2 RSCVH2 RSCG-B 
VH3 RSCVH3 RSCG-B 
VH4 RSCVH4 RSCG-B 
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Table 2.2.1.3b Standard multiplex mixture for PCR reactions. 
 
Component Concentration In 50 µL volume 
GoTaq Buffer (5 X) 1X 10.0 µL 
VL/VH Forward 
Primer (100mM) 
60 pM 0.5 µL 
VH/VL Reverse Primer 
(100mM) 
60 pM 0.5 µL 
MgCl2 1.5 mM 3.0 µL 
dNTP (50mM) 0.2 mM 1.0 µL 
cDNA 0.5 µg 1.0 µL 
GoTaq Polymerase 5 U/50 µL 0.25 µL 
H2O - 33.75 µL 
 
In order to efficiently amplify the antibody genes, optimization of the concentration of 
MgCl2 used was essential.   
 
Table 2.2.1.3c PCR program for GoTaq polymerase. 
 
Step Temperature  Time  Number of 
Cycles 
1 95 oC 2 minutes  1  
2 95 oC 
60 oC 
72 oC 
15 seconds  
30 seconds 
60 seconds 
 
30  
3 72 oC 5 minutes  1  
 4 oC Hold  
 
For PCR optimisation of variable light chain kappa 7 and 8 regions, the Phusion® High-
Fidelity DNA polymerase was used. The PCR reaction system was as follows:  
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Table 2.2.1.3d The standard multiplex mixture for the PCR reactions using Phusion 
DNA polymerase. 
 
 
Component Concentration In 50 µL volume 
Phusion Buffer HF/GC (5 X) 1X 10.0 µL 
Forward Primer (100mM) 60 pM 0.5 µL 
Reverse Primer (100mM) 60 pM 0.5 µL 
DMSO 3% (v/v) 1.5 µL 
dNTP(50mM) 0.2 mM 1.0 µL 
cDNA 0.5 µg 1.0 µL 
Phusion DNA Polymerase 1.0 U/50 µL 0.5 µL 
H2O - Make up reaction to 50 µL 
 
 
Table 2.2.1.3e The PCR program for using Phusion DNA polymerase. 
 
 
Step Temperature  Time Number of 
Cycles 
1 94 oC 2 minutes 1  
2 94 oC 
55 oC 
68 oC 
30 seconds 
30 seconds 
30 seconds 
 
30  
3 72 oC 8 minutes 1  
 4 oC Hold  
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2.2.1.4 Splice by overlap extension (SOE) PCR using VELOCITY™ DNA 
polymerase 
 
The primers used in SOE PCR were follows:  
RSC-F (sense) 5´ GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG 
CGG CCG AGC TC 3´ 
RSC-B (reverse) 5´ GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT 
GGC CAC TAG TG 3´ 
 
 
The combined VH and VL genes were generated by pooling amplified VH (VH1-4) and 
VL (VLκ and VLλ) in equivalent molar concentrations and then linked using SOE-PCR.  
 
Table 2.2.1.4a Reaction mix for SOE-PCR. 
 
Component Concentration In 50 µL volume 
HiFi Buffer 
(5 X, contains 10mM Mg2+) 
1X 10.0 µL 
Forward Primer 60 pM 0.5 µL 
Reverse Primer 60 pM 0.5 µL 
DMSO 3% (v/v) 1.5 µL 
dNTP(10mM)  0.2 mM 5.0 µL 
Template: VH 
                  VL 
100 µg 
100 µg 
0.17 µL 
0.2 µL 
VELOCITY DNA 
Polymerase 
0.4 U/µL 1.0 µL 
H2O - Make up reaction to 50 µL 
 
Table 2.2.1.4b The PCR program for SOE-PCR. 
 
Step Temperature  Time  Number of Cycles 
1 98 oC 2 minutes 1  
2 98 oC 
48 oC 
72 oC 
40 seconds 
30 seconds 
2 minutes 
 
30  
3 72 oC 6 minutes 1  
 4 oC Hold  
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2.2.1.5 Agarose gel electrophoresis   
 
Agarose gel electrophoresis was required to analyse the PCR products. A 1% (w/v) 
agarose gel was made up by heating the acetate-EDTA (TAE) buffer containing agarose 
powder at 100oC for 3-4 minutes. At high temperatures, the agarose dissolved in TAE. 
When it was cooled, 5 µL of SYBR®Safe DNA gel stain was added and manually mixed 
and the gel was poured into a prepared gel mold. DNA samples were prepared by 
mixing with DNA loading dye. A 1kb Plus DNA molecular weight ladder was required 
for size quantification. Gel electrophoresis was performed at a voltage of 100V until 
distinct ladder bands were observed.  
 
2.2.1.6 Purification of PCR products from agarose Gel using QIAquick ™ gel 
extraction kit   
 
Following the agarose gel electrophoresis of all the PCR products, the expected DNA 
bands were excised from the gel with a sterile, sharp scalpel, using a Darkreader 
transilluminator. The DNA was purified from the gel using the QIAquick Gel Extraction 
Kit. Once completed, the DNA products were quantified using the NanodropTM and 
stored at -20oC. 
 
2.2.1.7 Plasmid DNA purification  
 
Plasmid DNA purification was carried out using a NucleoBond® Xtro Midi/Maxi kit. 
The Escherichia coli strain, containing the pComb3XSS plasmid was cultured in SB 
broth containing carbenicillin (100 µg/mL) at 37oC overnight in an orbital shaker. 
Subsequently, the harvested bacterial cells were purified using NucleoBond® Xtro 
Midi/Maxi kit. The product was quantified using Nanodrop™ and stored at -20 oC. 
 
2.2.1.8 Restriction enzyme digestion of scFv insert and pComb3XSS vector  
 
SOE-PCR products were digested with restriction enzyme SfiI, whereas the plasmid 
DNA used in this recombinant phage display system was digested using restriction 
enzymes including SfiI, Xbal, and Xhol. After digestion, the pComb3XSS vector was 
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treated with Antarctic phosphatase to prevent re-annealing of the vector. Both digested 
SOE insert and pComb3XSS vector were electrophoresed on a 1.5 % (w/v) agarose gel 
and subsequently gel-purified, using the QIAquick gel extraction kit. Once complete, 
they were quantified using the Nanodrop™ and stored at -20 oC. 
 
Table 2.2.1.8 Components for restriction enzyme digestion of the SOE products and 
pComb3XSS. 
 
 Component Volume 
 
Digestion of SOE-
products 
10 X NEB buffer 2 10 µL 
100 X BSA 1 µL 
SfiI (20,000 U/mL) 18 µL 
SOE products 10 µg 
Water Make up to 100 µL  
 Incubation at 50 oC for 5 hours 
 
 
 
 
Digestion of pComb3XSS 
10 X NEB buffer 2 10 µL 
100 X BSA 1 µL 
SfiI (20,000 U/mL) 6 µL 
pComb3XSS 20 µg 
Water Make up to 100 µL  
Incubation at 50 oC for 5 hours 
Xbal 3 µL 
Xhol 3 µL 
Incubation at 50oC for 5 hours 
10 X Antarctic phosphatase 10 µL 
Incubation at 37oC for 30 minutes, then 65oC for 20 
minutes 
 
2.2.1.9 Ligation of SOE insert into pComb3XSS vector 
 
Ligation of the scFv fragment into pComb3XSS was carried out using T4 DNA Ligase. 
The designed vector pComb3XSS and SOE insert were mixed in a 2:1 (vector/insert) 
ratio. The samples were incubated at room temperature overnight. Additionally, two 
ligation controls were set up as well. The Control 1 was prepared to ligate vector DNA 
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with Stuffer generated from pComb3XSS digestion. The control 2 contained Ligase and 
vector. The components of the ligation reactions are shown in Table 2.2.1.9. After 
transforming each ligation samples by electroporation into E.coli cells, the ligation 
control 1 could be used to indicate the ligation efficiency of vector DNA, whereas the 
ligation control 2 could test the level of background ligation (the detail is discussed in 
next section).   
 
Table 2.2.1.9 Ligation mixtures for cloning rabbit scFv SOE-product into pComb3XSS 
vector. 
 
 Component Volume 
 
Ligation of SOE  
insert into  
pComb3XSS  
vector 
pComb3XSS vector 1.4 µg 
SOE insert 700 ng 
10 X ligase buffer 20 µL 
Ligase 10 µL 
Water Make up to 200 µL 
 
 
Control 1 was set up to check the ligation efficiency: 
 
 Component Volume 
 
Control 1 
 
pComb3XSS vector 140 ng 
Stuffer 140 ng 
10 X ligase buffer 2 µL 
Ligase 1 µL 
Water Make up to 20 µL 
 
 
Control 2 was set up to check re-annealing of the vector: 
 
 Component Volume 
 
Control 2 
 
pComb3XSS vector 140 ng 
10 X ligase buffer 2 µL 
Ligase 1 µL 
Water Make up to 20 µL 
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2.2.1.10 Transformation of XL-1 Blue E.coli cells with pComb3XSS vector 
containing SOE insert 
 
Transformation of the electrocompetent E.coli cells was carried out using the Gene 
Pulser X-cell electroporation system. After completely thawing E.coli cells on ice, 50 
µL of the cells were mixed with each ligation groups which included control and the 
SOE/vector samples. Three tubes were stored on ice for 1 minute. Each sample was 
transferred to a per-chilled electroporation cuvette (2 mm) and electrophoresed at a 
voltage of 2.5 kV and a capacitance of 2S µF, a resistance of 200 Ω. A volume of 1 mL 
of pre-warmed SOC medium was added into each cuvette and the samples were 
immediately transferred to a sterile tube, which contained 2 mL of pre-warmed SOC 
medium. The bacterial cultures were incubated at 37oC for 1 hour with shaking at 
250rpm before inoculation of serial diluted samples onto 2XTY agar plates, which 
contained carbenicillin (100 µg/mL).  These plates were incubated overnight at 37oC.  
 
The size of phage library was obtained by counting the colonies on the vector and scFv 
insert plates and calculating the number of transformants per µg of vector DNA. Ideally, 
the final phage library size should be several times 108 but at least 5×107 total 
transformants. Additionally, colonies obtained from ligation control 1 were counted. A 
yield of 108 colony-forming units (cfu) per µg of vector DNA can indicate good vector 
quality and ligation efficiency. Calculation of cfus per ug of vector DNA in ligation 
control 2 was performed to indicate background ligation, where the vectors were self-
ligated. Ideally, the colony number from control 2 should less than 10% from control 1.  
 
The ligated transformant colonies on the plates were scraped off and resuspended in 
20% (v/v) glycerol, then immediately stored at -80 oC after snap-freezing in liquid 
nitrogen. At this stage the phage library of anti-NeoSTX-KLH was ready for bio-
panning. 
 
2.2.1.11 Enrichment of rabbit phage library via bio-panning against 
immobilized STX-OVA conjugations 
 
The phage library was rescued using a stock of commercial M13K07 helper phage. 
Stored phage library (1mL) was inoculated into 400 mL of 2xTY medium, 
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complemented with 100 µg/mL carbenicillin. The culture was propagated at 37oC in an 
orbital incubator until an OD600 of 0.4 was reached. Helper phage (1mL) was added and 
incubated statically at 37°C for 30 minutes before being transferred to a 37oC orbital 
shaker for 2 hours. A final concentration of 50 µg/mL of kanamycin was added to the 
culture, and incubated overnight at 37°C.   
 
The STX-OVA conjugate was immobilised on NUNCTM immunotubes. The protocol 
was as follows: 500 µL of 50 µg STX-OVA in sterile-filtered PBS solution was added 
into an immunotube, and then left overnight at 4°C. It is crucial to keep the immunotube 
standing upright to ensure the bottom of immunotube was completely coated with 
antigen. The immunotube was blocked with 5% (w/v) milk powder (Marvel) in PBS for 
2 hours. Meanwhile, the phage library that was incubated overnight was harvested by 
PEG-NaCl precipitation.  Firstly, the phage library was centrifuged at 3,220 g in a GSM 
rotor (brake-on) for 15minutes at 4oC. The phage library was precipitated with 4 % 
(w/v) PEG and 3 % (w/v) NaCl by centrifugation on 18,514 g in a GSM rotor (brake-
off) for 20 minutes at 4 oC. The supernatant was poured off and the pellet was allowed 
to drain for 10 minutes before being resuspended in 1mL of KLH-PBS (1mg/mL). A 
further centrifugation step was carried out to precipitate excess bacterial pellet at 8603 g 
in an Eppendorf centrifuge (5018R) for 5 minutes at 4 oC. Subsequently, 500 µL of this 
supernatant was added to the immunotube, which has been washed with PBST (150 
mM, pH 7.4) and PBS (150 mM, pH 7.4). The immunotube was washed with PBST 
(150 mM, pH 7.4) and PBS (150 mM, pH 7.4) after incubation at 37°C for 2 hours. This 
procedure ensures the removal of the weak-binding phage. To elute the bound phage 
library, a 500 µL of 10 mg/mL Trypsin-PBS was added to the washed immunotube and 
incubated at 37°C for 20 minutes. Trypsin, one of the most wildly used enzyme  in 
proteomics, can cleave peptides on the C-terminal side of amino acid, a lysine and 
arginine. The eluted solution was transferred into new clean tube and labeled as  ‘output 
from the first round of panning’. For re-infection, 200 µL of output from the first round 
of panning was added to 4 mL of XL1-Blue cells (OD600 of approximately 0.5) and 
allowed to infect for 30 minutes at 37oC. This was plated onto 2xTY plates containing 
100 µg/mL carbenicillin and incubated overnight at 37oC. Input and output titres were 
determined by counting the number of colonies and calculating the number of 
transformants or colony forming units/mL (cfu/mL). The four rounds of bio-panning 
used are shown in Table 2.2.1.11. 
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Table 2.2.1.11 Details of panning strategy used. 
 
 Pan 1 Pan 2 Pan 3 Pan 4 
Coating conc. 
(STX-OVA) 
50µg/mL 25µg/mL 5µg/mL 2.5µg/mL 
Number of wash 5x 
PBST/PBS 
10x 
PBST/PBS 
15x 
PBST/PBS 
15x 
PBST/PBS 
Culture volume 400mL 100mL 100mL 100mL 
Helper phage volume 1000µL 200µL 500µL 500µL 
 
For soluble expression, the output phage from Pan 4 were re-infected into E. coli 
Top10F′. A volume of 200 µL of Pan 4 output was added into 4 mL of Top10F′ cells 
(OD600 of approximately 0.5) and allowed to incubate for 30 minutes at 37oC. This was 
plated onto 2xTY plates with 100 µg/mL carbenicillin and incubated overnight at 37oC. 
 
2.2.1.12 Polyclonal phage ELISA analysis 
 
A polyclonal phage ELISA was carried out with the output phage from Pan 1, Pan 2, 
Pan 3 and Pan 4. A 96-well plate was coated with 1 µg/mL of STX-OVA and 1 µg/mL 
of Neo-STX-KLH in PBS (150 mM, pH 7.4), and incubated overnight at 4°C. The 
following day, the plate was blocked with 200 µL of 3 % (w/v) milk powder (Marvel) in 
PBS (150 mM, pH 7.4) and incubated for 1 hour at 37°C. After washing 3 times with 
PBST (150 mM, pH 7.4) and PBS (150 mM, pH 7.4), 100 µL of outputs  (1:10 diluted 
in PBS) from each round of panning was added to the plate and incubated at 37°C for 
1hour. A further wash step was carried out to remove the weakly bound phage and then 
100µL of horse-radish peroxidase (HRP)-labelled anti-M13 antibody (diluted 1/1,000 in 
a 1 % (w/v) milk-powder/PBS) was added to each well.  After incubation for 1 hour at 
37°C, the final wash step was performed as above. A 100 µL volume of TMB substrate 
solution was prepared in 0.05M phosphate-citrate buffer, pH 5.0, and then added to the 
plate. The plate was then covered in tinfoil and left for 20 minutes incubation at 37°C. 
The reaction was stopped by addition of 50 µL per well of 10 % (v/v) HCl. 
Subsequently, the absorbance was determined at 450 nm with a Tecan™ Safire plate 
reader. 
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2.2.1.13 Direct monoclonal ELISA of solubly-expressed scFv fragments 
 
Single colonies were picked from pan 4 Top10F′ re-infection plates and transferred into 
sterile non-absorbent 96 well plates, contained 100 µL of SB broth and 100 µg/mL 
carbenicillin. These single clones were incubated at 37oC overnight in an orbital 
incubator and labeled as “stock plates”. Subsequently, 25 µL of each colony was 
transferred into new sterile non-absorbent 96 well plates, which contained 175 µL of SB 
broth and 100 µg/mL carbenicillin. The plates were incubated at 37˚C in an orbital 
incubator until an OD600 of 0.6-0.8 was reached. Meanwhile, the stock plates were 
mixed with 80% (v/v) glycerol to give a final concentration of 20 % (v/v). These plates 
were stored at -80 oC.  To induce expression of the scFv fragments, a final concentration 
of 1mM IPTG was added into each transferred colony culture and incubated at 37˚C 
overnight in an orbital incubator. The plates were then centrifuged at 3,220 g 
(Eppendorf centrifuge 5018R) for 40 minutes. The supernatant was carefully removed 
and the pellets were resuspended in 200 µL sterile PBS (150 mM, pH 7.4). In order to 
extract the periplasmic scFv from the precipitated cells, the plates were freeze-thawed 
three times. After the final thaw, the plates were centrifuged at 3,220 g (Eppendorf 
centrifuge 5018R) for 5 minutes and the supernatant containing the scFv fragment, was 
used for ELISA analysis. 
 
The 96 well ELISA plates (Maxisorp™, NUNC™) were prepared by coating wells with 
1µg/mL of STX-OVA and 1µg/mL Neo-STX-KLH in PBS (150 mM, pH 7.4), and 
incubating overnight at 4°C. The next day, 200 µL of 3 % (w/v) milk powder (Marvel) 
in PBS was added to each well and incubated for 1 hour at 37°C. After 3 washes with 
PBST (150 mM, pH 7.4) and PBS (150 mM, pH 7.4), the plates were incubated with 
100 µL per well of scFv-containing supernatant for 1 hour at 37°C. A further wash step 
was carried out to remove the weakly bound scFv fragments and a 1:2,000 dilution of 
HRP-labelled anti-rabbit polyclonal antibody was added to each well.  After 1 hour 
incubation at 37°C, a final wash step was performed. A 100 µL volume of TMB was 
directly added to the plates followed to 20 minutes incubation in the dark. The reaction 
was stopped using 50 µL per well of 10 % (v/v) HCl, after which the absorbance was 
measured at 450 nm on a Tecan™ plate reader. 
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2.2.1.14 Re-infection into Top10F' cells and scFv check via colony-pick PCR 
 
Individual colonies, which were re-infected into Top10F', were picked from pan 4 agar 
plates and inoculated into 50 µL sterile water for 10 minutes at 95oC to induce cell lysis. 
These lysed samples were PCR amplified, as described in Section 2.3.3. The PCR 
products were analysed by electrophoresis on a 1 % (w/v) agarose gel. 
 
2.3 Methods for development of microfluidic platforms 
 
In the following sections all methods applied for the preparation, processing and readout 
of the immunoassay cartridges are discussed. Initially the structures of the microfluidic 
platforms developed are illustrated. Fabrication methods for the microfluidic platforms 
are then presented. Subsequently, experimental setups for fluorescence-based 
microfluidic investigations are described. Finally, microfluidic immunoassay analysis 
methods are explained. 
 
2.3.1 Structures of microfluidic platforms 
 
In this study, three microfluidic platforms with different complexity of microchannel 
networks were developed. All of the microfluidic platforms were designed using the 
CAD software package Pro/Engineer (PTC, US). These three microfluidic platforms 
had a common feature, which is they consisted of laminated layers, including a Poly-
(methyl methacrylate) (PMMA), a pressure sensitive adhesive (PSA), and a cyclic 
olefin polymer (COP) slide (Zeonor®), or Zeonor slide. The PMMA layers were applied 
to provide big chambers for reagents, such as reservoirs, waste chambers. The PSA 
layers with a 50 µm thickness generally were used to provide microchannels, whereas, 
the COP layers were used as the substrate for solid-phase microfluidic assays. 
 
2.3.1.1 Flow-cell 
 
The flow-cell was a ‘proof-of-concept’ microfluidic platform with a relatively simple 
microchannel network. As shown in Fig. 2.3.1.1, it consists of five laminated layers. 
The first and the third layer were made from PMMA. The former provided loading and 
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venting holes whereas the latter provided reservoirs, valves and venting holes. The 
second and fourth layers of flow-cell were made from PSA, whose role was to provide 
microchannels and stick to the PMMA layers. On these four layers of the flow-cell, 
holes lying at same position provided a pin hole for the flow-cell assembly. The bottom 
layer was Zeonor slide made from COP (Zeonor®), on which the protein A was 
immobilized. The assembled five layers with different patterns constituted the flow-cell, 
which allowed three parallel assays.   
 
 
 
 
 
Figure 2.3.1.1 Schematic of flow-cell structure. The flow-cell contains five layers with 
different patterns: two PMMA layers, two PSA (pressure sensitive adhesive) layers and 
one Zeonor slide. The first PMMA layer acts as a cover of assay system, providing 
various holes. The second PMMA layer provides reservoirs and valves. The main 
functions of the two PSA layers are to adhere the PMMA layers and the Zeonor slide 
together and to provide the microchannels.   
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2.3.1.2 ‘Supercritical angle fluoresence’  (SAF) element compact-disc 
 
This microfluidic platform was also developed in a compact-disc (CD) format in our 
study. It was named a ‘SAF’ element CD due to the application of the supercritical angle 
fluorescence-based optical detection method, which is described in section 2.3.4. The 
‘SAF’ element CD consisted of laminated layers of PMMA, PSA and injection-moulded 
COP SAF (Zeonor® 1060R chips). The five different layers of the ‘SAF’ element CD 
were shown in Fig. 2.3.1.2. Additionally, the structure of ‘SAF’ element CD was 
illustrated in various perspectives. Fig. 2.3.1.2A shows the top view of the different 
layers, including the top disc, top PSA, middle disc, middle PSA and SAF disc. The top 
and the middle disc were made from PMMA. The former (1.5 mm thick) provided 
loading and venting holes whereas the latter (2.0 mm thick) provided reservoirs, and 
valves. The top and middle PSA (50 µm thick) provided microchannels and sticks the 
PMMA discs together. The bottom disc was an injection-moulded Zeonor slide (1.7 mm 
thick), with SAF optical structures. On these five discs, the extra three holes on the 
edges provided pin holes for the CD assembly. Fig. 2.3.1.2B illustrates the 3D layers of 
the ‘SAF’ element CD. The spatial sequence of CD layers is clearly exhibited. Fig. 
2.3.1.2C shows the top view of an assembled ‘SAF’ element CD. It contained 20 
microfluidic units, which allow 20 parallel assays.  This element was carried out in 
conjunction with researchers from the School of Physical Sciences at DCU. 
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Figure 2.3.1.2 Schematics of ‘SAF’ (supercritical angel fluorescence) elements of the 
CD structure at three angles of view. Fig. A shows the top view of the five different 
layers, including: (1) Top disc (1.5mm thick PMMA) with sample loading and air 
venting holes, (2) Pressure sensitive adhesive (50µm thick) with chamber features, (3) 
Middle disc (2.0 mm thick PMMA) with chamber features, (4) Pressure sensitive 
adhesive (50µm thick) with microchannel, (5) Bottom disc (1.7mm thick) with 20 SAF 
ring lens on the lower side. A schematic of the spatial sequence of these five discs is 
given in Fig. B. The top view of assembled ‘SAF’ element CD is illustrated in Fig. C. 
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2.3.1.3  Reagents delivery CD 
 
In the last section, the structure of ‘SAF’ element CD was introduced. In this section, 
another generation of CD which is designed with a combination of SAF detection and 
serial siphon will be described. This new generation of CD possesses advanced features 
of reagents sequential delivery, therefore; it is also named as ‘reagents delivery CD’.  
 
The 3D structure of reagents delivery CD was illustrated in Fig. 2.3.1.3. The reagents 
delivery CD contained four SAF chips and five layers with different patterns. Both layer 
1 and layer 5 were made from 1.5 mm thick PMMA. Layer 1 worked as the cover and 
provided loading and venting holes whereas layer 5 worked as the holder for SAF chips. 
Layer 3 was made from 2.0 mm thick PMMA, containing reservoirs and reagent 
delivery microchannels. Layers 2 and 4 were made from PSA with 50 µm thick 
provided microchannels. In addition, the PSA between PMMA layers worked as 
adhesives. . The four SAF chips with amine groups and optical ring lens, were adhered 
to the CD by a middle layer of PSA. Additionally, two pin holes on the edges were 
designed to assist the CD assembly.  The reagent delivery CD contained four parallel 
functional areas. For each of the assay areas, all four reagent chambers and the centre 
straight chamber were connected with designed serial siphons respectively. A waste 
chamber was designed for collecting reagents. 
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Figure 2.3.1.3 A schematic of reagent delivery CD structure. It shows the six different 
layers, including (1) top disc (1.5mm thick PMMA) with sample loading and air venting 
holes, (2) PSA (50µm thick) with loading and venting holes, (3) middle disc (2.0 mm 
thick PMMA) with reagent chambers and serial siphon features, (4) PBS (50µm thick) 
with assay channel, (5) SAF chips (1.7mm thick) with an amine surface for protein 
immobilization, (6) Bottom disc (1.5mm thick) to seal off the SAF chips.  
 
 
 
2.3.2 Fabrication methods for microfluidic platforms 
 
The microfluidic platforms in this study contain different layers with various materials 
and various sizes of channels, as introduced in the previous section. Therefore, different 
fabrication methods and tools were required to manufacture the micro-components. In 
this section, three machines used in this study are discussed, including a computer 
numerically controlled (CNC) laser cutting machine (Zing 16 Laser, Epilog, USA), a 
CNC milling machine (MDX-40A, Roland, Japan) and a knife-cutter plotter (Graphtec, 
Graphtec CE-2000, Japan). 
 
This laser cutting system was widely applied in manufacturing micro-components 
Layer 1 Top PMMA 
Layer 2 Top PSA 
Layer 3 Middle PMMA 
Layer 4 Middle PSA 
SAF chip 
Layer 5 Bottom PMMA 
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whose feature size is larger than 50 µm (Godino et al., 2012; Gubala et al., 2013; 
Nwankire et al., 2013;) due to the relatively low-cost, quick processing and ease of 
operation. In this study, it was used to mechanically manufacture the relatively large 
components in PMMA, including the outline of the flow-cell and disc, reservoirs, 
chambers and holes on the top layers.  
 
The CNC milling system shows significant potential for the manufacture of small 
micro-components with greater precision and a better surface finish (Karle et al., 2010; 
Mark et al., 2011). In this study, the Roland MSX-40A CNC machine with a powerful 
3D milling device, was applied to precisely manufacture the siphons and capillary 
valves on the middle PMMA layer of the reagents delivery CD.  
 
The cutter plotter was used to cut channels widths as narrow as 200 µm in thinner 
materials such as 50 µm PSA (Bartholomeusz et al., 2005; Siegrist et al., 2010). 
Acutter-plotter (Graphtec, Graphtec CE-2000, Japan) was used to cut PSA patterned 
with micro-components, such as microchannels. 
 
Once the design and machining of the mircrofluidic flow cells/CDs were completed the 
patterned layers of microfluidic platform were aligned and assembled with a 
temperature controlled roll laminator (Hot Roll Laminator, ChemInstruments, USA). 
Each of the mircofluidic structures was inspected for faults and imperfections when 
assembled before they were used for testing.  
 
 
 
2.3.3 Surface modification methods    
 
In this study, COP Zeonor™ was integrated into microfluidic platforms and was used as 
the substrate for solid phase assays. Although COPs have excellent properties for many 
applications, they are lacking in active groups to facilitate covalent functionlisation. 
Additionally, COPs are hydrophobic, and therefore need to be modified to provide 
hydrophilic properties. This can be achieved in several ways: e.g. photografting 
(Stachowiak et al., 2007) ozonolysis (Diaz-Quijada et al., 2007) or using oxygen 
plasmas (Larsson et al., 2007). Surface activation of COPs by use of oxygen plasmas 
was been demonstrated extensively (Borcia et al., 2006; Riyadh et al., 2007; Yu et al., 
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2015). The process of oxygen plasma-based surface modification is commonly applied 
because it is fast and homogeneous and no hazardous chemicals are required. After 
activation by oxygen plasma, the surface of the COP Zeonor™ was cross-linked with 
aminosilanes. APTES is one of the most commonly used aminosilanes due to its simple 
structure and minimal cost. There are two general APTES-based deposition methods i.e. 
liquid-phase and vapor phase deposition. Liquid-phase treatments with aminosilanes to 
create surfaces that are reactive towards antibodies and other specific binding molecules 
have been extensively investigated (Yakovleva et al., 2002; Bange et al., 2005; Kim et 
al., 2011; Nwankire et al., 2014). This method contains multiple steps and therefore is 
not suitable for large-scale production. In contrast to liquid-phase treatment, PECVD 
treatment is a fast and simple route to versatile amine-functionalized surfaces on COP 
plastics by a combination of the oxygen plasm activation method with plasma enhanced 
chemical vapour deposition from an aminated precursor (Volcke et al., 2010). It is a 
single step high throughput process, and is a versatile surface engineering technique 
which has proven to be an excellent tool for surface modification and large-scale 
production that does not leave behind liquid waste (Gandhiraman et al., 2010; 
Gandhiraman et al., 2012). 
                                                                                                                                            
Both surface modification methods were applied and developed in this study. The 
developments involved in the research described in this thesis, such as selection of  
concentrations of APTES applied and the curing times, are discussed in Chapter 4. 
Descriptions of two surface modification methods developed and used in this study 
follow. 
                                                                                                                                       
Before the surface modification step, the COP Zeonor™ slides/chips needed to be 
completely cleaned by ultrasonication to allow effective functionalisation of the surface. 
Hence, a 2% (v/v) solution of Micro-90™ was used to remove oil, grease, resin and any 
biological material by sonication at 50 °C for 30 minutes. Subsequently, the COP 
Zeonor™ slides were rinsed three times with deionised (DI) water and a 100% (v/v) 
solution of isopropyl alcohol. The slides were then rinsed again with DI water and dried 
with a stream of nitrogen. After cleaning, the COP Zeonor™ slides were placed in 
plastic bags and stored in a desiccator.                                                                                                                                                                                  
2.3.3.1 Amine surface functionalisation by liquid phase 
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For the liquid phase-based amine slide functionalisation, a multi-step procedure was 
performed. In this process the surface of the slides were activated by an oxygen plasma 
stream, which promote surface oxidation and hydroxylation (-OH groups). After that, 
the slides were coated with a solution of 3-aminopropyltriethoxysilane (APTES). The 
full procedure is outlined as below.  
 
A microwave-induced plasma was generated by a Harrick plasma cleaner. The 
operating pressure of the chamber was set using a scroll pump and a mass flow 
controller. The oxygen was applied as a gas stream, regulated by the integrated mass 
flow controller and adjusted to approximate 1000 mT. The Zeonor™ chips were 
exposed to the oxygen plasma for 10 minutes. The surface-activated slides were 
immediately placed into a solution of APTES as plasma treatment is highly unstable and 
decays rapidly. A 3% (v/v) solution of APTES that contained 5% (v/v) 2-propanol was 
used to amine functionalise the Zeonor™ slides. The slides were incubated in this 
solution at room temperature for 2 hours (Fig. 2.3.3.1). After functionalisation, the 
slides were ultrasonically cleaned for 15 minutes (2x) using a 100% (v/v) solution of 
isopropyl alcohol. The slides were then baked in an oven at 80 °C for 1 hour.  
 
 
 
Figure 2.3.3.1 A schematic of Zeonor slide functionalisation with plasma treatment and 
liquid-phase APTES deposition. A Zeonor slide was first hydroxylated through oxygen 
plasma treatment, followed by silanization with APTES solution. The –NH2 groups on 
the factionalised Zeonor surface were able to react with proteins. 
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2.3.3.2 Amine functionalisation by chemical vapour deposition 
 
In addition, to the liquid phase APTES surface functionalisation, a second method, 
plasma enhanced chemical vapour deposition (PECVD), was used to amine-
functionalise the surface of the Zeonor slides and the SAF ring lens chips. In contrast to 
liquid phase depositions described above, PECVD treatments tend to produces a more 
homogeneous and denser surface coating (Gandhiraman et al., 2011: Le et al., 2011;). 
 
An Oxford Plasmalab System100 PECVD reactor was used to carry out the deposition 
experiments. The process chamber is configured as a capacitance coupled system with 
an operating frequency of 13.56 MHz. This reactor was capable of distributing gas and 
APTES vapour uniformly in the chamber due to a combination of an electrically 
isolated gas spreader and a radio-frequency (RF) powered showerhead.  
 
Zeonor slides were placed in the chamber, which maintained at a pressure of 200 mTorr 
during all process phases. Prior to APTES deposition, plasma pre-treatment was 
performed to oxidise the surface of Zeonor slide, using a mixture of argon and oxygen, 
and input power was set to 150 W for 3 minutes. After this pre-treatment, oxygen flow 
was stopped; the process power reduced to 5 W, and then APTES vapour was 
introduced to the chamber. The liquid APTES was supplied to the chamber through a 
heated stainless steel canister. There was a tendency of the APTES vapour to polymerise 
between the canister and chamber due to the thermal contours within the gas lines. In 
order to suppress this condensation, which could lead to blockages or loss of flow to the 
chamber, the gas lines used were maintained at an elevated temperature. 
 
After either liquid phase or PECVD APTES treatments, the SAF chips were manually 
spotted with 30 µL of Protein A at a concentration of 10 µg mL-1 and incubated at 4 ºC 
overnight. Subsequently, the chips were blocked for 1 hour at 37 ºC with a 30 µL of a 
1% (v/v) solution of ‘IgG-free’ BSA. The chips were then washed 3 times with PBST 
and PBS, after which they were dried using either a stream of nitrogen or incubation at 
37 ºC for 20 minutes.  
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2.3.4 Hardware instrumentation 
 
2.3.4.1 Supercritical angle fluorescence (SAF) prototype detector 
 
For fluoroimmunoassays, a fluorescence binding protein (NeutrAvidin-Dylight 650) 
was used to detect human IgG. In order to efficiently detect the fluorescence signal, an 
"in house" prototype SAF optical reader system designed by Dr. Dirk Kurzbuch and Mr. 
Martin Sommers (DCU, BDI), was applied. A diagram of the prototype instrument is 
shown in Fig. 2.3.4.1. This prototype instrument allows the detection of low levels of 
analyte in small volumes. The system utilises a SAF signal enhancement element 
known as a SAF lens. Due to its high collection efficiency optics, this device can collect 
a large amount of fluorescent light. Furthermore, SAF detection allows the collection of 
fluorescence only from molecules that are in close proximity to the interface of the 
substrate and the sample solution and not from the bulk solution (Kurzbuch et al., 2009 
& 2013). This important aspect of SAF leads to substantial reductions in background 
signal and can be a substantial advantage over other methods especially in turbid media 
and autofluorescent environments. 
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Figure 2.3.4.1 Schematic representation of the SAF-reader. 
 
A laser diode (Roithner Lasertechnik, Austria) with a wavelength of 635 nm is used to 
excite the chip through a filter (FF01- 625/26-25, Semrock Inc., USA). The parabolic 
collector is made of Zeonex 480R, a high transmission, mouldable plastic, and features 
a diameter of 16 mm and a focal length of 100 mm. An aspheric lens (lens 2, f1 = 5 mm) 
focuses excitation light onto the top surface of the biochip. In the presence of oil 
immersion, supercritical angle fluorescence emitted between 61.5° and 76.0° is 
collected and collimated by total internal reflection at the parabolic surface. A 
planoconvex lens (lens 3 = 30 mm, diameter = 30 mm) is used to focus the emitted 
fluorescence through a detection aperture onto the photomultiplier (H8259-02 PMT 
module, Hamamatsu, Japan). A combination of an emission filter (FF01-676/29-25, 
Semrock Inc.) and detection aperture (diameter = 800 nm) is used to block excitation 
light. In this device, the minimum angle of collection is limited to 61.5◦ by the outer 
radius of the parabolic element, and maximum angle is limited to 76.0◦ due to geometric 
reasons. However, 98% of SAF signal was collected between these two angles. 
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2.4  Immunoassay experimental methods 
 
Initially optimisation of the hIgG fluorescence-immunoassay (FIA) was carried out 
using conventional 96-well microtitre plates. At this stage no surface modifications 
were necessary as microtitre plates are commercially manufactured with high capacity 
protein binding surfaces. 
 
2.4.1 Procedure for conventional hIgG FIA. 
 
Protein A  
Protein A, the IgG capture protein was diluted to 5 µg / mL in PBS (150 mM, pH 7.4) 
and 100 µL was added to the microtitre plate. The plate was covered and incubated at 
4°C overnight. After coating, the plate was washed 3 times with PBST (150 mM, pH 
7.4) and PBS (150 mM, pH 7.4), the plate was emptied and tapped to remove excess 
liquid after each wash cycle. 
 
Blocking 
A volume of 300 µL of 3% (v/v) BSA ‘IgG-free’ in PBS (150 mM, pH 7.4) was added 
to each protein A-coated well. After 1 hour of incubation at 37°C, the plate was then 
washed 3 times with both PBST and PBS. 
 
hIgG samples 
A series of dilutions of hIgG was prepared in PBS (150 mM, pH 7.4) and 100 µL of 
each sample was added to the plate. In addition, a negative control with no hIgG (100 
µL PBS) was also set up. The hIgG samples and the negative controls were then 
incubated at 37°C for 1 hour. Subsequently, the plate was washed 3 times with both 
PBST and PBS. 
 
Secondary antibody 
A biotinylated, secondary anti-human-IgG antibody was diluted to 1:500 in PBS 
(containing 1% (w/v) BSA). One hundred µL of the diluted solution was added to each 
well and incubated at 37°C for 1 hour. After the incubation, the plate was then washed 3 
times with both PBST and PBS. 
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The detector antibody 
A biotin-binding fluorescent protein conjugate, Neutravidin-Dylight 650, was diluted to 
1:500 in PBS and 100 µL of the diluted solution was added to each well. This was 
followed by incubation at 37°C for 1 hour, the plate was washed 3 times with both 
PBST and PBS. 
 
Fluorescence detection 
After addition of 100 µL of PBS to each well, detection was carried out on a Tecan 
Microplate ReaderTM with excitation at 654 nm and emission at 673 nm. The raw 
fluorescence signal values from each well were saved in an excelTM file. 
 
2.4.2 Procedure for FIA on microfluidic flow-cell devices 
 
Once the surface modification was complete, 30 µL of a solution of 10 µg/mL Protein A 
was spotted onto the Zeonor slide. After overnight incubation at 4 °C, the slide was 
blocked with 3 % (v/v) BSA in PBS. Following incubation at 37°C for 30 minutes, the 
slide was carefully rinsed with 1XPBST and PBS, and then carefully dried with 
nitrogen. Subsequently, the five layers of the flow-cell device were manually assembled 
in a clean room.  
 
The flow-cells were fitted into a ‘CD-like’ holder (Fig. 2.4.2). This holder was then 
placed onto an instrument which allows for centrifugal spinning, i.e. on the spin test 
stand. In total 30 µL of each of the assay reagents (BSA, PBS, hIgG, anti-human IgG 
and Neutravidin-DyLight) were sequentially loaded into a loading hole on the 
microfluidic flow cell. Centrifugal force was used to flow each solution over the protein 
A spot. The spin rate was adjusted manually to ensure that each liquid flowed at roughly 
the same speed. Each solution was removed from the microfluidic flow cell waste 
chamber before the addition of the next solution. After the addition of each solution the 
microfluidic flow cell was incubated at room temperature for 5 minutes. Fluorescence 
was measured immediately after the last wash step using the prototype SAF reader 
system. The excitation and emission wavelengths were 652 nm and 672 nm, 
respectively. 
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Figure 2.4.2 Illustration of holder for flow-cell immobilisation. 
  
2.4.3 Procedure for FIA analysis on microfluidic CDs 
 
In this section a description is given of the microfluidic FIA analysis, which utilises two 
different types of microfluidic CDs, shown in Fig 2.3.1.2 and Fig. 2.3.1.3.  
 
FIA analysis using SAF elements CD 
 
Prior to performing hIgG FIA analysis reagents were diluted with PBS (150 mM, pH 
7.4). In addition, a biotinylated anti-human-IgG antibody, and a Neutravidin-Dylight 
650 were diluted in PBS (150 mM, pH 7.4) at a ratio of 3:1. This mixed solution was 
covered with tinfoil and incubated at 37oC for 20 minutes. The FIA reagents (30 µL) 
were sequentially added in the reagent chambers through the loading hole, and 
centrifugally propelled across the ‘protein A’ capture spot. The loading sequence was as 
follows: BSA (3% (v/v) in PBS), hIgG standards, PBS (150 mM, pH 7.4), fluorescent 
detector reagent, and PBS (150 mM, pH 7.4). Fluorescence was measured immediately 
after the last wash step using our prototype SAF reader system. 
 
FIA analysis using reagents delivery CD  
 
Prior to microfluidic FIA testing, reagents were diluted with PBS and Tween® 20 (TW-
20) (PBST). In addition, a biotinylated secondary anti-human-IgG antibody, and a 
Neutravidin-Dylight 650 were diluted in PBS (150 mM, pH 7.4) at a ratio of 3:1. The 
fluorescent detection reagent was subsequently incubated in the dark at 37oC for 20 
minutes. FIA reagents (30 µL) were added in their designated chambers, and propelled 
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across the ‘protein A’ capture spot. The delivery sequence and TW-20 concentrations of 
the FIA reagents were as follows: BSA (1 % (w/v) in PBST with 0.6 % (v/v) TW-20), 
hIgG standards (0.16, 0.8, 2, 4, 20, 50, 100 µg mL-1) and diluted bioprocess sample 
(PBST with 0.6 % (v/v) TW-20), wash solution 1 (PBST with 0.4 % (v/v) TW-20), 
fluorescent detector reagent (PBST with 0.7 % (v/v) TW-20) and wash solution 2 
(PBST with 0.4 %v/v TW-20). Fluorescence was measured immediately after the last 
wash step using the prototype SAF reader system. The excitation and emission 
wavelengths were 652 nm and 672 nm, respectively.  
 
2.5 Immunoassay data analysis methods 
 
2.5.1 Fitting of microfluidic FIA curves and analysis of bioprocess samples using 
SigmaPlot®  
 
Quantitative immunoassay relies on a calibration curve to determine the analyte 
concentration in samples from the intensity of signal produced. The calibration curve is 
a plot of calibrator concentration against signal level. The SigmaPlot® software was 
used in this research to fit data generated by the microfluidic hIgG FIA curves. In 
addition, industrial bioprocess samples were also analysed. The macro panel in Fig. 
2.5.1 shows the various standard curve options. Analysis was performed as follows: 
 
(1) Select the 4-PL equation from the equation list and use this function to fit the 
curve  
(2) Select the columns to use for the X and Y data from the X data column and Y 
data column drop list boxes.   
(3) Use the Log format X data checkbox to select whether or not to plot the X-
axis using a common log-scale.  
(4) Select the ‘Predict unknowns’ option to compute results using the solution to 
the fit. Also select the Plot predicted values checkbox to plot the predicted values on 
standard curve. 
(5) When finished, click OK. A standard curve is created with plotted drop lines 
to indicate the unknown values.  
 
A sample of a plotted standard curve with indicated unknown is shown in Fig. 
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2.5.1 For the standard curve, the concentration valves were plotted against the response 
(with error bars), and the lines of dashes indicated the X and Y values of the unknowns. 
 
 
  
Figure 2.5.1 Illustration of the micro panel tabs in the Sigma Plot software. 
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2.5.2 Fluorescence image analysis using the Andor camera 
 
Fluorescence assay spots from microfluidic CD/slides were imaged using a (Olympus 
IX71) microscope that incorporated a unique camera (ANDOR iXon 885). The Andor 
camera was chosen as it has extreme sensitivity, rapid frame rates and high resolution. 
In this fluorescence microscope, polychrome V (PV) was used as the excitation light 
because 1) it provided the user with the ability to adjust the excitation wavelength and 
2) it shows over 60% quantum efficiency (QE) at 652nm, which is the wavelength of 
light needed to excite the NeutrAvidin DyLight-650 fluorophore.  In addition, this 
highly sensitive microscope also contains advance image analysis software.                                                                       
 
Each of the SAF ring lens chips was cut out of the CD using the CNC milling machine. 
Each ring lens chip was then analysed using the 4X objective lens on the Andor camera. 
A green filter was used for FLISA spot image generation as this offered better image 
clarity than the corresponding red filter. The image of emission light of the NeutrAvidin 
DyLight-650 fluorophore at a wavelength of 672nm was collected and then analysed 
using the microscope’s image analysis software.  
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2.6 Computational simulation   
 
Microfluidic networks offer several advantages over conventional microtitre plates 
where the assays are performed using much larger volumes and longer times. However, 
to take full advantage of microfluidic networks, it is important to understand the 
influence of factors (such as flow velocity, channel height and capture area length) on 
binding kinetics and to identify the major parameters affecting assay performance in 
microfluidics. In this section, theoretical models applied to investigate the effect of 
these factors are introduced.  
 
2.6.1 Theoretical models 
 
As shown in Fig. 2.3.1.3, the microfluidic networks are complicated due to the 
sequential delivery of reagents. However, the characteristics of assay related 
microchannels are simple as illustrated in Fig. 2.6.1. 
 
 
 
Figure 2.6.1 Schematic diagram of 2D model of the microchannel. The analyte 
molecules flow into this microchannel with a velocity which shows a parabolic profile. 
Then they will be transported to the capture area (functionalized and located between  
2×10-3 to 3×10-3 m on the wall), through convection and diffusion. The boundaries of 
this model were divided into six different surfaces with distinct conditions. 
 
This microchannel has a length of 6000 µm and height of 50 µm. The capture area had a 
length of 2000 µm. In the application, Protein A was immobilized on the capture area to 
bind IgG molecules. When the IgG in bulk solution flowed into the microchannel with a 
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certain velocity, there are three processes involved: (1) convection along the x-axis of 
the microchannel; (2) diffusion from the bulk solution to the capture area and (3) 
adsorption on the surface by binding to Protein A (Gulliver et al, 2007; Parsa et al., 
2008). These three processes are described by the convection-diffusion equation of the 
form !"!" = !∆! − !∇! + !                                       Equation (1) 
 
where !  is the  concentration of analytes in bulk solution, !  is the diffusion 
coefficient of analyte, !  is the value of local velocity of bulk solution in the 
microchannel, and R is the source term (Berthier et al., 2010). This partial differential 
equation obeys the law of conservation of mass, where the changes of analyte 
concentration in bulk (the left-hand side) equal the sum of replenishment of analyte by 
transport (diffusion and convection) and the consumption due to adsorption (the right-
hand side). Inside a rectangular microchannel with micrometer height, the fluid is 
typically laminar (Reynolds number Re<<1). Hence, the velocity profile is a Hagen-
Poiseuille flow profile (parabolic flow profile), with maximum velocity at the geometric 
center of the microchannel and zero velocity at the wall of microchannel (Berthier et al., 
2010). Therefore, ! in the microchannel is inconsistent. In the 2D case of a rectangular 
microchannel, the value of ! along vertical axis is 
 
                                          ! ! = !! ![1− ( !!/!)!]                                     Equation (2) 
 
where ! is the average velocity of fluid, ! is the height of microchannel (Berthier et 
al., 2010). The value of ! is the distance from random point to center of cross section of  
the microchannel. The source term !, in Eq. 1, represents the process of molecular 
adsorption from bulk to surface in our application. It can be described by a Langmuir 
equation 
                                       !!!!" = !!"!! Γ!"# − Γ! − !!""Γ!                      Equation (3) 
 
      where !!" and !!"" represent the association constant and dissociation constants, 
respectively. Γ is the concentration of adsorbed analyte on the surface by the capture 
molecule. Γ!"# is the maximum surface density of binding sites on the wall. !! is the 
analyte concentration in a solution layer adjacent to the capture area.  
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The relationship between the rate of analyte adsorption and the concentration gradient 
of analyte in solution layer on the wall is described by Fick’s law (Equation 4), 
 !!!" = −! !"!!! = −!∇!                                          Equation (4) 
 
To simulate the adsorption products concentration field, the Eq. 1 can be coupled to Eq. 
3 via Eq.4. The derivative equation is 
 
                                                Γ = !∇!!!!"!!!!"#!!"!!!!!""                                           Equation (5) 
 
In order to solve equations (1, 3 and 5) and simulate the behavior of analyte convection-
diffusion-adsorption in this particle microchannel, a set of additional restraints at the 
boundary domains (called the boundary conditions) were defined. These are based on 
the accurate modeling study by Squires’s group (Squires et al., 2008). The numerical 
approach applied to solve the ordinary differential equations (ODEs) was a finite 
difference approach based on the Crank-Nicholson semi-implicit scheme (Berthier et 
al., 2010). ! is the unit normal vector directed out of a surface. 
 
      Surface (1) →   0 ≤ !! ≤ !, ! = 0,! = !!                                                      (6) 
       
Surface (2) →   0 ≤ !! ≤ !, ! = !,!!∇! = 0                                                (7) 
 
Surface (3) →   0 ≤ ! ≤ !,!! = 0,!!∇! = 0                                                 (8) 
               
Surface (4) →   0 ≤ ! ≤ !!!! ,!! = 0,!!∇! = 0                                             (9) 
     
Surface (5) → !!!! ≤ ! ≤ !!!! , 0 ≤ !! ≤ !, !!!" = −! !"!"!                               (10) 
       
Surface (6) → !!!! ≤ ! ≤ !,!! = 0,!!∇! = 0                                              (11) 
 
Boundary condition (6) ensures that the input analyte solution has a consistent 
concentration, C0. Boundary conditions (7) (8) (9) and (11) define that no analyte 
diffuses out through the microchannel. The ‘Boundary condition’ (10) infers that the 
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analytes adsorption only happened at surface (5) and the adsorption kinetics of analyte 
at this functionalised capture surface (5) obeys Fick’s law. 
 
2.6.2 Numerical approach 
 
The numerical approach applied to solve the ordinary differential equations (ODEs) was 
the Crank-Nicholson semi-implicit scheme (Press et al., 1987). The details are included 
in Appendix chapter. 
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Generation of an Anti-
Neosaxitoxin Rabbit scFv Library 
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3.1 Introduction 
 
With the frequent worldwide occurrence of red tides, marine toxins have recently 
received a lot of attention. Paralytic shellfish poisoning (PSP) toxins are among the 
most deleterious marine neurotoxins, because of the severe effects these toxins can 
induce on humans. PSP are produced mainly by planktonic dinoflagellates, which 
belong to the genera Alexandrium and Gymnodinium. PSPs are ingested by plankton 
feeders such as bivalves and the toxin leaves appreciable amounts of PSP in their 
digestive glands. Although the toxin does not harm the bivalves, it can cause serious 
illness or death for people who consume the contaminated bivalves. No visible 
difference in appearance can be observed between harmless and toxic shellfish or water. 
Furthermore, PSP toxins are stable under high temperature. Therefore, they cannot be 
killed by cooking or freezing (Campbell et al., 2010). Symptoms of PSP can set in 
almost immediately or within hours. They include a tingling sensation that starts in the 
lips and tongue and moves to the hands and feet. This can be followed loss of control of 
the limbs, difficulty breathing. Depending on the amount of toxin ingested, PSP can 
paralyze breathing function and cause death in as little as 15 minutes. Currently, 
medical treatment for PSP is to provide respiratory support for patients and there is no 
antidote for PSP as the palliative care (Humpage et al., 2010). 
 
Fig. 3.1 shows that outbreaks of PSP found in Europe from 1993 to 2002 
(http://oceanworld.tamu.edu/resources/oceanography-book/harmfulagalblooms.htm). 
During the 10 years period, PSP toxin was presented in a significant high frequency in 
these coastal states, including Norway, Ireland, United Kingdom, France, Portugal and 
Spain. In the last decade, the presence of high levels of PSP toxins were reported 
continuously all over the world. For example, many PSP cases were discovered near 
Puget Sound, California and Northern Channel Islands in 2012, and Alaska in 2014, 
according reports by Food Poisoning Bulletin 
(http://foodpoisoningbulletin.com/tag/paralytic-shellfish-poison-psp/).  The frequently 
outbreaks of PSP seriously threaten human health. Additionally, it causes economic 
losses in coastal communities and aquaculture industries worldwide.  
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Figure 3.1 Outbreaks of PSP toxins in the coastal water in Europe during the year from 
1993 to 2002 (adapted from Harmful Alfal Blooms, last accessed on 1st Sep 2014, 
retrieved from http://oceanworld.tamu.edu/resources/oceanography-
book/harmfulagalblooms.htm). 
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3.1.1 Paralytic shellfish poisoning toxin (PST) 
 
Paralytic shellfish poisoning can cause respiratory-related death. The mode of action of 
PSP toxicity is that it can block sodium channels in excitable membranes, which leads 
to the stoppage of the propagation of neuronal impulses (Maria et al., 2014). The PSP 
toxins cover a group of toxins components whose structures are similar but with 
different groups (hydroxyl, carboxyl and sulfate moieties) at four sites on the backbone 
structure. Table 3.1.1a illustrates the isoform structures commonly observed in toxic 
dinoflagellates and toxin-contaminated shellfish, and it shows that these components are 
derivatives of Saxitoxin (STX) (Andrew et al., 2014).  
 
PSP toxins are generally water-soluble and heat stable. However, stability can change 
significantly depending on the pH and the toxins’ structure (Etheridge, 2010). For 
instance, toxin components degrade quickly at an alkaline pH. In most cases, toxins are 
stable under acidic conditions. Nevertheless, the stability of each PSP toxin depends on 
characteristics of the structure e.g. STX is very stable. 
 
Importantly, the potency of each toxin is dependent on its structure (Campbell et al., 
2011). Table 3.1.1b shows the specific toxicity of each toxin component expressed as 
mouse units (MU) per µmole of toxin, in which 1 MU is a dose of toxin that can kill a 
male mouse (ddY strain) in 15 min. The carbamate toxins are the most potent and they 
include STX, Neo and GTX1/4. The decarbamoyl toxins (dcSTX, dcNEO, dcGTX1/2) 
have intermediate toxicity and are reported in certain bivalves, but are not commonly 
found in toxic dinoflagellates. The N-sulfocarbamoyl toxins (GTX5 and C1/4) are less 
potent (Tatters et al., 2013). 
 
Bioconversion of PSP toxins components in shellfish has been demonstrated (Jeon et 
al., 2008).  Accumulated ciguatoxins (CTX) in shellfish gradually transform to STXs, 
and this transformation can occurred widely in many ecosystems. In addition, the rate of 
transformation is reported to be very slow, suggesting that the reaction is not enzymatic. 
However, this activity is not stable, and could be promoted by thiol compounds, 
especially glutathione (GSH)a biological reductant that is distributed widely in 
different organisms. 
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Table 3.1.1a Structures of PSP toxins components (adapted from Andrew et al., 2014).  
 
 
Component  R1 R2 R3 R4 
Saxitoxin  H H H CONH2 
Neosaxitoxin  OH H H CONH2 
Decarbamoyl saxitoxin  H H H H 
Decarbamoyol 
neosaxitoxin 
  
OH 
 
H 
 
H 
 
H 
Gonyautoxin 1  OH OSO3− H CONH2 
Gonyautoxin 2  H OSO3− H CONH2 
Gonyautoxin 3  H H OSO3− CONH2 
Gonyautoxin 4  OH H OSO3− CONH2 
Gonyautoxin 5  H H H CONHSO3− 
Gonyautoxin 6  OH H H CONHSO3− 
Decarbamoyol 
gonyautoxin 1 
 OH OSO3− H H 
Decarbamoyol 
gonyautoxin 2 
 H OSO3− H H 
Decarbamoyol 
gonyautoxin 3 
 H H OSO3− H 
Decarbamoyol 
gonyautoxin 4 
 OH H OSO3− H 
C1  H OSO3− H CONHSO3− 
C2  H H OSO3− CONHSO3− 
C3  OH OSO3− H CONHSO3− 
C4  OH H OSO3− CONHSO3− 
 
 
 
 
Common structure 
for PSP toxins 
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Table 3.1.1b Specific toxicity of each component (adapted from Tatters et al., 2013). 
 
Component Specific Toxicity (MU) 
STX 2483 
neoSTX 2295 
deSTX 1274 
GTX1 2468 
GTX2 892 
CTX3 1584 
GTX4 1803 
dcGTX2 1617 
dcGTX3 1872 
GTX5 160 
C1 15 
C2 239 
C3 33 
C4 143 
  
1MU is a dose of toxin that can kill a male mouse in 15 minutes 
 
3.1.2 Methods for PSTs detection  
 
To date, several methods for detecting PSP toxins are available. The mouse bioassay is 
the most commonly used method to determine the presence of PSP toxins. It is 
accredited by the Association of Analytical Communities (AOAC) and accepted 
internationally as the official method in most countries for the quantitative measurement 
of the PSP toxins in shellfish (Horwitz, 2000). The mouse bioassay is performed by the 
application of potentially contaminated samples on mice or rates, and then monitoring 
of the symptoms and time to death. The toxicity of sample can be directly analysed 
though this method. However, ethical issues due to the utilization of animals exist. 
Additionally, this assay shows many technical limitations, including: poor specificity 
with low sensitivity, low sample throughput, high cost and it is labor-intensive 
(Humpage et al., 2010; Turner et al., 2012). 
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Chemical methods used for the determination of PSP toxins include high performance 
liquid chromatography (HPLC) methods with fluorescence detection (Asp et al., 2004; 
Lawrence et al., 2005), liquid chromatography/mass spectrometry (LC/MS) (Song et 
al., 2013), and capillary electrophoresis (CE) (Juan-Garcia et al., 2005). Some chemical 
methods are non-quantitative, and do not enable identification of the different 
components of PSP toxins in the sample but yield an overall estimate of total toxin 
content. Additionally, these methods are time-consuming, costly, and labor-intensive.  
 
Immunochemical-based techniques, like ELISA, are developed for analytical detection 
of PSP toxins. In the last decade, this approach was increasingly established in their use 
for toxicology screening (Wong et al., 2010; Garet et al., 2010; Fraga et al., 2013; 
Szkola et al., 2013; Kawatsu et al., 2014), because it provided a rapid and effective way 
to detect toxins in complex biological matrices without major purification by utilization 
of antibodies.  
 
3.1.2.1 Antibody-based methods for PST detection 
 
Many heterologous assay formats have been developed to detect PSTs. Generally, the 
assays show high sensitivity, but inaccurate results as a result of the antibody specificity 
(Dubois et al., 2010). Several developed antibodies for detecting PSTs are outlined in 
Table 3.1.2.1. These antibodies show cross-reactivity to the different components of 
PSTs, which causing specificity issues relating to the analysis of sample with diverse 
components. For example, the monoclonal antibody raised to GTX 2/3 illustrated 100% 
cross-reactivity to GTX 2/3 but less cross-reactivity to the other toxin analogues 
(Campbell et al., 2007). Therefore, it can be applied to quantitatively analyse the 
amount of GTX 2/3 in samples lacking other toxins. However, it could induce 
underestimation and overestimation issues when applied to screen real unknown 
samples. For regulatory purposes, underestimation could have severe health 
implications to the consumer whereby contaminated material is declared safe for 
consumption, whereas overestimation could cause detrimental economic losses to the 
industry through the unnecessary closure of harvesting beds.   
 
A novel approach to alleviate the problem of underestimation of results is to combine 
two or more antibodies of varying reactivity into the test format. Several assays have 
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been investigated (Jellett et al., 2002; Campbell et al., 2009; Bratcher et al., 2011; 
Campbell et al., 2011; Zhang et al., 2014). In these assays, cocktails of antibodies raised 
to different PSPs analogues were employed. Therefore, the overall PSPs can be 
quantified in a sample. Additionally, these assays were simple, rapid, sensitive and gave 
high output. Compared with the mouse bioassay and the chemical methods, they are 
more suitable for PSP toxin screening, but are incapable of indicating exact toxicity of 
samples.  
 
Ideal antibodies applied to detect PSP toxins in samples should possess a similar cross-
reactivity to a full range of PSP toxins. This is because an antibody with different cross-
reactivity to various components of PSP toxins is incapable of accurate detection of 
various components of PSP toxins in samples. However, the ideal antibody is not 
available. Currently, the accuracy of these developed assays depends heavily on the 
toxin profile. Therefore, these methods have the limitation in determination of overall 
PSP toxicity in the samples containing several PSPs.  
 
It was reported that antibodies raised against STX groups had low cross-reactivity to 
NeoSTX groups, and vice versa, if PSPs were subdivided into STX (non-hydroxylated) 
and NeoSTX (hydroxylated) groups from an immunological point of view. Therefore, to 
incorporate the full spectra of PSP toxins to an equivalent extent, antibodies produced to 
both the non-hydroxylated (STX) or hydroxylated toxins (NEO) will have to be utilized 
(Usleber et al., 2001). 
 
Thus, Chu et al. found poor correlation between assays based on either anti-STX 
antibodies or anti- neoSTX antibodies, but combining the results from the two assays 
markedly improved the detection rate, to the extent that these authors concluded that 
their combined use could screen out 80–85% of MBAs that produce negative or low 
positive results. Continuing the theme of multiple assays to improve specificity, 
Kawatsu et al. raised monoclonal antibodies (designated GT-13A) to GTX2/3 to 
complement those previously raised against STX and neoSTX. These antibodies 
retained the STX/neoSTX lineage discrimination found in other antibodies, but did have 
a near equal affinity for GTX2/3, dcGTX2/3, and C1/2. This multiple assay approach 
was taken even further by Garthwaite et al., who recommended the use of a suite of 
ELISAs to screen shellfish samples for not only PSTs, but also amnesic, diarrhoeic, and 
neurotoxic shellfish poisons. 
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Table 3.1.2.1 Outline of developed antibodies for PSTs detection. 
 
       Antibody  
    Type 
Immunogen Specificity 
(from high to low)  
        Ref. 
STX Polyclonal Ab 
(Rabbit) 
STX-FA-BSA STX,  
GTX 1/4 
Chu and Fan, 
1985 
STX Polyclonal Ab 
(Rabbit) 
STX-FA-KLH STX,  
dc-STX,  
GTX 2/3,  
NeoSTX,  
B1,  
C1/2,  
GTX 1/4 
Renz, 1988 
STX Polyclonal Ab 
(Rabbit) 
STX-GA-poly-
alanine lysine 
STX,  
NeoSTX,  
GTX 2/3 
Cembella et al., 
1990 
STX Monoclonal Ab STX-PJ-Gox STX,  
GTX2/3,  
dc-STX,  
B1,  
NeoSTX,  
GTX1/4,  
C1/2 
Dietrich et al., 
1996 
Neo-STX Polyclonal Ab 
(Rabbit) 
Neo-FA-KLH NeoSTX,  
GTX 
Chu et al., 1992 
Neo-STX Polyclonal Ab 
(Rabbit) 
Neo-PJ-GOx NeoSTX,  
GTX 1/4,  
STX,  
GTX 1/4 
Burk et al., 
1995 
GTX 2/3 Monoclonal Ab GTX 2/3-KLH GTX2/3,  
dc-GTX2/3,  
C1/2,  
GTX 1/4,  
STX,  
NeoSTX 
Kawatsu et al., 
2002 
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3.1.2.2 Leporine host 
 
Immunoglobulin (Ig) rearrangements are a major contributor to the generation of a 
diverse primary antibody repertoire.  During the Ig rearrangement, heavy and light 
chain variable region are assembled in developing B lymphocytes (Sehgal et al., 1999). 
The heavy chain variable region is composed by variable (V), diversity (D) and joining 
(J) gene segments, while light chain variable region consists of V and J gene segments. 
Unlike rodents and other primates, the antibody diversity generated by VH(D)JH 
rearrangement in rabbits does not depend on the use of many variable gene segments. In 
rabbits, one out of >50 functional VH gene segments, VH1, is predominently used 
(Becker et al., 1990; Bassing et al., 2002). The advantage of this for recombinant 
antibody work is that a relatively small number of primer sets are required, compared to 
mice and other primates.  
 
In contrast to VH, the rabbit light kappa chain (VKJK) rearrangements are much more 
diverse. Rabbits have two K chain isotypes, κ1 and κ2.  Normally, ~70-90% of the 
serum antibodies are the K1 isotype in rabbit. In the mutant Besilea strain, K2 isotype is 
predominantly expressed. κ1 includes four different allotyoes, b4, b5, b6 and b9 
(Popkov et al., 2003). After rearrangement, diversity of the rearranged VH (D)JH and 
VKJK are further developed by of somatic hypermutation and gene conversion-like 
changes in B-cells, which migrate to the appendix and other gut-associated lymphoid 
tissues (GALT) in young rabbits.  Thus, the K light chain appears to be a major 
contributor toward the generation of the antibody diversity of the rabbit immune 
repertoire. Although, antibody diversity generated by VHDJH rearrangements in rabbits 
is much more restricted than in mice or humans, a significant amount of diversity is 
obtained from VKJK rearrangements.  
 
The unique diversification and gene rearrangement features of the rabbit make it an 
ideal choice for recombinant antibody development as it combines high specificity with 
high avidity and affinity (Rader et al., 2000). 
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3.2 Aim of this chapter 
 
The objective of the research discussed in this chapter was to generate and isolate 
antibodies that would recognise a range of saxitoxin derivatives such as neosaxitoxin, 
gonyautoxin, decarbamoyl and saxitoxin itself.   
 
3.3 Results 
 
3.3.1 Immunisation of rabbit with Neosaxitoxin-KLH 
 
Immunisation of a rabbit with NeoSTX-KLH conjugation was successfully performed 
by Queen’s University Belfast (QUB). Serum samples, bone marrow and spleen were 
also obtained and transferred to DCU for use. The serum was tested by direct ELISA 
using three conjugates: Neo-STX-BTG, GTX1-4-PER and STX-OVA, which were 
synthesized at QUB. The serum from the NeoSTX-KLH-immunised rabbit also showed 
cross reactivity to STX-OVA. 
 
3.3.2 Isolation of RNA from bone marrow and spleen and first-strand DNA 
sysnthesis 
 
Bone marrow and spleen were extracted from the immunised rabbit and phenol-
chloroform extraction was carried out for isolation of RNA. The cDNA from both the 
bone marrow and spleen were synthesised by reverse transcription. Subsequently they 
were quantified and pooled in a 1:1 ratio.  
 
3.3.3 Amplification of rabbit antibody heavy and light chains and PCR 
optimisation 
 
In order to obtain a sufficient quantity of genetic material for antibody gene library 
construction, magnesium chloride (MgCl2) concentration gradient from 0.5mM to 6mM 
was employed in the PCR (Fig 3.3.3.1). In addition, Go Taq® DNA polymerase was 
used. The condition of 100pmol primer combinations and 2mM MgCl2 provided the 
clearest target band (~400bp) with the least non-specific amplification (~700bp), as 
shown in Fig 3.3.3.1.  
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Figure 3.3.3.1 PCR optimisation of rabbit variable heavy chain (~400 bp) genes using 
different primer combinations and increased MgCl2 concentrations. In the group 1, 
primer combination with a concentration of 100 pmol was applied in the PCR reaction 
system. In the group 2, 200 pmol of primer combination was used. In each groups, the 
concentrations of MgCl2 from lane A to lane G were 0, 1, 2, 3, 4, 5 and 6 mM, 
respectively. Lane M represents a 1KB plus DNA ladder.  
  
          Group 1 – Primer (100 pmol) 
 Group 2 – Primer (200 pmol) 
      M       A        B       C      D        E       F      G 
  1000bp 
    400bp 
    400bp 
  1000bp 
      M       A        B       C      D        E       F       G 
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Large-scale PCR amplification of the variable heavy chains was carried out using the 
optimised conditions. These were shown to be a 100 pmol primer combination and 
2mM MgCl2. The correct band of 400 bp was isolated using gel electrophoresis and 
purified using QIAquick gel extraction. 
 
 
 
Figure 3.3.3.2 Amplification of rabbit heavy chain genes (~400bp amplicon) using the 
cDNA from a Neosaxitoxin-immunised rabbit. The 4 combinations for the heavy chain 
regions were amplified successfully, utilising the primer combinations; RSCVH1 and 
RSCG-B (VH1), RCSVH2 and RSCG-B (VH2), RSCVH3 and RSCG-B (VH3), and 
RSCVH4 and RSCG-B (VH4). Lane M represents a 1 KB plus DNA ladder. Lanes A to 
D represent VH1, VH2, VH3, and VH4, respectively.  
 
 
  
  M      A                   B                   C                   D 
  1000bp 
    400bp 
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In the next stage, PCR amplifications were carried out for the variable light (kappa) 
regions, using the primers sets RSCVK1 and RKB9J10-BL (VK1), RSCVK1 and 
RKB9Jo-BL (VK2), RSCVK1 and RKB42Jo-BL (VK3), RSCVK2 and RKB9J10-BL 
(VK4), RSCVK2 and RKB9Jo-BL (VK5), RSCVK2 and RKB42Jo-BL (VK6), RSCVK3 
and RKB9J10-BL (VK7), RSCVK3 and RKB9Jo-BL (VK8), RSCVK3 and RKB42Jo-
BL (VK9). All the variable kappa chains amplified successfully at 400 bp with GoTaq™ 
polymerase, except for the VK7 and VK8 primer sets. Subsequently, the correct band of 
400 bp was isolated using gel electrophoresis and purified using QIAquick gel 
extraction.  
 
 
 
 
Figure 3.3.3.3 PCR amplifications for the variable light (kappa) genes (~400 bp).  Lane 
M represents the 1 kb Plus DNA ladder. Lanes A to I represents the VK1 to VK9.  
 
Further optimisation was carried out on the VK7 and VK8 variable light kappa primer 
combination, for the purpose of obtaining a sufficient quantity of DNA material for 
library construction. Phusion® Taq High-Fidelity DNA polymerase was utilised instead 
of Go Taq, with two different buffers. There are two possible reaction buffers for PCR 
reactions using Phusion® Taq polymerase, i.e. 5X Phusion® GC buffer and 5X Phusion® 
HF buffer. The error rate of HF buffer (4.4 x 10-7) is lower than that in GC buffer (9.5 x 
10-7). The GC buffer can improve performance on difficult or longer templates. A hot 
start reaction was carried out for this PCR to aid in amplification efficiency. As 
illustrated in Fig. 3.3.3d, the correct band was obtained for amplification of VK7 and 
  M      A             B             C           D             E            F             G             H              I 
  400bp 
  650bp 
	 108 
VK8 with the inclusion of HF buffer. A weaker band was obtained for VK7 and VK8 with 
the inclusion of GC buffer. 
 
 
 
 
 
Figure 3.3.3.4 PCR optimization of VK7 and VK8 variable light regions using Phusion® 
Taq High-Fidelity DNA polymerase with HF and GC buffers. Lane M represents the 1 
kb Plus DNA ladder. Lane A and lane B represent VK7 using HF and GC buffers. Lane 
C and lane D represent VK8 using HF and GC buffers. 
  
   M       A        B        C        D 
  400bp 
  200bp 
     VK7          VK8 
   HF     GC      HF     GC 
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Using the optimised conditions, a large-scale PCR amplification of VK7 and VK8 was 
performed (Fig 3.3.3.5).  
 
 
 
Figure 3.3.3.5 Large-scale PCR amplification of VK7 and VK8 variable light regions 
using Phusion® Taq High-Fidelity DNA polymerase with HF buffer. Lane M represents 
the 1 kb Plus DNA ladder. Lanes A to C represents VK7. Lanes D and F represent VK8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  M               A        B        C                 D       E       F 
  400bp 
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For PCR optimization of the variable light lambda (Vλ) regions, a MgCl2 concentration 
gradient from 0 to 4 mM was prepared. In addition, Go Taq® DNA polymerase was 
utilised in the PCR reaction. The clearest band with the least amount of smearing was 
obtained with a MgCl2 concentration of 1 mM. An additional band at 250 bp was also 
obtained due to non-specific amplification (Fig 3.3.3.5). PCR amplification of Vλ was 
then performed (Fig 3.3.3.6). The correct band of 400 bp was isolated using gel 
electrophoresis and purified using QIAquick gel extraction. 
 
 
Figure 3.3.3.6 MgCl2 optimisation of rabbit variable light chain lambda (Vλ) (~400 bp) 
amplification. Lane M represents a 1 kb plus DNA ladder, lane A to lane E, respectively, 
represent amplicons with increased concentration of MgCl2 (0, 1, 2, 3 and 4 mM). 
  400bp 
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Figure 3.3.3.7 Optimised PCR amplification of rabbit variable light chain lambda 
antibody gene sequences. Lane M represents a 1 kb plus DNA ladder, and lanes A and B 
represent VLλ genes.  
  
After the successful large-scale PCR amplification of variable heavy and light chain 
antibody gene sequences, each of the variable heavy chains (VH1-4) and light chain 
(VK1-9, VKλ) were quantified and pooled in a 1:1 ratio. In the next stage a PCR splice 
overlap extension of variable rabbit heavy and light chains was performed.  
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SOE-PCR of the rabbit variable heavy and light chain antibody genes  
 
Construction of the rabbit scFv library proceeded by fusing equimolar concentrations of 
the variable heavy and variable light chain mixtures using the overlap primers, RSC-F 
and RSC-B. These primers were utilised to amplify a fusion product with a short serine-
glycine linker (GGSSRSS). Velocity DNA polymerase was employed for this 
amplification reaction as it possesses high thermostability combined with its 5ʹ-3ʹ DNA 
polymerase and 3ʹ-5ʹ proofreading exonuclease activities. This ensures a low PCR 
error-rate, and enhanced DNA processivity. The reaction was carried out in the presence 
of 3% (v/v) DMSO. No optimisation of the PCR was required. The target DNA of 
approximately 750 bp was then purified by gel extraction. 
 
 
 
Figure 3.3.3.8 Splice by extension overlap PCR (SOE-PCR) of variable heavy and 
variable light chain fragment to form complete scFv fragment. The expected molecular 
weight of this amplicon was 750 base pairs. Lane M represents a 1 kb plus DNA ladder, 
lanes A and B represent scFv genes, and lane C represents a negative control with 
absence of DNA template.  
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3.3.4 Cloning the SOE product into the pComb3XSS vector through restriction 
digestion 
 
The scFv SOE product was cloned into the pComb3XSS vector using a SfiΙ restriction 
enzyme. The pComb3XSS was employed as a vector as it contains a double Stuffer 
fragment between the two SfiI cloning sites in the heavy and light chain regions, which 
allows for efficient cloning. Culture of pComb3XSS was performed, as described 
previously in Chapter 2. The plasmid DNA was purified using a NucleoBond® Xtra 
Midi/Max kit. The digestion of purified SOE product and vector was carried out using 
SfiI, XbaI, and XhoI. The digestion sites are illustrated in Fig 3.3.4a. Before the ligation 
step the digested pComb3XSS vector was treated with the enzyme, Antarctic 
phosphatase, which prevents self-ligation of the vector.  
 
 
 
 
Figure 3.3.4a The pComb3XSS phagemid vector map and relevant digestion sites. 
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Figure 3.3.4b Digestion of the SOE product and the pComb3XSS vector. Lane M 
represents a 1 kb plus DNA ladder, lanes A to C represents the digestion of the 
pComb3XSS vector to produce a heavy chain Stuffer fragment (~1200 bp), a light chain 
Stuffer fragment (~300bp), the double-cut vector (~3400bp), and the PelB leader 
(~100bp). Lane D and E are SOE products (~750) and digested SOE products (~700bp). 
 
Both digested vector and SOE genes were extracted from an Agrose/TAE gel and 
concentrated and purified using ethanol precipitation. Subsequently, a ligation 
procedure was performed to clone the scFv fragment genes into pComb3XSS vector. 
Following the ligation, the ligated products were transformed into electrocompetent 
XL1-Blue cells by electroporation (Section 2.3.10). The transformed rabbit scFv library 
had a size of 9.2X106 cfu/mL. The library was enriched via phage display-panning using 
immobilised STX-OVA on immunotubes. The M13K07 helper phage was applied in the 
bio-panning process. Four rounds of bio-panning were performed using decreasing 
concentrations of STX-OVA conjugate from 50 to 2.5µg/mL, and an increasing the 
number of wash steps and reducing the culture volume (Table 3.3.4a). This strategy was 
designed to enhance the selection of binding clones that have high affinity. Table 3.3.4b 
presents the inputs and outputs form each bio-panning round.  
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Table 3.3.4a Bio-Panning strategy for the Neo-saxitoxin rabbit scFv library. 
 
 
  
Pan 1 
 
Pan 2 
 
Pan 3 
 
Pan 4 
Coating conc. 
(STX-OVA) 
 
50µg/mL 
 
25µg/mL 
 
5µg/mL 
 
2.5µg/mL 
Number of 
washes 
5x 
PBST/PBS 
10x 
PBST/PBS 
15x 
PBST/PBS 
15x 
PBST/PBS 
 
Culture volume 
 
400mL 
 
100mL 
 
100mL 
 
100mL 
Helper phage 
volume 
 
1000µL 
 
500µL 
 
500µL 
 
500µL 
 
 
Table 3.3.4b Bio-panning inputs and outputs of the rabbit anti-Neosaxitoxin phage 
library. 
 
 
  
Input (cfu/mL) 
 
Output (cfu/mL) 
Pan 1 9.8X108 1.3X105 
Pan 2 9.1X109 2.4X105 
Pan 3 7.1X1010 4.7X106 
Pan 4 6.9X109 9.2X106 
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3.3.5 scFv check via ‘colony-pick’ PCR 
 
Following bio-panning, a soluble monoclonal ELISA was performed on clones from 
round 4 outputs. However, no positive clones were observed.  To ensure that the 
antibody library contained scFv inserts, a colony-pick PCR was performed. Colonies 
were picked from the pan 4 output and the SOE insert were amplified by PCR. The 
SOE primers, RSC-F and RSC-B, as well as Go Taq DNA polymerase were used for 
SOE PCR amplification. The PCR products were subsequently analysed using a 1% 
(w/v) agarose gel. 
 
Figure 3.3.5 Colony-pick PCR. Lane M represents a 1 kb plus DNA ladder, lane A to 
lane H represent the amplified SOE products (~750bp) from panning 4 output colonies. 
In total the 4 of 8 colonies contained the inserted scFv gene. 
 
3.3.6 scFv check via soluble monoclonal ELISA 
 
A total of 96 colonies were picked from the pan 4 output and tested by monoclonal 
ELISA. However none of the clones tested showed any significant binding to either 
STX-OVA or NeoSTX-KLH. Positive clones were identified. However, the signal was 
very low (Fig. 3.3.6). After repeating this monoclonal ELISA analysis using the same 
96 clones, it was observed that the results were not reproducible and no STX-OVA or 
NeoSTX-KLH-binding clones were isolated.  
  1000bp 
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Figure 3.3.6 Soluble monoclonal ELISA of phage clones from panning round 4. In (A), 
each ELISA well was coated with 1µg/mL STX-OVA conjugation. A 1:2,000 (v/v) 
dilution of a peroxidase- conjugated rat anti-HA monoclonal antibody conjugated with 
peroxidase (1:2000) was used to detect scFvs. In (B), the same protocol was performed 
except that 1µg/mL NeoSTX-KLH was coated on the wells. In both cases, the blank 
horizontal lines represent the background signal.   
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3.4 Discussion 
 
PSTs has previously been identified as a key target for establishment of alternative 
detection methodologies to animal toxicity assays and analytical techniques. 
Development of rapid testing methodologies, such as those incorporating immune 
recognition elements, would serve to support existing techniques, such as HPLC and 
mass spectral analysis, by providing a rapid warning mechanism for toxin outbreaks. 
Both monoclonal and polyclonal antibodies have been generated to date, but no reported 
recombinant antibodies exists to PSTs. Having a recombinant source of antibody would 
provide the advantage of superior affinity, stability and specificity. Recombinant 
antibodies have potential for incorporation of tags for functionalisation, immobilisation, 
purification and detection.  
 
In this work, an immune AZA single chain antibody fragment (scFv) library was 
constructed from an immunised rabbit host. A rabbit was chosen as the host animal 
because of its suitability for antibody generation to small-molecular weight targets and 
because of its unique diversification and gene rearrangement capabilities (See Section 
4.1.3). This chapter describes the construction of a rabbit anti-Neo-STX-KLH scFv 
library. A rabbit was chosen as the host animal and it was immunized by injection with 
Neo-STX-KLH. The rabbit antibody library was constructed by PCR amplification of 
VH and VL genes, as well as linking VH and VL fragments. A scFv fragment phage 
library was generated by cloning the gene fragment library into the pComb3XSS 
phagemid vector and transforming into E. coli cells. The phage library was rescued by 
infection with helper phage and screened against immobilised STX-OVA conjugate.  
 
There are many reasons to hinder the isolation of a recombinant antibody. Firstly, 
immunization problems caused by the toxic nature of the immunogen and the size of the 
hapten and the quality of conjugation, may lead to poor immune response of an animal. 
PSPs possess small molecular weights. For such hapten targets, there are limited 
functional groups to conjugate to a protein carrier for antibody production. Only a few 
chemical reactions can be used to synthesise immunogen. The formation of the toxin 
protein conjugate must also reduce the toxicity of the toxin before animal immunisation 
(Campbell et al., 2011). In an ideal situation, conjugates would be fully characterised 
with comprehensive analytical techniques before immunisation or screening. The 
analysis would provide invaluable information regarding molecular mass of the 
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conjugate and hapten incorporation ratios. However, in this project the analytical 
systems were not available and the large size of the protein carriers would have made 
the analysis extremely complex and difficult.  
 
Secondly, the amplification problems during the construction of the antibody library 
may lead to inefficient variable gene assembly and a poor diversity of scFv library. Due 
to the diverse VKJK rearrangements, the generation of a rabbit antibody repertoire 
requires many V-specific oligonucleotide primers. This in turn, can require extensive 
optimisation to amplify the various light chain and heavy chain sequences and capture a 
good representation of the repertoire (Barbas et al., 2004). Furthermore, if the overlap 
PCR product of the variable heavy and variable light chains is not highly efficient, 
sequence frame shifts may occur resulting in poor quality of the library (Koohapitagtam 
et al., 2010). These factors may have contributed to the production of an inferior scFv 
library, with minimal specificity for PSPs. 
 
A further problem is that the elimination of useful clone during selection of target-
binding phage. The selection of target-binding clones from phage display libraries is 
driven by two processes: (1) the panning step. Clones that bind to the desired target or 
any other physical moieties present during the panning step, such as walls of the 
vessels, are enriched (Menendez et al., 2005). (2) the amplification step. Infection of 
bacteria by a single phage particle and the secretion of ~1,000 copies of phage (Barbas 
et al., 2001). The undesired loss in target-binding clones after the amplification step was 
commonly present in the past, when researchers could only isolate and characterise a 
small sub-population of phage clones. Derda and coworkers demostrated that a library 
of phage-displayed peptides contains clones that bind to a target better than other clones 
and clones that amplify faster than other clones. Herein, the amplification of a library 
leads to loss of diversity of clones. It was reported that the simplest strategy to bypass 
this problem is to skip the amplification steps altogether. The method has been used 
successfully in several instances (Arap et al., 2002; Krag et al., 2006; Brown et al., 
2010). An alternative strategy is to provide uniform amplification for selected clones 
which can be achieved by: (1) isolating clones from one another; (2) supplying each 
clone with an equal number of bacteria. 
 
The main limitation of this project work was the scarcity and high price of purified 
toxin material. If a reliable, purified source of toxin material becomes available in the 
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future, it may be possible to isolate the recombinant antibody to PSPs from the existing 
immune libraries. 
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CHAPTER 4      
Development of Microfluidic 
System for Rapid HIgG Detection  
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4.1 Introduction 
4.1.1 Manufactaring process of monoclonal antibody 
Monoclonal antibodies (mAbs) are a major class of human therapeutics and have been 
widely used for the treatment of cancer, autoimmune, cardiovascular and inflammatory 
diseases, as well as organ transplantation. These glycosylated proteins have many 
strengths that include their specificity and strong affinity, effector functions and other 
biological activities (Booy et al., 2006). One of the greatest advantages is the potential 
ease of generating mAbs with high affinity and specificity to virtually any target of 
therapeutic interest (Carter, 2011). So far, over 30 mAbs have been licensed by the 
United States Food and Drug Administration (FDA) for clinical application meanwhile 
hundreds of candidate molecules are in clinical and pre-clinical stages of testing. A 
substantial proportion of these approved and candidate antibody therapeutics are in an 
IgG format (Li & Zhu, 2010; Boonsopon et al., 2015). Worldwide sales of therapeutic 
mAbs have risen dramatically and the market for therapeutic mAb derivatives is one of 
the fastest growing sectors in the pharmaceutical industry.  
 
Typical mAb production is carried out on an industrial scale using very large bioreactor 
vessels. This process can be broken down into two major stages: the upstream processes 
and the downstream processes. An overview of these manufacturing processes is 
illustrated in Fig. 4.1. The upstream process includes the culture of the hybridomas or 
cell lines for generation of therapeutic antibodies or their derivatives and primary 
recovery (Jain & Kumar, 2008) (Fig. 4.1A), whereas the downstream processes ensure 
the removal of process-related impurities (e.g. Protein A) to safe levels in the final drug 
product (Fig 4.1B) (Shukla & Thömmes, 2010). The potential for product failure or 
issues with quality control is high, as these procedures are complex and involve 
multiple steps as well as long production times. Therefore, efficient controlling and 
monitoring of the manufacturing process is a critical issue.  
  
An ideal process monitoring system should be non-invasive by providing detailed 
process information without interference with the process itself. ‘On-line’ bioprocess 
monitoring is important for early detection of problems such as infections, to provide 
the opportunity to react immediately. Optical sensors are now applied for ‘on-line’ 
bioprocess monitoring. They are ideal for monitoring cultivation processes because the 
testing can be performed within the process (in situ), with living cells (in vivo), and ‘on-
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line’ and can be very sensitive. Optical, noninvasive measurements do not interfere with 
the growth of the cells and no analyte is consumed. Measurements in ‘real-time’, with 
no time delay, allow effective control and early detection of problems (Werner, 2004). 
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(A) Upstream processing  
 
(B) Downstream processing   
 
Figure 4.1 Schematic of the mAb manufacturing process (adapted from Shukla & 
Thömmes, 2010). (A) The upstream process started with vial thawing and expansion of 
cells via a series of inoculum steps. The cells were then expanded in a series of seed 
bioreactors before being transferred to the production bioreactor, where the mAb was 
expressed into the medium. Centrifugation and a series of filtration steps were used to 
harvest the cell culture broth from cells and cell debris. (B) The downstream process 
started with Protein A chromatographic capture and includes two subsequent polishing 
chromatographic steps for impurity removal. The process also included two dedicated 
orthogonal steps for viral clearance: low pH viral inactivation after protein A 
chromatography and viral filtration. The final process step was 
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ultrafiltration/diafiltration (UF/DF) to formulate and concentrate the product. 
 
4.1.2 Microfluidics  
Microfluidics-based technologies have revolutionized the possibility for new assay 
format development and implementation (Beebe et al., 2002; Vilkner et al., 2004). 
Compared to conventional immunoassay formats, microfluidic platforms possess 
remarkable features such as high surface-to-volume ratios and nanoliter microchannel 
volumes which, in turn, can dramatically impact interfacial reaction kinetics in solid-
phase-based immunoassays. Consequently, these features allow a ‘sample-to-answer’ 
test to be generated with short analysis times, small samples volumes, integrated fluidic 
handling, and ‘at-line’ processing (Bange et al., 2005). In a recent report, sales of 
advanced microfluidics devices are estimated to be up to 23% annual compound growth 
until 2016, expanding the sector to almost $4 billion. Microfluidics technologies in the 
Life Science fields include different applications such as drug delivery, industrial and 
environmental testing, analytical devices, pharmaceutical science uses, point-of-care 
testing and clinical diagnostics. During such applications, immunoassay is the most 
widely applied analytical technique (http://www.i-micronews.com/). In addition, the relative 
increase in associated publications reveals that microfluidic techniques have been 
employed extensively in many immunoassay systems (Becker et al., 2003; Henares et 
al., 2007; Mark et al., 2010; Yeo et al., 2011; Yetisen et al., 2013; Tam et al., 2014).  
 
Currently, the focus of microfluidic platforms for diagnostics or bioprocess monitoring 
is on the integration of several analytical steps leading to direct ‘sample-to-answer’ 
systems. One of the main challenges of integration is the requirement for serial valving 
to allow the sequential release of fluids in a temporally and spatially controlled manner. 
In this work, the experimental serial siphon was shown to be robust and reproducible. 
However, there can be variability in the fluidic release from siphon valves due to 
dependence on contact angle, rotation velocity, and fluidic properties (e.g. surface 
tension). To date, liquids with different properties (e.g., surface tension and viscosity) 
are required to be released at the appropriate time and to the appropriate location. Serial 
siphons and capillary valves in centrifugal microﬂuidic platforms have been 
demonstrated to meet this need (Jia et al., 2006; Bergeron et al., 2008; Siegrist et al., 
2010; Nwankire et al., 2013; Kitsara et al., 2014). 
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The working mechanisms and features of the simplest double siphon device on a 
microfluidic CD are illustrated in Fig. 4.1.2. Siphon valving required a hydrophilic 
surface to allow capillary pumping (Siegrist et al., 2010). After fluid was loaded into 
the upper reservoir chambers, the CD was spun at a high speed to trap the fluid into the 
siphon channels. The fluid in the siphon channel is static when its position is radially 
equivalent to the reservoir fluid height. At this stage, capillary forces are equal to the 
centrifugal forces  (Fig. 4.1.2a). If the rotation velocity is reduced to a lower speed, thus 
allowing capillary force to overcome the centrifugal force, the fluid in the siphon 
channels are pushed over the first siphon crest and are then detained by the next in-line 
capillary valve (Fig. 4.1.2b). The capillary valve is formed by an abrupt widening in the 
siphon channel. This provides higher surface tension forces than centrifugal and 
capillary forces. A high spin speed causes an increase in the centrifugal force which can 
burst the capillary valve. When the fluid is in a channel which contains one siphon 
component, the fluid will completely flow into the lower chamber. However, the fluid in 
the channels comprised of two siphons, flows into the next siphon and stops at the 
position radially equivalent to the reservoir fluid height (Fig. 4.1.2c). When the rotation 
speed is reduced, the fluid is primed over the crest of the following siphon loop (Fig. 
4.1.2d). The fluid bursts the capillary valve under a high rotation speed and then the 
fluid flows into the lower chamber (Fig. 4.1.2e). In this manner, the different fluids are 
sequentially delivered into one chamber through controlling the CD spin speed.    
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Figure 4.1.2 A schematic of the simultaneous function of single (left, red) and double 
serial (right, blue) siphon valve channels between chambers (adapted from Jia et al., 
2006).
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4.2 Aims of this chapter  
The aim of the research described in this chapter is the application of microfluidic 
technology for bioprocess sample analysis. To achieve this goal, an immunoassay 
possessing high sensitivity and specificity for detecting IgG needed to be designed 
and developed. Meanwhile, development of an advanced detection system with high 
sensitivity was also essential. In addition, microfluidic cartridges with advanced fluid 
handling functions needed to be developed.    
 
4.3 Results  
4.3.1 Components of the  human IgG (hIgG) immunoassay  
An indirect fluorescence-labeled immunoassay (FLISA) was initially designed to 
detect hIgG molecules by Dr. Gerard Donohoe. The components of this hIgG indirect 
FLISA included: a capture protein i.e. protein A; the target analyte, hIgG; 
biotinylated anti-hIgG antibody and the detector complex consisting of NeutrAvidin 
Dylight 650 (Fig. 4.3.1). Protein A was coated on the solid phase (microtitre plate), 
and then binds to the Fc region of hIgG with a high affinity. The biotinylated anti-
hIgG is added and specifically binds with bound hIgG. Finally, NeutrAvidin with a 
conjugated fluorescent label, binds with biotin which is conjugated to the anti-hIgG 
antibody. The utilisation of the ‘biotin-neutravidin’ system in this assay can provide 
high signal amplification with associated high sensitivity, often significantly greater 
than achieved with other labelling approaches. 
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                   Protein A            hIgG                 Biotinylated              NeutrAvidin 
                                                                       anti-hIgG Ab                  Dylight 650 
 
Figure 4.3.1 Schematic of an indirect hIgG immunoassay.  
 
 
4.3.2 Optimisation and development of hIgG FLISA on an ELISA plate 
The designed hIgG FLISA was further optimised on an ELISA plate.  After 
optimisation the concentrations of protein A, biotinylated anti-hIgG and standards 
(hIgG), a standard curve with optimal performance was developed on an ELISA 
plate. Additionally, some other aspects of the development of hIgG indirect 
immunoassay were carried out, such as the timing of the sequence of addition of 
reagents and the influence of incubation time. 
 
 
 
 
 
 
	 130	
4.3.2.1 Optimisation of the protein A coating concentration and biotinylated 
anti-hIgG concentration  
The optimal ELISA plate coating concentration of protein A was determined. The 
coating concentrations of protein A (0.2 µg/mL, 1 µg/mL, 5 µg/mL and 25 µg/mL) 
were compared with ultilisation of a 1:250 dilution of mouse anti-hIgG antibody and 
a 1:2,000 dilution of NeutrAvidin Dylight 650 in PBS. The fluorescence intensity 
was ploted against hIgG concentration in Fig.4.3.2.1a. The data showed that protein 
A concentrations below 5 µg/mL generated low fluorescence intensity. In contrast, 
the 25 µg/mL concentration of protein A generated the highest fluorescence intensity 
withhIgG concentrations ranging from 10-2 to 101 µg/mL and generated satisfactory 
dose-response curves (approx dynamic range of 2.5 logs).  
 
Subsequently, a checkerboard ELISA was performed to determine the optimal 
concentration of the biotinylated anti-human IgG antibody. Several dilutions of this 
antibody were prepared (1:250, 1:500, 1:1,000, and 1:2,000).  In addition, the 
Neutravidin Dylight 650 conjugate was diluted to 1 in 2,000 in PBS and the protein 
A coating concentration was 25 µg/mL. After detection, hIgG concentrations were 
plotted against fluorescence intensity with a 4-PL model (Fig. 4.3.2.1b). A 1:250 
dilution of the biotinylated anti-human IgG antibody yielded the highest fluorescence 
intensity with a hIgG concentration ranging from 10-2 to 101 µg/mL and gave the best 
dose-response curve. 
 
 
 
 
 
 
 
 
 
 
	 131	
 
Figure 4.3.2.1a Optimisation of Protein A coating concentration using conventional 
FLISA . Each sample was tested in triplicate and the error bars represent the standard 
deviation. 
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Figure 4.3.2.1b Optimisation of conventional FLISA anti-human IgG antibody 
concentration. Each sample was tested in triplicate and the error bars represent the 
standard deviation. 
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4.3.2.2 Determination of influence of addition of reagents  
Although  a  number of centrifugal microfluidic platforms  were successfully 
demonstrated for immunoassays (Honda et al., 2005; Ukita et al., 2012; Kinahan et 
al., 2014; Hasegawa et al., 2014), most of these platforms were designed with 
complex microchannel networks, which were required for a multi-step immunoassay. 
The complex microchannel networks hindered the generation of  a high-performance 
device enabling easier operation, short analysis times and full automation. Therefore, 
this study was carried out to simplify assay steps and then obtain a rapid assay. 
 
To this end, further development of the hIgG indirect immunoassay were carried out 
by analysis of the influence of the sequence of addition of reagents and incubation 
times. In order to reduce the number of steps of indirect hIgG immunoassay, the 
effect of the use of a mixture consisting of biotinylated anti-hIgG and NeutrAvidin 
DyLight 650 was tested in a  96-well plate. The hIgG indirect assay was carried out 
by using a mixture of  biotinylated anti-hIgG and NeutrAvidin DyLight 650 instead 
of using separate additions (Fig. 4.3.2.2A). On comparison with the initial assay 
results, the assay using the reagent mixture shows greatly enhanced sensitivity, 
which is demonstrated by the curve obtained. Additionaly, ultilisation of a reagent 
mixture contributes a simpler and faster assay.  
 
In addition, another study was carried out to determine the influence of incubation 
time on the stability of the reagent mixture  (Fig. 4.3.2.2B). The reagent mixture 
prepared by pre-incubation at 37°C for 20 minutes was compared withthe reagent 
mixture prepared immediately before analysis without incubation. The data shows 
that such an incubation step provides a more sensitive and robust assay by reducing 
reagent-induced variations. Furthermore, it indicates that the incubation for 20 
minutes at 37°C is sufficient for equilibration  of the biotinylated anti-hIgG and 
NeutrAvidin DyLight 650 reaction. This result suggests that mixing and incubation 
of the anti-hIgG and NeutrAvidin DyLight-650  molecules prior to addition to the 
assay surface, can reduce steric hindrance and enhance binding. 
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Figure 4.3.2.2 Effect of mixing reagents (biotinylated anti-hIgG and 
NeutrAvidin DyLight-650) on the hIgG indirect assay performance. (A) 
comparison of hIgG assay results with or without mixing of reagents. The green 
curve represents the assay without the application of mixed reagentsIn contrast, 
the blue curve represents the assay adopt the mixing of reagents.   (B) Comparison of 
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hIgG assay results with/without incubation during mixture preparation. The green 
curve represents the assay using the mixed reagents without incubation at 37°C for 
20 minutes. The blue curve represents the assay adopting the mixed reagents 
prepared with incubation at 37°C for 20 minutes. Each sample was tested in triplicate 
and the error bars represent the standard deviation. 
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4.3.2.3 Optimising the ratio between biotinylated-antiIgG and NeutrAvidin 
Dylight 
In order to establish whether or not the ratio of biotinylated anti-hIgG and 
NeutrAvidin DyLight-650 in a mixture was a critical parameter, numerous assays 
were performed using different ratios of biotinylated anti-hIgG and NeutrAvidin 
DyLight in mixtures. The mixtures were prepared by mixing biotinylated anti-hIgG 
and NeutrAvidin DyLight-650 in 1:1, 2:1, 3:1, and 1:2 ratios, followed by incubation 
for 20 minutes at 37°C prior to addition to the plate. After detection of the 
fluorescence signal from assay plates, data were analysied by plotting the 
fluorescence signal against the human IgG concentrations. Under the condition of 
using mixing of biotinylated anti-hIgG and NeutrAvidin DyLight-650 in 1:2 and 1:3 
ratios, the assays were negatively affected (data not shown). Fig. 4.3.2.3 shows the 
dose-response curves of the assays with application of the mixing biotinylated anti-
hIgG and NeutrAvidin DyLight-650 in 1:1, 2:1 and 3:1 ratios. Comparision of  
different ratios of biotinylated anti-hIgG and NeutrAvidin DyLight-650 indicated that 
the 3:1 ratio was superior since the curve was saturated at higher human IgG 
concentrations and has a larger dynamic range. 
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Figure 4.3.2.3 Optimisation of ratios in mixing biotinylated-anti-hIgG and 
NeutrAvidin DyLight. The mixtures were prepared with different ratios of 
biotinylated-anti-hIgG and NeutrAvidin DyLight-650 (1:1, 1:2, 1:3, 2:1 and 3:1). 
Each samples was tested in triplicate and the error bars represent the standard 
deviation of the mean of three measurements. The fluorescent signal was normalised 
(F/F0) before plotting against hIgG concentration. 
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4.3.3 Development and optimisation of a hIgG FLISA on a ‘proof-of-concept’ 
microfluidic platform with flow-cells  
4.3.3.1 Design of ‘proof-of-concept’ microfluidic platform with flow-cells  
The next stage of assay development involved the design, production and testing of 
simple microfludic flow-cells. These devices are composed of multilayered materials as 
previously described (section 2.3.1.1). Each flow-cell contains 3 individual microfluidic 
units. In addition, a spin holder was designed to accommodate four separate flow-cells 
(Fig. 4.3.3.1). This structure allows the processing of 12 assays simultaneously. Each 
reagent is manually loaded into the flow-cell using a pipette via a loading hole. Reagent 
delivery is achieved by a combination of centrifugal and capillary forces. For each 
microfluidic unit a microchannel spans the loading hole and the reagent waste chamber. 
The protein A capture spot is located near the end of the microchannel close to the waste 
chamber. When a reagent is loaded into the top chamber through a loading hole, it will 
be held in this chamber due to capillary forces. It is only after the application of 
centrifugal force, which overcomes weaker capillary forces, that the reagent is pumped 
through the microchannel. As hIgG flows through the microchannel it encounters the 
protein A assay spot and binds to it. Excess reagent is subsequently collected in the 
waste chamber. This simple microfluidic design has several advantages: (1) assay time 
can be dramatically shortened due to the rapid transport of reagents ; (2) reagent volume 
can be reduced; (3) assay steps can be simplified; (4) flow-cell design allows for testing 
of different surface materials; and (5) a closed microfluidic system with disposable 
cartridges can increase operator safety especially when used for testing of hazardous 
biological materials. 
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Figure 4.3.3.1 Illustration of flow-cell designs. The spin holder with two flow-cells is 
illustrated on the top. A whole flow-cell structure is also shown. The flow-cell contains 
3 individual microfluidic units, on which two reagent-chambers is connected by a 
microchannel. The figure on the right shows an enlargement of microchannel which 
provides a capillary valve and an assay spot. 
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4.3.3.2 Surface functionalisation 
 
Before the hIgG immunoassay could be applied to the microfluidic flow-cells, a 
variety of surface materials and immobilisation methods were analysed (Table 
4.3.3.2). In total, three different substrates were tested: Zeonor®, Nunc™ and glass. In 
addition, serveral surface modification methods were compared i.e.  PECVD, 
TEOS/AA, EDC/NHS, and use of an oxygen plasma. Furthermore, curing (baking) 
times, temperatures and Protein A concentrations were also evaluated. The results 
showed that three experimental arrangements gave homogenous fluorescent hIgG 
spots. These groups were: (1) commercial Nunc™ slides, coated with 500 µg/mL 
protein A; (2) Zeonor® slides treated with an oxygen plasma for 10 minutes and 
subsequently treated with APTES. The zeonor slides were then baked at 80oC for 1hr 
and coated with 50 µg/mL protein A; (3) Glass slides treated with plasma for 5 
minutes and coated with an APTES solution. Curing was performed at 60oC for 1hr 
and the slides were coated with 5 µg/mL of protein A. Zeonor® was chosen as the 
substrate for the microfludic devices. This material is optically clear and has low 
autofluoresence. Glass was not used as it would have proved cumbersome in device 
manufacture. Although the commerical Nunc™ substrate performed as well as the 
Zeonor® polymer it was not used in device manufacture due to its high cost. 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 141	
Table 4.3.3.2  Optimization of surface modification conditions with different 
materials. 
 
Slide Surface Activation Chemistry Curing Pr A conc. 
(µg/mL) 
Outcome 
Zeonor ® None None None 200 X 
Zeonor® PEVCD/TEOS/ AA EDC/NHS None 200 X 
Zeonor® PEVCD/TEOS / AA EDC/NHS None 500 X 
Nunc™ None None None 500 GOOD 
Zeonor® Plasma (1min) EDC None        500 X 
Zeonor® Plasma (5min) APTES 2hrs 
80oC 
400 X 
Zeonor® Plasma (5min) APTES 1hr  
80oC 
500 X 
Zeonor® Plasma (10min) APTES 1hr  
80oC 
50 GOOD 
Glass Plasma (5min) APTES 1hr 
60oC 
5 GOOD 
X represents a poor outcome 
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4.3.3.3 Determination of the influence of removal of the washing step during 
flow-cell-based hIgG immunoassay  
 
As outlined in Table 4.3.3.3, flow-cell-based hIgG FLISA has six steps, consisting of 
(1) BSA blocking, (2) PBS wash, (3) addition of hIgG sample, (3) PBS wash, and (4) 
addition of mixed biotinylated anti-hIgG and Neutravidin DyLight 650 (anti-
IgG/Dylight) followed by (5) a PBS wash.  In order to generate a quick 
immunoassay on a flow-cell, further development was carried out by evaluating the 
influence of removing wash steps from the assay protocol. To this end, several hIgG 
FLISAs were performed on a flow-cell removing different wash steps. It included the 
removal of the wash step after BSA blocking, the wash step after loading hIgG, the 
wash step before and after loading the mixture of anti-IgG/Dylight. The results were 
analysed and compared with the established hIgG FLISA (performed with the 
standard procedure in Table 4.3.3.3). It demonstrated that the assay result can be 
dramatically affected by the removal of wash steps, with the exception of the wash 
step after BSA blocking (Table 4.3.3.3). Fig. 4.3.3.3, compares the assay data from a 
standard procedure with all wash steps against procedures without the wash step after 
BSA blocking. The checkerboard result of assays under different conditions is 
illustrated in Fig. 4.3.3.3. Three hIgG samples with concentrations of 0.5, 5 and 50 
µg/mL were tested to analyse the trend in the fluorescence signals. The fluorescence 
intensity  (F) for each concentration was normalised by transformation to F/F0. The 
F/F0 values from standard procedure were lower than the procedure, in which the 
wash step after BSA blocking was removed. However, a lower F0 was obtained from 
the assay without wash step after BSA blocking. The result indicates that, without a 
wash step, extra BSA molecules adsorbing on the  channel walls, can dramatically 
reduce unspecific binding on the inside of the channel. Additionally, the extra 
adsorbed BSA induced a signal decline on both background (F0) and fluorescence 
intensity (F). In our study, the signal decline on F0 was more remarkable than F and 
the F/F0 values were increased. Additionally, the reduced F values were still above 
the detection limitation of a designed fluorescence detection system. Therefore, it is 
possible to remove a wash step after BSA blocking in this flow-cell based hIgG 
FLISA. 
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Table 4.3.3.3  Outline of hIgG FLISA procedures on flow-cell. 
 
 Reagents addtion sequence  
Standard procedure  1. BSA,	 2.	 PBS,	 3.	 	 hIgG,	 4.	 PBS,	 5.	 Anti-hIgG/Dylight,		6.	PBS		
BSA wash removed procedure    1.BSA,  2.hIgG, 3.PBS, 4.Anti-hIgG/Dylight, 5.PBS  
 
 
 
Figure 4.3.3.3   Checkerboard FLISA on flow-cells for determination of the 
influence of removal of the wash step after BSA blocking. Black bars represent 
the nomilised fluorescence intensity generated by the assay using the standard 
optimised procedure. Gray bars represent the normalised fluorescence intensity 
generated from the assay without the wash step after BSA blocking. Three hIgG 
samples with concentrations of 0.5, 5 and 50 ug/mL were tested in both procedures. 
The error bars represent the standard deviation of the mean of three measurements.  
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Hence, the developed flow-cell-based hIgG FLISA has five steps, consisting of (1) 
BSA blocking, (2) addition of hIgG sample, (3) PBS wash,  (4) addition of mixed 
anti-hIgG/Dylight followed by (5) a PBS wash. To run this hIgG FLISA in flow-
cells, these reagents were added sequentially into the reagent chamber and delivered 
to the sensor area of the flow-cell under centrifugal force (Fig. 4.3.3.1). By 
utilization of the developed procedure, the assay time was reduced from more than 6 
hours (using 96-well microtitre plates) to approximately 20 minutes (using flow-
cells).  
 
4.3.3.4 Comparision of results of flow-cell-based hIgG FLISA with two different 
APTES solvents   
 
An ideal microfluidic system for diagnostic or monitoring should be disposable and 
low cost. However, a large amount of ethanol was required during process of 
convenient liquid APTES deposition. Herein, the study was carried out to investigate 
an ethanol substitute.   
 
As described in Fig 4.3.3.1, the flow-cell was composed of plastic (PMMA and 
COP) and PSA. These substrates do not possess native functional groups for 
specifically interacting with biomolecules and need to be pretreated before 
fabrication. In our study, the pretreatment includes a wash step to eliminate adsorbed 
unknown biomolecules and a liquid APTES-deposition step to enhance target 
biomolecular adsorption. This pretreatment process consumes a large amount of 
ethanol as solvent. It dramatically increases the cost to produce flow-cells.  
Therefore, a new solvent with low cost and good performance was considered. 
Isopropyl alcohol was tested as the APTES solvent and wash solution instead of 
ethanol in the surface pretreatment stage. The effect of using isopropyl alcohol on 
surface functionalisation was shown by comparing with the assay results on ethanol 
pretreated flow-cells (Fig. 4.3.3.4a). In addition, two hIgG samples with the 
concentrations of 0.5 and 5 µg/mL were tested, respectively.  
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After analysis of these two hIgG samples on the flow-cells with two distinct solvents, 
the image data was measured from assay spots on flow-cells using an ANDOR iXon 
885 camera coupled fluorescence microscope. The image data can directly reveal the 
distribution of fluorescence on the assay spot and can be used to assess the surface 
functionalisation method. Herein, a uniform fluorescence distribution on the image 
data represents a well functionalised surface; and an increased fluorescence from a 
hIgG sample with high concentrations represents an efficient surface 
functionalization. Several conclusions can be obtained from the image data in Fig. 
4.3.3.4a. They are (1) all image data show relatively uniform morphology for the 
assay spot; (2) a high concentration of hIgG gave the highest fluorescence signal; (3) 
for the same hIgG sample, brightness of image data from the two functionalized 
surfaces is similar. These results indicated that isopropyl alcohol shows good utility 
for surface modification and can be a potential ethanol substitute during substrate 
pretreatment.  
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Image data from fluorescence microscopic analysis 
 
 
Figure 4.3.3.4a Comparison of morphology of assay spots between flow-cells 
prepared using isopropyl alcohol and ethanol. The image data exhibited by the 
assay spot with associated fluorescence signal, was measured using an ANDOR iXon 
885 camera coupled to a fluorescence microscope. 
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Additionally, the fluorescence intensity of assay spots was analysed by a SAF 
detector. The fluorescence intensity detected was plotted against hIgG concentrations 
in Fig. 4.3.3.4b. The error bars represent the standard deviation from triplicate 
measurement on each sample. Furthermore, the intra-day coefficient of variation 
(CV) was analysed from duplicate samples. Compared with the ethanol group, 
isopropyl alcohol gave a slightly lower fluorescence signal for same concentration of 
hIgG. However, the CV percentages for each concentration, using isopropyl alcohol, 
were less than 3%, whereas those using ethanol were up to 11%. All of the results 
indicate that isopropyl alcohol could be applied instead of ethanol during surface 
modification of the flow-cells. 
 
Figure 4.3.3.4b Checkerboard FLISA for comparison of flow-cells prepared 
with ethanol and isopropyl alcohol. The error bars indicate the standard deviation 
from triplicate measurements on each sample. The CV percentage illustrated the 
intra-day coefficient of variation from duplicate samples. 
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4.3.3.5 Stability study of surface chemistry on flow-cells  
 
The liquid-APTES deposition process was widely used for surface modification of 
microfluidic systems (Howarter et al., 2006; Lapin et al., 2009; Zhao et al., 2012; 
Liang et al., 2014). During this process, the amine groups of APTES were introduced 
on the surface and could bind to target proteins. The existing methods of APTES 
deposition were modified to produce a stable layer of APTES film for uniform 
immobilization of biomolecules. The stability of deposited APTES can directly 
influence the shelf-life of a developed microfluidic system. This study was carried 
out to evaluate the stability of APTES film on a PMMA substrate and predict the 
shelf-life of a flow-cell with a deposited APTES film. 
 
In this study, the stability of the liquid-APTES deposition surface was assessed by 
comparison of hIgG immunoassays performed on flow-cells stored in a desiccator 
for zero days, two weeks and one month, respectively. Three hIgG samples with 
concentrations of 0.5, 5 and 50 µg/mL were tested on each of the flow-cells. The 
fluorescence intensity data from each flow-cell was normalised and compared in Fig. 
4.3.3.5.  An increase in fluorescence response with increased hIgG concentration was 
observed on the flow-cell stored for zero days (Fig. 4.3.3.5). The fluorescence 
response generated on a flow-cell stored for two weeks are similar to the one with 
zero days storage time. In contrast, the fluorescence response detected from the flow-
cell stored for one month showed a decreasing response with increasing hIgG 
concentrations. This result indicated that the liquid APTES is stable for two weeks in 
a desiccator. However, they should not be used if stored for one month. 
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Figure 4.3.3.5 Checkerboard FLISA on flow-cells for stability testing. Protein A  
(10 µg/mL) was spotted on the modified assay spot surface. Before the test, the flow-
cells were stored in a desiccator for zero days, two weeks and one month, 
respectively. The mixture of biotinylated anti-human-IgG antibody and Neutravidin-
Dylight 650, diluted in PBS (150 mM, pH 7.4) at a ratio of 3:1, was pre-incubated at 
37oC for 20 minutes.  Each sample was tested in triplicate and the error bars 
represent the standard deviation.  
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4.3.3.6 Generation of a calibration curve for FLISA in flow-cells and 
quantification of IgG concentrations in a sample from a bioprocess run 
 
A callibration curve for an IgG immunoassay was successfully generated in the flow-
cells. In order to generate the optimal callibration curve, functional groups for 
biomolecule adsorption were first introduced on the surface by using an oxygen 
plasma and liquid-APTES deposition methods. Protein A with a concentration of 10 
µg/mL was adsorbed on the surface-modified assay spot. Serial dilutions of hIgG, 
ranging from 0.3 to 10 µg/mL, were prepared as the standard samples. The mixture 
of biotinylated anti-human-IgG antibody and Neutravidin-Dylight 650, diluted in 
PBS (150 mM, pH 7.4) at a ratio of 3:1, was pre-incubated at 37oC for 20 minutes. 
The procedure for running FLIA on flow-cells was previously described in section 
2.4.3. In total, seven hIgG standards were measured in triplicate using the SAF 
detection system. In Fig. 4.3.3.6 (A),  the inter-day hIgG calibration curve in a flow-
cell exhibited a CV of 6.3  to 12.6 % across the entire hIgG concentration range, and 
the working range from 0.5 to 5 µg/mL.  Meanwhile, a calibration curve for IgG 
immunoassay was established on a microtitre plate. The protocol for a microtitre 
plate-based hIgG FLISA was desctibed in section 2.4.1. Analysis of each sample 
required 100 µL of the following reagents: protein A (5 µg / mL), hIgG samples, 
biotinylated anti-human-IgG antibody (1:500 in PBS) and Neutravidin-Dylight 650 
(1:500 in PBS). The fluorescence intensity was measured using a Tecan Microplate 
ReaderTM. In Fig. 4.3.3.6 (B), the inter-day hIgG calibration curve on a microtitre 
plate exhibited a CV of 5.9 to 18.9 % across the entire hIgG concentration range, and 
the assay working range was from 0.1 to 10 µg/mL. An unknown bioprocess sample, 
was quantified using calibration curves from the microtitre plate and flow-cell 
formats. The concentration prediction of the bioprocess sample was determined using 
the results to generate a curve drawn using SigmaPlot. The concentration of the 
sample determined using both methods was similar, as conventional FLISA analysis 
yielded an unknown concentration of  approximately 9.3 mg/mL, whereas, the flow-
cell-based calibration curve yielded an unknown concentration of approximately 10.1 
mg/mL.  
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Figure 4.3.3.6 Illustration of bioprocess sample quantification based on two 
formats. (A) shows the assay performed using a flow-cell and the developed assay 
format. The predicted hIgG concentration of the bioprocess sample is 10.1mg/mL. 
(B) This shows the assay carried out on a microliter plate. The predicted hIgG 
concentration of the bioprocess sample is 9.3 mg/mL.  
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4.3.4 Development and optimisation of the first design of microfluidic compact 
‘disc-like’ platform (CD) – ‘SAF-element’ CD 
4.3.4.1 The design of SAF-element CD 
The actual overall design of ‘SAF-element’ CD was led by Dr. Charles E. Nwankire 
in DCU but virtually all of the development work and production was performed by 
the candidate. The design of the ‘SAF-element’ CD was based on the previous 
microfluidic flow-cell structure. This new structure was superior due to the 
utilisation of the SAF ring lens and integrated ‘CD-like’ design. The major features 
of the SAF-element CD were outlined below: 
 
Centrifugal force 
Centrifugal force was employed in the ‘SAF element’ CD due to advantages such as 
miniaturisation, parallelisation, high-throughput, and low-cost (Duff et al., 1999; 
Madou, 2002; Madou et al., 2006). A drawback of centrifugal pumping was that it 
was unidirectional  fluids flow only from the centre of the CD and radiates 
outward. However, this shortcoming was eliminated by the radially design of flow 
channels on the ‘SAF-element’ CD.  
 
Capillary valves 
Capillary valves were utilised in this CD to efficiently deliver fluids. The capillary 
valving was achieved by an abrupt widening in a narrow hydrophilic channel, where 
a larger surface tension force was formed. It can be opened and closed by controlling 
the spin frequency.  When a certain higher frequency, known as the burst frequency, 
was reached, the centrifugal forces overcame the surface tension forces and push the 
fluid down the channel (Johnson et al., 2001; Badr et al., 2002; Lai et al., 2004; Cho 
et al., 2007). 
 
SAF element layer 
In addition, a ring lens optical component (supercritical angle fluorescence (SAF)) 
was designed to achieve highly efficient fluorescence collection with bound 
substrates. This system consisted of a spherical ring lens for SAF collection and an  
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Figure 4.3.4.1a   A schematic cross-section of a ring lens structure. SAF light typically propagates within the substrate at angles within the 
range of ~61.5° - 80°. The spherical lens shape (highlighted with green lines) was designed to allow the collection of fluorescence in the 
above range. The aspheric lens (red line) and aperture (blue line) were designed to focus the excited fluorescence light.            
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aspherically shaped focusing lens (Fig. 4.3.4.1a). SAF light typically propagates 
within the substrate at angles within the range of ~61.5° - 80°. The lens shape was 
designed to allow optimal fluorescence collection. Zeonor® was used as the material 
of choice, since 1) it had better optical properties than most other moldable 
plastics, and (2) it was previously used as the substrate in the  analysis of proteins 
and nucleic acids (Lutz et al., 2011).  
 
The first design of a ‘SAF-element’ CD employed a 20-SAF elements layer (Fig. 
4.3.4.1b). Importantly, the availability of more SAF-elements provided more 
flexibility for microfluidic design on a CD and furthermore allowed for the 
possibility of multiplex analysis.  
 
 
 
 
Figure 4.3.4.1b   A schematic of the SAF layer with 20-SAF elements. Each SAF 
layer contained 20 SAF elements. The conic holes facilitated the assembly of the 
SAF layer with other CD layers. 
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Each SAF element CD contained 20 microfluidic units, which allows for 20 parallel 
assays (Fig. 4.3.4.1c). This multiple unit structure provided the possibility to reduce 
the coefficient of variation created by CD manufacture and manipulation. Similar to 
the structure of the flow-cell, each microfluidic unit had two chambers (loading 
chamber and waste chamber), which was connected by a microchannel. In addition, a 
capillary valve and assay spot was contained in the microchannel. However, a SAF 
ring lens was used as the bottom layer in the ‘SAF-element’ CD instead of a Zeonor® 
slide. Furthermore, the vent on each chamber could prevent accumulation of dead 
fluid in the microchannel. The delivery of fluid in the SAF element CD was achieved 
by the balancing of centrifugal force and capillary valving. When a reagent was 
loaded into the top chamber through a loading hole, it was held in this chamber by 
the capillary force. However, the centrifugal force produced by rotation can 
overcome the capillary barriers and pump the reagent into the microchannel. In 
addition, when the reagent flowed through the assay spot, the immune complex is 
formed. The excess reagent was then collected in the waste chamber under continuse 
centrifugal force. 
 
 
 
 
 
 
 
 
 
 
	 156	
 
 
 
Figure 4.3.4.1c A schematic of the microfluidic unit on the ‘SAF-element’ CD. 
The design of the ‘SAF-element’ CD was shown on the left. It contains 20 
microfluidic units and one of them was enlarged on the right. Each microfluidic unit 
has two chambers (loading chamber and waste chamber), which was spanned by a 
microchannel. A capillary valve was located before the assay spot to control the fluid 
in the microchannel. In addition, the vents designed on chambers can prevent 
accumulation of dead fluid in the microchannel. 
 
 
4.3.4.2 Custom-engineered system for performing microfluidic immunoassays  
A custom-engineered system, which can provide centrifugal force and monitor the 
liquid flow in the microchannel, was built in the BDI (Fig. 4.3.4.2). This system 
played a very important role in the development of microfluidic immunoassays on 
CDs before the generation of the automotive spin cycle protocol. The whole 
microfluidic CD testing setup includes two major parts: the test stand is comprised of 
a computer-controlled motor and a stroboscopic light for imaging a chosen area on 
the disc during rotation; the control of the motor using a custom LabVIEW program 
interfaced with a data acquisition system. 
Loading(hole(
Vent(
Vent(
SAF(ring(lens(
Capillary(valve(
Waste(chamber(
Loading(chamber(
Flow(
direc<on(
	 157	
 
 
Figure 4.3.4.2 The testing setup for hIgG microfluidic immunoassay on CDs. 
The whole testing setup includes two major parts (separated with red lines): (1) the 
test stand is comprised of a motor and a stroboscopic light, and (2) the control of PC 
and other control components (zoom control, delay box). 
 
4.3.4.3 Optimisation of microchannel diameters on ‘SAF-element’ CDs 
The flow rate can dramatically influence the result of flow-based assays. Therefore, a 
variety of immunoassay experiments were performed using various reagents and 
microchannel diameters. The reagents used include: 3% (w/v) BSA (a standard 
immunoassay blocking reagent) in hIgG FLISA, 3% (w/v) BSA containing 0.25% 
(v/v) Tween-20®, and PBS. In addition, the ‘SAF-element’ CDs were manufactured 
with different microchannel designs that included 0.5 µm, and 0.8 µm with and 
without capillary valves. A 30 µL volume of each reagent was added into the loading 
chambers of the ‘SAF-element’ CDs, and then flow was tested and monitored using 
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the test stand setup. The results are listed Table 4.3.4.3. Compared with the 0.8 µm 
diameter microchannel, the 0.5 µm microchannel diameter was too narrow to allow 
reagents to flow, even when the reagent tested was PBS. Furthermore, the 0.8 µm 
diameter microchannel without valves had the required flow-rate and significantly 
reduced bubble formation with addition of Tween-20®.  
 
Table 4.3.4.3. Optimisation of SAF element CD design using various reagents. 
 
Items 0.5 micrometer 
diameter 
0.8 micrometer 
diameter valve 
0.8 micrometer 
diameter 
without valve 
3% (w/v) BSA 
with 0.25% (v/v) 
Tween-20® 
Bubbles produced  Bubbles produced  Good  
3% (w/v) BSA Dead flow  High spin speed 
required   
Good  
PBS High spin speed 
required  
Good  Good  
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4.3.4.4 Generation of hIgG calibration curve using optimal conditions on ‘SAF-
element’ CDs 
After numerous optimisations were carried out, a calibration curve for hIgG 
detection was successfully generated with on the ‘SAF-element’ CD. In this assay, 10 
µg/mL of protein A and 6% (v/v) Ab&Dy was used. In addition, the concentration of 
hIgG standards ranged from 0.16 to 100µg/mL. Data was plotted using a 4-PL 
model. Error bars were generated by analysing samples in triplicate (Fig. 4.3.4.5). 
The developed calibration curve had a dynamic range of quantification of 
approximately 2 logs, intra- coefficients of variation of approximately 10%, and can 
detect concentrations of hIgG in the nanogram range. 
 
 
Figure 4.3.4.4 A schematic of calibration curve of hIgG FLISA based on the 
‘SAF-element’ CD. The vertical bars indicate the SD from triplicate samples. 
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4.3.4.5 Stability study of surface chemistry on ‘SAF-element’ CDs 
In the hope of improved reproducibility and reduced processing time, the advanced 
PECVD method was introduced for APTES deposition during the surface 
functionalisation period. The previous liquid phase deposition method required 
manual intervention during the process to introduce the precursors (e.g. APTES), 
resulting in unpredictable variations and low reproducibility. Also, in the plasma 
treatment step, the oxygen was introduced from the side of the chamber inducing 
poor uniformity of surface coating.  In contrast, in the new PECVD strategy had the 
ability to automate the whole deposition process. Additionally, a showerhead was 
used to distribute a uniform coating with good repeatability. Furthermore, processing 
time was reduced by processing multiple samples simultaneously. 
 
A stability study on the PECVD-APTES-treated chips was also performed. The 
PECVD-APTES-treated chips were stored in a desiccator to prevent further 
oxidization. Then the results obtained with chips prepared freshly and stored for one 
month were compared.  Human IgG samples, with concentrations of 0.5 µg/mL and 5 
µg/mL, were tested on these two differently stored chips. After performing hIgG 
FLISA, the assay spots were analysed using the ANDOR iXon 885 camera-coupled 
fluorescence microscope. In Fig. 4.3.4.5, the image data illustrated shows that the 
morphology properties of both chips, with different storage times, is similar. The one 
month storage time did not affect the fluorescence intensity. Experimental analysis 
found that the PECVD-APTES-treated chips can be stored for at least one month 
without any significant deterioration in surface performance. Importantly, prolonged 
storage of the PECVD-APTES-treated chips does not negatively impact the surface 
capture of protein A. This allows for greater flexibility in the scheduling and running 
of the hIgG immunoassay. In addition, a significant workload in relation to the 
manual APTES liquid phase treatment of chips was eliminated. 
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Figure 4.3.4.5 Stability of PECVD-APTES surface during prolonged storage. 
After APTES-deposition, protein A with a concentration of 10 µg/mL was spotted on 
the assay spots. Mixtures of biotinylated anti-hIgG antibody and Neutravidin-Dylight 
650 were diluted in PBS (150 mM, pH 7.4) at a ratio of 3:1, followed by incubation 
at 37oC for 20 minutes. The loading sequence of reagents for the hIgG assay on 
‘SAF-element’ CD was as follows: BSA (3% (v/v) in PBS), hIgG standards, PBS 
(150 mM, pH 7.4), the mixture, and PBS (150 mM, pH 7.4). 
 
  0.5 µg/mL hIgG 
0 day storage time 
             0.5 µg/mL hIgG 
1 month prolonged storage time 
    5 µg/mL hIgG 
0 day storage time 
              5 µg/mL hIgG 
1 month prolonged storage time 
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4.3.5 Development and optimisation of the second design of a microfluidic 
compact ‘disc-like’ platform (CD) – ‘reagent delivery’ CD 
4.3.5.1 The design of the microfluidic CD-like platform   ‘reagent delivery’ CD 
Based on the study of the ‘SAF-element’ CD, a new design of the microfluidic CD 
was generated by the incorporation of serial siphon valves with a SAF ring lens. In 
addition, centrifugal force was also applied as the fluid delivery force. Other features 
of the ‘reagents delivery’ CD were as follows: 
 
Serial siphons imbedded with capillary valves 
The working mechanisms and features of a simple double siphon device on a 
microfluidic CD were illustrated previously in section 4.1.2. In this work, the siphon 
device was expanded by combining serial siphons with capillary valves. In addition, 
the application of four siphons with an increasing number of loops allows the 
sequential release of four reagents. One of the microfluidic units on the ‘reagents 
delivery’ CD is shown in Fig. 4.3.5.1. Four reservoir chambers are linked with 
increasing numbers of serial siphon components. The reagents in these reservoir 
chambers can be sequentially released during each high-low cycle of CD spinning: 
 
 
Figure 4.3.5.1 A schematic of a microfluidic unit on a  ‘reagents delivery’ CD. 
Each microfluidic unit contains the following components: four reagent delivery 
ports, serial siphons, washing/blocking port, assay region and waste chamber. 
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4.3.5.2 SAF detector for SAF ring lens 
 
Normally, fluorescence signals obtained from microfluidic chips are quantified by 
analysis of images obtained with a commercial fluorescence microscope. This 
method is unnecessarily expensive, time consuming, and requires significant 
operator training, particularly when considering future clinical translation of the 
technology (Wang et al., 2014). In this study, an ‘in-house’ detector system used to 
scan fluorescent spots deposited on SAF ring-lens chip was designed and is 
illustrated in Fig. 4.3.5.2. This SAF detector includes a 635-nm laser diode for 
excitation, optical elements such as filters, lenses, and detector aperture for 
collimation and focusing and a photomultiplier (PMT) for detection. In addition, the 
system contained the following: a parabolic mirror was used to collect SAF emission 
light; a baffle below the parabolic mirror was used to hold the mirror element and 
block SAF from lower angles; lens 2 in the former device which was used to focus 
emitted light was replaced due to the use of the SAF ring lens. The entire system was 
run using a standard laptop computer. This detector can precisely position the on-disc 
SAF chips and selectively collect SAF fluorescence above 61.5˚.  This prototype 
instrument allows the detection of low levels of analyte in small volumes and the 
collection of fluorescence only from molecules that are in close proximity to the 
interface of the substrate and the sample solution and not from the bulk solution. 
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Figure 4.3.5.2 A schematic of the SAF detector for the SAF chip. 
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4.3.5.3 Optimisation of Tween-20® concentration for siphon valving 	
Due to the hydrophobic nature of the PMMA substrate (water contact angle ~60˚), 
and the increased surface roughness due to micro-milling of the channels, priming of 
the siphons was extremely difficult. In previous work, the polymer and adhesive 
layers of the disc platform were plasma treated before assembly in order to facilitate 
the priming of the siphons. However, hydrophobic recovery of plasma-treated 
polymer substrates is well documented in the literature (Nwankire et al., 2011), 
making this technique highly unreliable. 
 
In order to reduce the surface tension and making it easier to prime the siphons, a 
titration study of the assay reagents and surfactant-Tween-20® concentrations were 
carried out. Fig. 4.3.5.4 demonstrates that it was critical to specifically optimise the 
Tween-20® concentration for each assay reagent. Therefore, following a series of 
empirical optimisations, the range for the ideal and absolute working contact angle 
were determined. 
 
The ideal working range (33˚–37˚) is the preferred contact angle, while the absolute 
working range (30˚–40˚) constitutes the limit of the upper and the lower contact 
angle, outside of which the siphons do not function reliably, e.g. they are either very 
hydrophobic (reagent does not prime the siphons) or very hydrophilic (reagent 
primes the siphons uncontrollably, that the inline capillary valves are unable to 
function properly). Therefore, prior to testing the microfluidic platform, the contact 
angle of the reagents is measured to ensure that they at least fall within the absolute 
working range. 
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Figure 4.3.5.3 Optimisation of the microfluidic assay conditions by varying 
Tween-20® (TW-20) concentration in the FLISA reagents. (A) Contact angle 
measurements of similar concentrations of Tween-20® in the four FLISA reagents on 
an  untreated PMMA substrate. (B) Contact angle measurements of the different 
optimized concentrations of Tween-20® in the reagents on untreated PMMA 
substrates. The ideal working range corresponds to the preferred contact angle for 
proper functioning of the siphons, while the absolute working range is the upper and 
lower limits, outside of which the siphons will not operate. 
(A) 
(B) 
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4.3.5.4 Characterisation of serial siphon valving 
Although serial siphoning on centrifugal microfluidic platforms has previously been 
reported (Siegrist et al., 2010), this valving scheme has not been implemented to 
automate the controlled, sequential release of multiple reagents fora heterogeneous, 
flow-based immunoassay (Fig. 4.3.5.4).  
 
To characterise the microfluidic platform and siphon valves, contrast agent (< 1% 
v/v) was added to PBS (pH 7.2) and loaded onto the disc. Aliquots (30 µL) that 
included the sample, wash 1, label, and wash 2 were first manually pipetted onto the 
disc. The appropriate spin protocol was then initiated, consisting of four consecutive 
repeats of ~975 revolutions-per-minute (RPM) to burst the inline capillary valves (< 
30 s), followed by 30 s at ~75 RPM to prime the siphon(s) via capillary action, and a 
final 4 min at ~375 RPM to flow the reagent across the active assay area on the SAF 
chip. An incubation step of 2 minutes was observed in-between each assay reagent 
flowing over the active assay spot. The design of the serial siphons, inline capillary 
valves and the spin profile were specifically optimized for this application. 
Visualization and monitoring of the on-disc fluidics was realized using a servo-motor 
coupled to a stroboscope imaging system, similar to systems previously reported in 
the literature (Grumann et al., 2005).  
 
The entire siphon valving sequence for all reagents was completed in less than 30 
minutes, without the need for operator intervention. The micro-milled channels 
exhibit a cross section of 250 µm × 250 µm. Overall, the serial siphons proved their 
ability to provide adequate flow control capability for the liquid handling when 
implementing the IgG assay. 
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Figure 4.3.5.4 Frame sequence of the serial siphons interspersed by inline capillary valves showing the sequential 
delivery of four reagents over the sensor spot. (A) At high spinning frequencies ~ 975 RPM, the capillary valves burst, and 
the centrifugal force holds back the liquid in the siphon channels. (B) At low frequencies ~75 RPM, liquid reagent primes the 
siphon channel by capillary action, and stops at the next inline capillary valve. (C) At ~375 RPM, liquid reagent is delivered to 
the sensor spot. This spin protocol is repeated (D-J) to sequentially deliver all four reagents to the sensor spot. 
	 169	
4.3.5.5 Generation of calibration curve on ‘reagents delivery’ CDs and 
quantification of bioprocess sample  
 
A callibration curve for an IgG immunoassay was successfully demonstrated using 
centrifugal microfluidics and a SAF prototype detector. In total, seven hIgG 
standards, a bioprocess sample and a blank sample were measured in triplicate using 
microfluidic serial siphon valves and the SAF detection system. Analysis was 
performed on two different days. Fig. 4.3.5.5B shows an inter-day hIgG calibration 
curve exhibiting an inter-day CV of 2.2 % to 12.6 % across the entire hIgG 
concentration range. In contrast, the conventional FLISA (Fig. 4.3.5.5A) displayed 
greater imprecision as the within-day CV range was 5.9 % to 18.9 %. 
 
Calibration curves from both analyses were used to quantify an “in-house” 
bioprocess sample which had an IgG concentration of ~10 mg/mL. There was good 
agreement between both methods as conventional FLISA analysis yielded an IgG 
concentration of 9.6 to 10.1 mg/mL, whereas, the serial siphon-based centrifugal 
microfluidic platform yielded an IgG concentration range of 9.6 to 9.9 mg/mL.  
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Figure 4.3.5.5 hIgG FLISA calibration curves. A) Conventional FLISA performed 
with high protein binding well plates and a commercial fluorescent detector. B) 
Microfluidic FLISA performed with an experimental PECVD-APTES-treated 
Zeonor® surface, microfluidic serial siphon valving system and a prototype SAF 
detector. Each sample was tested in triplicate and the error bars represent the 
standard deviation.  
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4.4 Discussion 
 
Microfluidic systems are expected to play an important role in the achievement of 
the next generation of diagnostic systems, based on small sample volume 
consumption, high-speed of reaction, large-scale and parallel assays, and 
compactness (Lee et al., 2010; Sin et al., 2011; Hugo et al., 2014). However, some 
important and challenging issues are yet to be resolved. In particular, the 
development of automatic systems that can sequentially release and deliver assay 
reagents is necessary for their wider applications. The concept of centrifugal 
microfluidics can be applied in realising fully automated microfluidic systems 
without external syringe pumping systems by using single motor control (Amasia et 
al., 2010; Noroozi et al., 2010; Mark et al., 2012). In this work, centrifugal force-
based microfluidics was developed for bioprocess sample analysis with high-speed, 
parallel operations and automatic reagents delivery.  
 
In the first part of this chapter, a ‘proof-of-concept’ microfluidic system for rapid 
quantification of hIgG in a bioprocessing matrix was initially demonstrated. The 
development can be broken down into the following stages. As a first step toward a 
microfluidic platform for rapid FLISA in ‘flow-through’ conditions, the hIgG 
indirect FLISA was optimised on a microtitre plate, in relation to assay components 
and concentrations. In particularly, the addition sequence of assay reagents was 
analysed. It was demonstrated that premixing and preincubating of secondary 
antibody and detector reagents was superior to sequentially adding reagents. The 
similar study was carried out on a competitive lateral flow immunoassay by 
Geertruida (Geertruida et al., 2008). In their study, a quick competitive immunoassay 
was achieved by the immediate addition of all reagents in the cartridge. These studies 
show that the investigation of the addition sequence of assay reagents is important 
for transition to the development of convenient FLISA. 
 
Secondly, the "in house" prototype SAF optical reader system designed by Dr. Dirk 
Kurzbuch and Mr. Martin Sommers (DCU, BDI), was successfully developed for 
efficient detection of fluorescence signals. On the one hand, this prototype 
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instrument allows the detection of low levels of analyte in small volumes, and 
collection of fluorescence only from molecules in close proximity to the interface of 
the substrate by utilisation of the SAF signal enhancement element known as a SAF 
lens (Kurzbuch et al., 2009 & 2013). This important aspect of SAF leads to 
substantial reductions in background signal. On the other hand this SAF prototype 
instrument provides outstanding properties in contrast to fluorescence microscopy, 
which is unnecessarily expensive, time consuming, and requires significant operator 
training (Wang et al., 2014). 
 
In addition, a ‘proof-of-concept’ system featuring micro-channels molded in PMMA 
and PSA, with manipulation of SAF optical detection, was achieved. This initial 
microfluidic design enables 12 parallel FLISAs to be performed by manually loading 
assay reagents after each flow and incubation. The Zeonor® slide, used both as a 
solid phase to support the formation of the reactive immune complex and as an 
essential optical component in SAF detection, needs to be functionalised and protein 
A coated before its assembly into a microfluidic flow-cell. The SAF optical 
instrument can specifically collect the fluorescence signal inside the microfluidic 
system from the immune complex, not the bulk solution above. In addition, a 
standard curve for the quantification of hIgG using a flow-cell was demonstrated, 
exhibiting nanomolar sensitivity, a dynamic range of quantification of 2 logs, and 
intra- coefficients of variation of about 10%.  
 
The development and optimization of two generations of microfluidic CDs for hIgG 
immunoassay was described i.e. the ‘SAF-element’ CD and ‘reagents delivery’ CD. 
These two CDs were designed with three-dimensional (3D) microstructure and 3D 
microchannel networks. The 3D microstructure and 3D microchannel networks are 
one of the key technologies for achieving the high-density integration of multiple 
microreactors and in realising highly functionalized microsystems (Kikutani et al., 
2002; Xia et al., 2005; Yoshiaki et al., 2012).  
 
The ‘SAF-element’ CD was built based on the study of flow-cells, that have a 
straight flow microchannel. This new CD provides more microfluidic units on each 
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platform which allows analysis of 20 samples simultaneously. This design can reduce 
the assay variations from different batches of CDs. In addition, another development 
was that the SAF optical element was initially incorporated onto the microfluidic 
disc itself, which enhanced the sensitivity of fluorescence detection. The successful 
incorporation of an optical component onto a microfluidic platform can facilitate the 
miniaturization of the fluorescence detection system. A new strategy for surface 
functionalization, which is PECVD-APTES, was introduced in surface preparation 
and compared with the liquid-APTES method. It was demonstrated that the PECVD-
APTES could provide assay spots with better morphology and a more stable 
functionalised surface, which can effectively reduce the inter- and intra coefficients 
of variation.  
 
One of the main challenges to realise automatic operation on microfluidic systems is 
the sequential release of fluids in a temporally and spatially controlled manner. The 
serial siphon valve has great potential to sequentially release fluids on centrifugal 
force-based platforms (Siegrist et al., 2010). The ‘reagents delivery’ CD was 
designed by incorporating serial siphon valves with the SAF technique on centrifugal 
microfluidic platforms. The automatic hIgG FLISA on this ‘reagents delivery’ CD 
was achieved by analysis of the best surface contact angle, determination of the 
concentration of Tween-20® in each of the assay reagents and characterisation of 
rotation protocol for the serial siphon valving. A calibration curve for the hIgG 
FLISA was optimised on ‘reagents delivery’ CDs, and a bioprocess sample was then 
quantified. Interestingly, comparison of both callibration curves revealed that the 
microfluidic FLISA provides less inter-day CV. However, a shift in the range of the 
IgG assay was also observed. The conventional FLISA had a range of 0.08 – 10 
µg/mL, in contrast, the microfluidic FLISA had a range of 0.8 – 50 µg/mL. This 
result was not unexpected as our device is a prototype system that contains not only 
an experimental protein capture surface but also experimental signal detection and 
reagent delivery systems. In contrast, conventional hIgG FLISA analysis was carried 
out with standard microtitre plates that have excellent protein binding properties as 
well as low autoflouresence levels. In addition, a commercially available microplate 
reader with high fluorescent sensitivity was used for sample analysis. To date, very 
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few microfluidic platforms were developed to detect hIgG using ELISA/FLISA 
technique (Pereira et al., 2011; Kim et al., 2011; Seia et al., 2012; Li et al., 2016). 
One of the microfluidic platform demonstrated by Li’s group, provided a lower 
limited detection of 0.03 ng/mL. However, multiple loading of assay reagents was 
required during assay procedure in the reported microfluidic platforms. A real 
automatic microfluidic system for hIgG detection was not demonstrated. An easy-to-
use microfluidic system for human IgG detection with high sensitivity was 
demonstrated with amperometric and fluorescence detection methods by Pereira’s 
group and Seia’s group, respectively. This microfluidic chip processes very simple 
microchannel network, only containing two straight channels. However, the size of 
the whole system was relatively large due to the application of a syringe pump 
system. Additionally, seven different assay reagents were required to sequentially 
pump into the chip in this immunoassay. As a result, this system cannot meet the 
requirement of a portable and ‘sample-to-answer’ system.  Kim’s group developed an 
automated microfluidic system for the complete performance of magnetic bead-
based immunoassay for mouse IgG detection. The assay on the chip is easily 
parallelized for high-throughput analysis and easily interfaced with various assay 
substrates by using an APTES micro-patterning method. However, a compact 
portable external instrument was not reported in this work.  Whereas, the research 
described in this thesis, when compared with the work described above, has many 
advantages including the provision of a ‘sample-to-answer’ system with an 
automated hIgG immunoassay, with acceptable sensitivity and on a portable 
instrument. 
 
Further optimisation of the microfluidic design, surface chemistry and the 
fluorescence detector has the potential to yield a lower IgG working range for the 
SAF-based microfluidic method. However, for our particular application the target 
analyte is in relative abundance. For example, bioprocess samples typically contain 
milligram amounts of IgG (Schepter et al., 1999). Therefore, the shift in assay range 
was not undesirable, as it reduced the dilution needed to allow the sample to fall 
within the linear range of the calibration curve. 
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CHAPTER 5 
Numerical Simulation of HIgG 
Immunoassay in Microchannels 
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5.1 Introduction 
 
5.1.1 Numerical simulation of microfluidic immunoassay 
 
Microfluidics-based technologies have revolutionized the possibilities for new assay 
format development and implementation. Compared to conventional immunoassay 
formats, microfluidic platforms provide remarkable new features. A high ‘surface-to-
volume’ ratio within microchannels, for instance, is capable of dramatically influencing 
interfacial reaction kinetics in solid-phase-based immunoassays and handling of 
reagents in the micro and nano-litre range (Whitesides, 2006; Janasek et al., 2006; 
Hartman et al., 2009; Konry et al., 2011). Consequently, these features allow a ‘sample-
to-answer’ test to be generated with short analysis times, minimal reagent consumption, 
integration, automation and parallel processing, leading to ‘in-line’, ‘at-line’ and in-situ 
processing of samples (Lee et al., 2009; Ko et al., 2011). Furthermore, centrifugal 
microfluidic platforms inherently possess additional advantages when compared to 
other lab-on-a-chip systems, due to the absence of expensive syringe pumps. Thus, disc 
platforms enable full integration of multiple liquid handling and assay processes 
including pumping, metering, mixing, reagent storage and sequential reagent delivery 
(He et al., 2008; Martinez-Duarte et al., 2010; Amasia et al., 2012; Wang et al., 2013). 
To this end, several multi-step and multiplex assays can be integrated onto the platforms, 
and with further development, they can facilitate the integration of optical sensors or 
other detections strategies.  
 
In the last decade, the modeling of microfluidic assays has received considerable 
attention. Numerical studies on the kinetics of binding in a heterogeneous microfluidic 
bioreactor by using a simple 2D model were extensively reported (Zimmermann et al., 
2005; Gervais et al., 2006; Friedrich et al., 2008; Fu et al., 2009; Hansen et al., 2012; 
Selmi et al., 2016). Zimmermann et al. investigated the key parameters of a direct 
immunoassay such as flow rate, surface feature size, and binding constants in a 
capillary-driven system (Zimmermann et al., 2005). Gervais and Jensen investigated the 
different regimes for diffusion-limited transport in microfluidic devices with respect to 
two key parameters i.e. the capture fraction of the bulk analyte at the surface and the 
saturation time-scale of the reactive surface (Gervais & Jensen, 2006). Fu et al.  
analyzed the fractional sensitivity of a competitive heterogeneous assay in a 
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microchannel with respect to analyte concentration, flow rate, initial surface density of 
binding sites, and antibody concentration (Fu et al., 2009).  Friedrich et al., used a 
theoretical model to demonstrate three approaches to optimize analyte transport in 
microchannels (Friedrich et al., 2008). Hansen and co-workers studied the transport 
dynamics in a model geometry of a surface plasmon resonance sensor  (Hansen et al., 
2012) while Selmi et al. investigated the electrothermal effect on a binding reaction by 
performing a 2D simulation on the immunoassay in a microchannel with asymmetrical 
interdigitated electrodes using the finite element method (Selmi et al., 2016).  
 
To date, most of the literature cited focused on investigating the binding kinetics of 
analyte in a microchannel. The computational modeling was applied to investigate the 
influence of critical factors of the binding kinetics of analyte, by predicting the amount 
of bounded analytes at one specific concentration of analyte reagent as a function of 
time. These simulated results can reveal how a change in a critical factor affects the 
binding kinetics with regard to one specific concentration of analyte reagent. However, 
these data cannot intuitively and accurately reflect the influence of a critical factor on 
the entire working range of analyte concentrations or the features of a standard curve, 
which is more essential and valuable for the design of a microfluidic sensor. Generally, 
the effect caused by a critical factor varies for different concentrations of analyte and 
analysis of a calibration curve is an essential method to evaluate any developed 
microfluidic systems (Wakayama et al., 2013; Krause et al., 2013; Shamsi et al., 2014). 
Unfortunately, there is no study dealing with the influence of the critical factors (such as 
flow velocity, channel height, capture area length and concentration of assay 
components) on the standard curve under microfluidic conditions. Hence, this study was 
carried out to fill this gap. 
 
5.1.2 Simulation conditions 
 
We have previously developed a prototype system for ‘at-line’ and ‘sample-to-answer’ 
bioprocess monitoring (Nwankire et al., 2013). In this system, microfluidic networks 
were developed for a surface-based immunoassay for IgG. The antibodies that were 
immobilized on one wall of a microchannel captured analytes flowing in the 
microchannel. This technology is capable of detecting analytes from sub-microliter 
volumes of sample within 30 min, whilst, achieving reasonable sensitivity. In this 
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system, the heterogeneous indirect assay for hIgG detection included four reagents, 
which are the capture molecule, Protein A, analyte molecules such as  hIgG, the anti-
hIgG (biotinylated, chicken IgY) antibody and the detection molecule, NeutrAvidin-
DyLight 650 conjugate (Fig. 5.1.2). Protein A is immobilized on the functionalized 
solid surface, which contains amine groups. It can capture the hIgG molecule in the 
fluid by binding to the Fc region of hIgG with a high affinity. The biotinylated anti-
hIgG is added and specifically binds with captured hIgG on the surface. The 
NeutrAvidin, conjugated with the fluorescent molecule, specifically binds with biotin, 
which is conjugated to anti-hIgG. The fluorescence signal produced by DyLight-650 
responds to the amount of hIgG in the samples. The utilisation of the ‘biotin-avidin’ 
system in this assay can provide high signal amplification effects and associated high 
sensitivity. In the following sections, these reagents are denoted as Protein A, hIgG, 
anti-hIgG and NeutrAvidin, respectively. This assay involves three heterogeneous 
binding reactions, which are the reaction between initial capture molecules (Protein A) 
and analytes (hIgG), hIgG molecules and anti-hIgG and, anti-hIgG and the final 
detector reagent (DyLight-labelled Neutravdin).  
 
 
Figure 5.1.2 Schematic of the hIgG immunoassay. 
 
5.2 Aims of this chapter 
 
In this paper, the theoretical modeling focuses on an investigation of the impact of some 
critical factors (such as flow velocity, channel height, capture area length and 
concentration of assay components) on the performance of the previously developed 
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microfluidics-based immunoassay. Additionally, the investigation of the impact of the 
critical factors on the standard curves is presented from two different aspects. On the 
one hand, ideal conditions (such as no constraints on reagent availability and assay time) 
were assumed by most papers in the literature reporting studies of a microfluidic-based 
immunoassay. The predicted data under ideal conditions can reveal how a change in 
conditions like velocity and channel height, would affect the binding kinetics during the 
entire assay working range without any change in the volume of reagents., However, 
additional studies were performed under conditions with finite volumes of reagents and 
specific assay times. Under experimental conditions, however, the microfluidic assays 
are performed under many constraints. For example, the microfluidics for analytical 
applications (e.g., ‘point-of-care’ assay or ‘time-to-result assay’), were designed to 
reduce sample consumption and assay time. This is important as it is not possible to use 
large amounts/volumes of reagent and hour-long assay times in a microfluidic system. 
Therefore, it may be beneficial to predict the standard curves within the ‘real-world’ 
constraints, which can really contribute to the design and optimization of microfluidic 
systems in practical experiments. 
 
5.3 Results  
 
In order to solve the system of ODEs, a number of experimentally derived parameters 
were used. Protein A was immobilized on the sensor area with an available binding site 
density of 2×10-8 site/m2. The diffusivity of hIgG molecules is 3.89×10-11 m2/s (Chang 
et al., 2012). The kon and koff for Protein A and hIgG binding is 8.02×103 m3/mol∙s and 
2.7×10-4 s-1 (Saha et al., 2003), respectively. The diffusivity of anti-hIgG molecules is 
1×10-10 m2 /s (Lionello et al., 2005). In this simulation, the binding reaction between 
hIgG and biotin conjugated anti-hIgG was assumed as the binding between hIgG and 
anti-hIgG molecule. Additionally, the k on and koff for hIgG and anti-hIgG binding is 
2.5×105 m3/mol∙s and 3×10-4 s-1 (Hu et al., 2007), respectively. The hIgG samples with 
concentrations of 1, 5, 12.5, 25, 62.5, 125, 312.5, 625 and 1250 nM were used which 
was consistent with the previously developed microfluidic-based immunoassay 
(Nwankire et al., 2013). The flow velocity is 3.75×10-4 ms-1, which is obtained from our 
experimental data. The cross-section area of the microchannel in our developed 
microfluidic system was 4×10-8 m2 with dimensions of 8×10-4 m in width and 5×10-5 m 
in height.  
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5.3.1 Influence of the flow velocity  
 
One of the most important parameters in the simulation was the flow velocity. In this 
study, the way in which a change in flow velocity would affect the assay performance, 
was examined under the conditions of infinite and finite volumes of reagents, 
respectively. For the investigation of the binding reaction between Protein A and hIgG 
under infinite volume conditions, hIgG and its residence time was not limited. The 
standard curve of hIgG adsorption under these non-limited conditions was obtained by 
plotting the binding rate (Γ/Γmax) at one defined moment against the corresponding 
analyte concentrations. However, the time selected to plot and analyse the standard 
curve had to be considered carefully. According the equation 5 described in previous 
section 2.6.1, Γ is not related to flow velocity, but depends on the concentration of bulk 
solution (Cw). For one defined concentration of hIgG reagent (Cw), although the 
velocity is different, the Protein A surfaces are ultimately saturated and reach the 
maximum binding density (Γmax) at infinite time. The velocity of hIgG reagents only 
affects the saturation time of the Protein A surface or equilibrium time of hIgG 
adsorption, except the Γmax. The lower velocity needs a longer saturation time. 
Therefore, in this scenario, flow velocity cannot affect the Γ/Γmax if the residence time 
is adequately long. In other words, the curves predicted with varying flow velocity 
would be coincident when the residence time is infinite. 
 
In order to prevent this problem, 40s is applied as a moderate residence time for each 
velocity. In Fig. 5.3.1a, the simulated surface-binding rate (Γ/Γmax) at 40s was plotted 
against the hIgG concentrations. The standard curves of Protein A and hIgG reactions 
with varying flow velocity and the same residence time, were compared. With 
increasing hIgG concentrations from 10 to 1000 nM, it can be observed clearly that a 
higher velocity provides more binding. The utilisation of higher velocity can shift 
standard curves to the left along the x-axis, where the assay is more sensitive to measure 
the analyte at lower concentrations. This phenomenon was explained by the profiles of 
free hIgG concentration above the sensor surface. Fig. 5.3.1b shows the hIgG 
concentration gradient of the reaction at the same time but with varying velocities. The 
red color represents high concentrations of hIgG. The blue color represents low 
concentrations of hIgG. In Fig. 5.3.1b, the free hIgG concentration gradient above the 
capture surface can be observed. The hIgG concentration gradient was formed above the 
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capture surface if the hIgG adsorption on the capture surface was quicker than the hIgG 
transport from bulk to the surface. In this context, the hIgG concentration near the 
capture surface is now much lower than the initial input hIgG concentration. This low 
hIgG concentration area is called the depletion area. As a result, the analyte adsorption 
process is retarded by the existing depletion area. Therefore, in order to accelerate the 
adsorption process, reducing the depletion area thickness was considered. Additionally, 
it can be clearly observed that the blue area shrunk above the capture surface with 
increase of flow velocity. Fig. 5.3.1b reveals the depletion area can be reduced due to 
the rapid delivery of hIgG as a result of the higher velocity.  
 
However, finite assay time and a large volume of reagent are not expected for the 
development of an ideal microfluidic system in practice. For a certain volume of reagent 
(e.g. 30 µL) and channel geometry (e.g. 8×10-4 m (W) + 5×10-5 m (H)) in our previously 
developed system, the residence times for velocities of 1.88×10-4 ms-1, 3.75×10-4 ms-1 
and 7.50×10-4 ms-1 were 40s, 20s and 10s, respectively. As a result of the change in 
residence time, the benefit on assay performance introduced by the high flow velocity 
would be reduced. In order to investigate the effect of flow velocity in the practical 
situation, the simulations were carried out with the constraint conditions shown in Fig. 
5.3.1c. The predicted standard curves of Protein A and hIgG reactions were obtained by 
plotting the binding rate (Γ/ Γmax) with various velocities and residence times against 
the corresponding analyte concentrations. According to the data in Fig 5.3.1c, with the 
higher velocity of 7.50×10-4 ms-1, there was less binding due to the short residence time 
(10s). Conversely, the lower velocity of 1.88×10-4 ms-1 demonstrated more binding as a 
result of longer residence time (40s). Additionally, the assay with velocity of 1.88×10-4 
ms-1 generated a better sensitivity at a concentration of 100 nM hIgG, but required 
longer assay time, whereas, in contrast, the assay with a velocity of 3.75×10-4 ms-1 had 
a similar working range and relatively short assay time. For the conditions of the higher 
velocity e.g. 7.50×10-4 ms-1, the curve was shifted to the right, where it is not sensitive 
for detection of hIgG at low concentrations. 
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Figure 5.3.1 Influence of flow velocity on microfluidic assay performance. (a) 
Predicted standard curves without constraint on reagent at 40s. The flow velocities were 
1.88×10-4 ms-1, 3.75×10-4 ms-1 and 7.50×10-4 ms-1 respectively.  (b) The profiles of hIgG 
concentration in the microchannel. They showed the hIgG distribution at 100s with 
velocities of 1.88×10-4 ms-1, 3.75×10-4 ms-1 and 7.50×10-4 ms-1. (c) Predicted standard 
curves with same volumes of reagents. In the designed microchannel with a specific 
geometry, 30 µL of each reagent flowing with varying velocities (1.88×10-4 ms-1, 
3.75×10-4 ms-1 and 7.50×10-4 ms-1) had different residence times (i.e. 40s, 20s and 10s).  
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5.3.2 Influence of channel height on assay performance 
 
With the aim of reducing analyte depletion and accelerating analyte adsorption, the 
impact of a change in channel height on the binding process was investigated. 
Simulations were carried out by comparing the predicted standard curves with the 
application of the different channel heights, which had the values of 1×10-5, 5×10-5 and 
20×10-5 m, respectively. The fluids had a constant velocity of 3.75×10-4 ms-1. 
 
According the equation 5 described in section 2.6.1, Γ is not related to channel height. 
For one defined concentration of IgG reagent (Cw), although the channel heights are 
different, the Protein A surfaces are ultimately saturated and reach the maximum 
binding density (Γmax) at infinite time. Therefore, without the constraints on reagent 
and residence time, the influence of channel height on the predicted standard curves 
would be rarely observed when the residence time is adequately long. This similar 
problem was discussed in the last section. In this scenario, a moderate time of 20s is 
applied as the residence time for each simulation. The simulations of a standard curves 
under these non-limited conditions were obtained by plotting the binding rate (Γ/ Γmax) 
at 20s against the corresponding analyte concentrations in Fig. 5.3.2a. At 20s, a channel 
height of 5×10-5 m provided a higher binding rate, whereas the values of channel height 
larger or smaller than 5×10-5 m induced a declining trend in binding rate. It revealed 
that the binding rate did not increase continuously with the increasing height of channel. 
Therefore, it was essential for development of an efficient fluidic sensor that 
optimization of the channel height occur. The assay with a channel height of 5×10-5 m 
possesses a working range from 25 nM to 1,000 nM. In contrast, the assays with heights 
of 1×10-5 and 20×10-5 m, showed a small working range.  
 
In order to investigate the influence of channel height on the microfluidic assay 
performance, the simulations had to be carried out with the real-world constraints. We 
assumed a fluid, with volume of 30 µL, flowing into microchannels with different 
heights, which were 1×10-5, 5×10-5, and 20×10-5 m, respectively. As a result of the 
infinite reagent availability, the residence time for a 30 µL fluid volume varied. In this 
case, the fluids had a constant velocity of 3.75×10-4 ms-1. Therefore, the residence time 
corresponding to the increasing channel heights (1×10-5, 5×10-5, and 20×10-5 m) were 
100s, 20s, and 5s, respectively. The effects of channel height are different between the 
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conditions of finite volumes (Fig. 5.3.2b) and infinite volumes (Fig. 5.3.2a) of reagent 
availability. From Fig. 5.3.2b it can be observed that the surface-binding rate for each 
hIgG concentration was obviously increased with the microchannel height of 1×10-5 m, 
especially for hIgG concentrations above 10 nM. Corresponding to the increasing 
surface binding rate, these three curves were significantly different with respect to 
working range. With a volume of 30 µL of hIgG, the height of 1×10-5 m provided a 
sensitive assay in a working range from 0.8 to 125 nM, but needs a relatively longer 
assay time (100s). The height of 5×10-5 m provided an assay with good sensitivity in a 
working range from 25 to 625 nM, and a 20s assay time, whereas, the height of 20×10-5 
m showed a working range of high concentration of hIgG, which cannot effectively be 
applied for our application. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 186 
 
Figure 5.3.2 Influence of channel height on assay performance. (a) Predicted standard 
curves without constraint on reagent at 20s. The flow channel heights were 1×10-5 m, 
5×10-5 m and 20×10-5 m, respectively.  (b) Predicted standard curves with same volume 
of reagents. In the microchannels with heights of 1×10-5 m, 5×10-5 m and 20×10-5 m, 30 
µL of each reagent with the velocity of 3.75×10-4 ms-1 had residence times of 100s, 20s 
and 5s. 
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5.3.3 Influence of the sensor area  
 
In the 2D simulation (Fig. 2.6.1), the microchannel, including the capture area on the 
wall, was defined with two dimensions, which are length and height. The width of 
capture area was not considered because the mass transport in this direction did not 
contribute to binding kinetics. In this section, the influence of capture area length on 
microfluidic assay performance was determined by using different capture area lengths, 
which were 0.1×10-3, 2×10-3 and 4×10-3 m. For a fluid with a constant volume in the 
microchannel, the change in capture area length would not affect the residence time. 
Hence, the influence of capture area length on the assay performance is consistent under 
finite or infinite reagent availability.  In Fig. 5.3.3a, the predicted standard curves were 
produced by plotting the surface binding rate at 20s against the hIgG concentrations. 
The surface binding rates are dramatically increased by using a shorter capture area 
length. The curve generated with a capture area length of 0.1×10-3 m shows an 
enhanced sensitivity with a working range from 5 to 125 nM, whereas the curves with 
large capture area length shows working ranges with higher hIgG concentrations. 
Alternatively, the influence of the analyte-capture area length was verified by 
simulating distributions of the free hIgG concentration at 20s in the modeled channel, 
where the capture area lengths were 0.1×10-3, 2×10-3 and 4×10-3 m, respectively (Fig. 
5.3.3b). In the simulation above, the capture areas with increasing length started from 
the same position (1×10-3 m) along the x-axis of the microchannel. Additionally, a fluid 
that contains 625 nM of hIgG flows over the capture areas with a velocity of 3.75×10-4 
ms-1. 
 
At 20s, the capture area with a length of 0.1×10-3 m was fully covered by the red color 
without any blue color (depletion area). It revealed that the binding sites on this capture 
area have been saturated and the value of the surface binding rate (Γ/ Γmax) was 1, 
which was consistent with the data in Fig. 5.3.3a. However, the capture area with a 
length of 2×10-3 m was partly covered by the red color, which occupies approximately 
25% of the length of this capture area. This revealed that the capture area was partly 
saturated, and the remaining part of the capture area was also covered by a depletion 
area. Meanwhile, the capture area with a length of 4×10-3 m located from 1×10-3 to 
5×10-3 m on the wall, has a large blue area, which occupies more than 75% of the whole 
capture area. In conclusion, the capture area with a length of 0.1×10-3 m had the largest 
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proportion of saturated area and the one with a length of 4×10-3 m had the smallest 
proportion. The proportion of the saturated area indicated the surface binding rate (Γ/ 
Γmax). Hence, a smaller sensor can provide a higher surface binding rate in a 
microchannel as deduced from this simulation. Additionally, it was shown that the 
present of surface saturation started from one end of the capture area to the other end 
along the x-axis of the microchannel.  
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Figure 5.3.3 Influence of sensor area on assay performance. (a) Predicted standard 
curves with same volume of reagents (30 µL), residence time (20s) and flow velocity 
(3.75×10-4 ms-1). The three curves were generated by using different sensor lengths, 
which were 0.1×10-3, 2×10-3 and 4×10-3 m. (b) Predicted profiles of free IgG 
concentration at 20s in microchannels, where the sensor lengths were 0.1×10-3, 2×10-3 
and 4×10-3 m. 
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5.3.4 Simulation of the indirect hIgG assay in microchannel 
 
For most of the developed microfluidic immunoassay applications, the assay format is a 
heterogeneous assay with multiple reagents and reactions. In our previous study (Fig. 
5.1.2), the hetergeneous indirect assay including three binding reactions. In order to 
investigate the influence of concentrations of assay reagents on the assay performance, 
simulations of this indirect hIgG assay in the microfluidic system were carried out witha 
finite volume of reagents (30 µL) and the same residence time (20s) for each flow.  
 
The density of initial binding sites in surface immunoassays usually plays an important 
role in defining the maximum number of analyte molecules that can be captured. The 
influence of the initial density of Protein A was investigated at the begnning of this 
section. Protein A surfaces with different densities ( 1×10-9, 5×10-9, 2×10-8 and 1×10-7 
site/m2 )were used to capture serial concentrations of hIgG reagents. The densities of 
captured hIgG were the plotted against the hIgG concentrations, as shown in Fig 5.3.4a. 
It was demonstratedthat increased density of Protein A biunding sites dramatically 
enhanced sensitivity. 
 
Based on the data in Fig 5.3.4a, the influence of concentration of secondary assay 
reagent on assay performance was investigated by simulation of the binding reaction 
between captured hIgG on the surface and anti-hIgG in solution. The simulation was 
carried out using the density of captured hIgG (Γ) as the surface density of binding 
(Γmax) for the secondary reaction. The density of captured hIgG (Γ) was determined 
from the first reaction with the Protein A with a density of 2×10-8 site/m2 as shown in 
Fig 5.3.4a. Additionally, varying concentrations of anti-hIgG solutions of50, 100, 200 
and 2000 nM, were applied in the secondary reaction. The densities of captured anti-
hIgG on the microchannel surface were plotted against the hIgG concentrations in Fig 
6.2.4b. The standard curve generated with the higher concentration of anti-hIgG shows 
the significantly increased sensitivity. This result indicates that the application of 
sufficient secondary reagent can provide an enhanced sensitivity to the assay through 
saturation the entire surface binding site which was generated from first reaction.  
 
The reaction of the biotin labelled anti-hIgG and with the fluorescently labelled 
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NeutrAvidin dye relies on the biotin-NeutrAvidin binding, which exhibits the highest 
known affinity (KD=1015 M-1) in the nature. Therefore, we did not take this reaction into 
account because it is generally not the limitation in immunoassays. 
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Figure 5.3.4 Influence of reagents concentrations on assay performance. (a) 
Optimisation of initial density of binding sites by comparing first-reaction performance. 
(b) Optimisation of anti-hIgG concentration by comparing second-reaction performance. 
(c) Optimisation of combination of assay reagents by analysis of assay performance 
with different reagent concentrations.  
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In Fig 6.2.4c, the standard curves of this hIgG indirect immunoassay in the 
microchannel with different concentrations of Protein A and anti-hIgG were compared. 
Both curves generated with 500 nM anti-hIgG reveals that 500 nM anti-hIgG is 
sufficient to saturate the captured-hIgG on the surfaces, where the concentrations of 
Protein A on the surface is 2×10-8 or 1×10-7 site/m2.  In contrast, the curves with 120 
nM anti-hIgG shows dramatic reduction in assay sensitivity since it was not sufficient to 
saturated hIgG binding sites. For the curves generated with the high initial binding site 
numbers (1×10-7 site/m2 ), the superior binding rate presenting in first reaction can be 
eliminated by shortage of anti-hIgG (120 nM). However, it did not indicate that the 
assay with high concentrations of each reagent would provide the ideal performance. 
Comparing the two curves with 500 nM anti-hIgG and different Protein A densities, the 
curve generated with a Protein A of 2×10-8 site/m2 possessed a better sensitity than the 
curve with a Protein A of 1×10-7 site/m2 during the range from 50 nM to 1000 nM, 
which was more accurate for detection of  small amounts of analyte. Forthermore, the 
high sensitivity and extremly large working range presenting in the curve with a Protein 
A of 1×10-7 site/m2, generally did not exist in practice  due to limitations of active 
binding density and the detection technique. 
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5.4 Discussion  
 
Microfluidic platforms offer several advantages over conventional microtiter plates 
where the assays are performed using much larger volumes and longer times. However, 
to take full advantage of microfluidic platforms, it is important to understand the 
influence of major parameters on the binding kinetics and identify the major parameters 
affecting assay performance in microfluidics. In previous studies, computational 
modeling was applied to investigate the influence of major parameters on the binding 
kinetics in the microchannel by simulating binding of the analytes with specific 
concentrations as a function of time (Zimmermann et al., 2005; Parsa et al., 2008). 
These simulated results show how a change of variable parameter affects the binding 
kinetics with regard to one specific concentration of analyte. It is not clear what the 
influence on the entire working range of analyte concentrations, This is essential for 
good design of a microfluidic sensor with outstanding binding kinetics and optimisation 
of the immunoassay thus providing good sensitivity across the entire working range. 
 
In this study, we investigated the influence of the major parameters (flow velocity, 
channel height, capture area length and concentration of assay components) on assay 
performance (standard curves). For a defined volume of reagent, the variation in flow 
velocity or channel geometry can induce a change influid residence time, leading to a 
barrier for the analysis of the influence of these two factors on the assay performance. 
Hence, the study of flow velocity and channel geometry was performed under 
conditions of both finite and infinite volume of assay reagents.  
 
The high flow velocity of reagents above the capture area can accelerate the binding 
process without considering reagent volume and time constraints. This viewpoint was 
proved by comparing the rate of analyte binding with different flow rates in Fu’s study 
(Fu et al., 2009). However, finite assay time and a large volume of reagent are not 
expected for the development of an ideal microfluidic system in practice. 
 
There are several studies considering the effect of microchannel geometry on mass 
transport. Dutta’s group investigated the effect of aspect ratio on solute dispersivity in 
pressure-driven flow systems for a fixed channel depth. They showed that the solute 
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dispersion coefficient decreased monotonically with an increase in the aspect ratio of 
the channel (Dutta et al., 2006). Squires discussed the physical process of analyte 
transport within microchannels of various sizes by computing several dimensional 
parameters. In their study, it was theoretically proved that a smaller aspect ratio of the 
capture area could reduce analyte transport (Squires et al., 2008). Our research analysed 
both the effect of height of microchannel on the standard curves and also precisely 
computed the criteria associated with microchannel height for our specific microfluidic 
system.  
 
This study on the influence of capture area confirmed previous studies (Zimmermann et 
al., 2005; Zhao et al., 2010) that a smaller capture area can increase the rate of binding 
for microfluidic-based assay. Furthermore, we demonstrated the effect of the capture 
area on the sensitivity of the standard curve, which provided a direct guideline for 
design and optimization of the microfluidic system. 
 
Using theoretical modeling, we investigated the effect of the varying flow velocity, 
channel height, and analyte-capture area length on the binding rate of analytes at 
different concentrations. This simulation revealed that depletion caused by mass-
transport limitation is one of the key bottlenecks to the sensitivity of a solid-support 
based microfluidic assay. Without considering the constraints of reagent availability and 
assay time, this limitation can be reduced through faster flow velocity, reducing the size 
of the capture area, or optimising the channel height.  
 
On the other hand, we examined the effect of these varying assay parameters on the 
capture of analytes at different concentrations under real-world operating conditions. 
Under the constraints of reagent and time, the simulations revealed trends that are not 
necessarily intuitive according to generic considerations of microfluidic advantages. For 
example, a 30 µL of sample with a high velocity resulted in a relatively low binding rate 
due to the fact that the contact time was reduced. In terms of producing guidelines for 
best practice, the simulation of the assay performance (e.g. standard curve) under real-
world constraints was more convincing..  
 
The influence of assay components on the performance of microfluidic system was 
investigated by simulation of the entire indirect assay in a microchannel. The simulated 
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data revealed the necessaryamount of each reagent required for contributing to a 
sensitive assay. In addition, it was important for to optimise the concentrations of each 
of the assay components. Overall, this approach can provide very useful insights to aid 
in the optimisation of microfluidics-baseed immunoassays and can contribute to recent 
findings in the field (O’Kennedy, 2017) 
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CHAPTER 6  
Overall Outcomes and 
Conclusions 
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The goals of the work presented in this thesis were to develop immunoassays and 
microfluidic systems for rapid detection of selected targets such as marine toxins and 
human IgG. The strategies employed involved the construction of a recombinant 
scFv library for the toxins and the isolation of high affinity scFv antibodies from the 
recombinant library. In addition, the techniques of microfluidics and SAF detection 
were applied for development of a rapid immunoassay system for IgG. 
 
Chapter 3 described the production of a recombinant antibody against both STX and 
Neo groups of PSTs. Firstly, the anti-Neo-STX-KLH scFv library was constructed. 
Then phage display was employed to isolate STX-OVA-specific scFv from anti-Neo-
STX-KLH scFv library via biopanning. After 4 rounds of bio-panning, recombinant 
antibodies, with high affinity to STXs, were not isolated. There are a variety of 
reasons to hinder the isolation of a recombinant antibody. The immunisation 
associated problems caused by the toxic nature of the immunogen and the size of the 
hapten and the quality of conjugation, may lead to poor immune responses inan 
animal (Campbell et al., 2011). Amplification problems during the construction of 
the antibody library may lead to inefficient variable gene assembly and a poor 
diversity within thescFv library (Koohapitagtam et al., 2010). The undesired loss 
oftarget-binding clones during biopanning was commonly reported(Barbas et al., 
2001). The main limitation tothis project work was the scarcity and high price of 
purified toxin material. If a reliable, purified source of toxin material becomes 
available in the future, it may be possible to isolate the recombinant antibody to PSPs 
from the immune libraries generated during this project and this work is currently 
ongoing. 
 
The development of a new immunoassay system for rapid quantification of hIgG, 
was described in chapter 4. In the initial part of this chapter a hIgG FLISA was 
successfully developed on an microtitre plate by optimizing the assay reagents’ 
concentrations. Additionally, the application of mixture of anti-hIgG and DyLight 
gave this assay a reduced completion time and larger working range.  This hIgG 
assay was then transferred onto a ‘proof-of-concept’ microfluidic system, with flow-
cells, incorporating a number of optimized parameters: (1) use of a reduced volume 
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of assay reagents (from 100 µL reduced to 30 µL), (2) shortened assay-time (from 
one day to 20 minutes). (3) optimized surface chemistry for protein A 
immobilisation, and (5) a reduced number of assay steps. The study revealed that the 
immunoassay could be further developed by changing the addition sequence of assay 
reagents. In particular, it was initially demonstrated that premixing and pre-
incubating of secondary antibody and detector reagents under ideal conditions was 
superior to sequentially adding reagents.  
 
The ‘proof-of-concept’ microfluidic-flow-cells feature straight micro-channels 
molded in PMMA and PSA. The initial microfluidic design enabled 12 separate 
immunoassays to be performed simultaneously. However, manual loading was 
required for each immunoassay reagent. The SAF optical instrument was modified to 
specifically collect the fluorescence signals inside the microfluidic system from the 
immune-complexes and not from the bulk solution. The Zeonor® slide, was used both 
as a solid phase to support the formation of the reactive immune-complex and as an 
essential optical component in the SAF detection system. A calibration curve for the 
quantification of hIgG based on the ‘proof-of-concept’ microfluidic system was 
established. This microfluidic immunoassay is capable of detecting hIgG in the lower 
nanogram range. In addition, the assay had a dynamic range of quantification of 
approximately 2 logs with inter-day coefficients of variation of approximately 10%. 
This compares favorably to the conventional hIgG immunoassay. Furthermore, an 
industrial bioprocess sample was quantified using the microfluidic ‘flow-cell’ device. 
Both conventional and flow-cell methods yielded comparable results.  
 
In the rest of chapter, two generations of microfluidic CDs were successfully 
developed for hIgG immunoassay. They are the ‘SAF-element’ CD and a ‘reagents 
delivery’ CD. These two CDs have improved design with three-dimensional (3D) 
microstructure and 3D microchannel networks. The ‘20-SAF-element’ CD contains 
20 separate microfluidic units and incorporates the optical elements into each units. 
A new strategy for surface functionalization (PECVD) was introduced in surface 
preparation. It was demonstrated that PECVD-functionalisation using APTES 
generated better assay spot morphology and a more stable functionalised surface than 
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liquid-phase APTES depositions.  
 
In the next iteration of microfluidic design, serial siphon valves were incorporated 
into the CD. The automatic hIgG FLISA on this ‘reagents delivery’ CD was realized 
through optimisations that included: (1) surface contact angle, (2) Tween-20® 
concentrations and (3) use of the serial siphon valving rotation protocol. A 
calibration curve for the hIgG immunoassay was successfully demonstrated using the 
serial siphon CD and the SAF prototype detector. The inter-day hIgG calibration 
curve exhibited an inter-day coefficient of variation (CV) of 2.2 % to 12.6 % across 
the entire hIgG concentration range tested. In contrast, the conventional FLISA 
displayed greater imprecision as the inter-day CV range was 5.9 % to 18.9 %. 
Furthermore, quantification of a bioprocess sample based on both calibration curves 
revealed comparable results.  
 
A calibration curve for hIgG FLISA was optimised on ‘reagents delivery’ CDs, and a 
bioprocess sample was then quantified. Interestingly, comparison of both callibration 
curves revealed that microfluidic FLISA provides less inter-day CV. However, a shift 
in the range of the IgG assay was also observed. The conventional FLISA had a 
range of 0.08 – 10 µg/mL, in contrast, the microfluidic FLISA had a range of 0.8 – 
50 µg/mL. This result was not unexpected as our device is a prototype system that 
contains not only an experimental protein capture surface but also experimental 
signal detection and reagent delivery systems. In contrast, conventional hIgG FLISA 
analysis was carried out with standard microtitre plates that have excellent protein 
binding properties as well as low autoflouresence levels. In addition, a commercially 
available microplate reader with high fluorescent sensitivity was used for sample 
analysis. Further optimisation of the microfluidic design, surface chemistry and the 
fluorescence detector has the potential to yield a lower IgG working range for the 
SAF-based microfluidic method. However, for our particular application the target 
analyte is in relative abundance. For example, bioprocess samples typically contain 
milligram amounts of IgG (Schepter et al., 1999). Therefore, the shift in assay range 
was not undesirable, as it reduced the dilution needed to allow the sample to fall 
within the linear range of the calibration curve. 
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Modeiling of the hIgG indirect immunoassay in a microchannel was described in 
chapter 5.  Using theoretical modelling, several important parameters related to 
reaction binding rate were investigated. These included flow velocity, channel 
height, analyte-capture area length and reagent’ concenration. This simulation 
revealed that depletion caused by mass-transport limitation above sensor area is one 
of the key bottlenecks to the sensitivity of solid-support-based  microfluidic assays. 
Without considering the constraints of reagent availability and assay time, this 
limitation can be reduced through faster flow velocity, reducing the size of the 
capture area, or optimising the channel height. However, in practice, these real-world 
constrains have to be considered to develop a microfluidic system. Under the 
constraints of reagent and time, the simulations revealed trends that are not 
necessarily intuitive according to generic considerations of microfluidic advantages. 
For example, a 30 µL of sample with a high velocity resulted in a relatively low 
binding rate due to the fact that contact time was reduced. In terms of producing 
guidelines for best-practice, the simulation of the assay performance (e.g. standard 
curve) under real-world constraints was more convincing. In order to develop the 
microfluidic assay performance, the solutions place constraints on the operations. 
Therefore, the simulations have to be considered with some assay factors. In the rest 
of chapter 5, the influence of assay components on the performance of microfluidic 
system was investigated by simulation of the entire indirect assay in microchannel. 
The simulated data revealed the necessaryamount of each reagent required for 
contributing to a sensitive assay. In addition, it was important to optimise the 
concentrations of each of the assay components.  
 
The key outcomes from the study can be concluded as follows: 
(1) for the first time, SAF optical detection has been integrated with a 
centrifugal microfluidic platform, to enable surface-specific fluorescence detection in 
a heterogeneous immunoassay,  
(2) in addition,the SAF optical elements have been incorporated onto the 
microfluidic disc itself,  
(3) plasma technology was used to polymerise APTES onto the surface of the 
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SAF chip to mediate immobilisation of specific capture probes,  
(4)  a quantitative, surface-based, IgG immunoassay was developed and used 
to test this system,  
(5) the concentration of Tween-20 in each of the assay reagents was 
optimised, so as to facilitate the function of the serial siphon and capillary valves,  
(6)  additionally, the hardware interface with such an integrated microfluidic 
platform was successfully developed, 
(7)  furthermore, mdelling of the hIgG indirect microfluidic immunoassay 
was established and can be applied to optimise other similar microfluidics systems 
for further study.  
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Computer program for simulation of hIgG immunoassay in microchannel 
 
 
clc;        % Clear Command Window Screen 
clear all;  % Clear Matlab Memory 
close all;  % Clear all figures 
  
% Configuration for simulation 
make_video = 0;             % 0: do not make video clip; 1: make video 
clip. 
  
% Advection-Diffusion Equation Variables ------------------------------ 
D    = 4*(10^-11);          % Diffusivity  
C0   = 6*(10^-6);           % Bulk concentration   
k_on = 2.5*(10^3);          % Constant of hybridization. 
k_off= 5*10^-3;             % Constant of desorption.  
gamma0 = 2*10^8;            % Initial concentration in available 
hybridization sites. 
v_mean = 3.75*10^-4;        % Mean velocity (m/s) 
  
% Temporal Variables -------------------------------------------------- 
ts    = 0;                  % Start Time (s) 
t_off = 3000;               % Time to turn off the flow (s) - 1 minute = 
60s 
tf    = 5000;               % Final Time (s) 
tw    = 4000;               % Time to finish washing   
dt    = 1;                  % Time Step, Delta T (s) 
  
% Spatial Variables --------------------------------------------------- 
xs = 0;                     % Start x-location (m) 
xf = 10*10^-3;              % Final x-location (m) 
ys = 0;                     % Start y-location (m) 
yf = 10*10^-6;              % Final y-location (m) 
  
discretisationx = 400;      % No of points per mm 
discretisationy = 40;       % No of points per mm 
dy = (yf-ys)/discretisationy;% Delta x (m) 
dx = (xf-xs)/discretisationx;% Delta y (m)     
Nx = (xf-xs)/dx+1;          % Number of Nodes 
Ny = (yf-ys)/dy+1;          % Number of Nodes 
N  = Nx*Ny; 
x  = [xs:dx:xf]';           % Store X values for each node of the 
solution 
y  = [ys:dy:yf]';           % Store Y values for each node of the 
solution 
  
C_matrix = sparse(Ny,Nx);   % The unknown matrix 
C_array  = reshape(C_matrix,N,1); % Turn the matrix into array - to form 
A*x = b 
  
x_chip_s = 4*10^-3; x_chip_s_index = floor(x_chip_s/dx)+1;  % start x-
location of the Biochip  
x_chip_f = 5*10^-3; x_chip_f_index = floor(x_chip_f/dx)+1;  % end   x-
location of the Biochip 
x_chip   = x_chip_s:dx:x_chip_f;                           
x_chip_index = x_chip_s_index:x_chip_f_index; 
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v = 3/2*v_mean*(1-(2*(y-(yf-ys)/2)/(yf-ys)).^2); 
  
%********************************************************************** 
%                   BUILD SYSTEM OF LINEAR EQUATIONS 
%********************************************************************** 
  
% Build LHS and RHS Coefficients -------------------------------------- 
L1 = -D/2/dx^2; 
L2 = -D/2/dy^2; 
L3 =  D/dx^2 + D/dy^2 + 1/dt; 
R1 = -L1;  
R2 = -L2; 
R3 = -D/dx^2 - D/dy^2 + 1/dt; 
  
% Build "A" Matrix ---------------------------------------------------- 
A = sparse(N,N);            % Define a sparse nxn Matrix "A" 
B = sparse(N,N);            % Define a sparse nxn Matrix "B" 
c = zeros(N,1);              
d = zeros(N,1); 
gamma = zeros(Nx,1);        % Define Gamma on the BIOCHIP 
  
for ct1 = 1:Ny              % Set Boundary Conditon for the "inlet" - 
surface 1 
    A(ct1,ct1) = 1; 
    d(ct1) = C0; 
end 
  
for ct1 = N-Ny+1:N          % Set Boundary Conditon for the "outlet" - 
surface 3 
    A(ct1,ct1)   = 1; 
    A(ct1,ct1-1) = -1; 
end 
  
for ct1 = Ny+1:N-Ny         % Loop through Inner Matrix & set values 
    y_index = mod(ct1,Ny); 
    x_index = floor(ct1/Ny); 
     
    if y_index == 1         % Set Boundary Conditon for the lower surface 
(surface 2) 
        A(ct1,ct1)  = 1; 
        A(ct1,ct1+1)=-1; 
    elseif y_index == 0     % Set Boundary Conditon for the upper surface 
(surface 4) 
        A(ct1,ct1)  = 1; 
        A(ct1,ct1-1)=-1; 
    else       
        v_inst  = v(y_index); 
        A(ct1,ct1-1) = L2; 
        A(ct1,ct1)   = L3 + v_inst/dx;  
        A(ct1,ct1+1) = L2; 
        A(ct1,ct1-Ny)= L1 - v_inst/dx;  
        A(ct1,ct1+Ny)= L1; 
         
        B(ct1,ct1-1) = R2; 
        B(ct1,ct1)   = R3;  
        B(ct1,ct1+1) = R2; 
        B(ct1,ct1-Ny)= R1;  
        B(ct1,ct1+Ny)= R1; 
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    end 
end 
  
%********************************************************************** 
%                            RUN SIMULATION  
%********************************************************************** 
t_index = 0; figure;  
t_array = []; 
for t = ts+dt:dt:tf     % Loop through time (dt increment) 
    t_array = [t_array; t]; 
    if mod(t_index,1000) == 0 
        fprintf('Simulation is running at t = %d\n',t_index); 
    end 
     
    if t > t_off            % Turn off the flow 
        v = zeros(Ny,1); 
         
        % Change the boundary condition for the "inlet" surface 
        for ct1 = 1:Ny               
            A(ct1,ct1)   = 1; 
            A(ct1,ct1+1) = -1; 
            d(ct1) = 0; 
        end 
    end 
     
    if t > tw 
        v = 3/2*v_mean*(1-(2*(y-(yf-ys)/2)/(yf-ys)).^2); 
       
        for ct1 = 1:Ny              % Set Boundary Conditon for the 
"inlet" - surface 1 
            A(ct1,ct1) = 1; 
            A(ct1,ct1+1) = 0; 
            d(ct1) = 0; 
        end 
    end 
     
    % Update value of gamma 
    t_index = t_index + 1; 
    C_mat = reshape(c,Ny,Nx); 
    for ct1 = 1:Nx 
        if (ct1 >= x_chip_s_index) && (ct1 <= x_chip_f_index) 
%             gamma(ct1) = (k_on*C_mat(1,ct1)*(gamma0-gamma(ct1)) - 
k_off*gamma(ct1))*dt + gamma(ct1); 
            gamma(ct1) = (gamma(ct1) + k_on*C_mat(1,ct1)*gamma0*dt)/( 1 + 
(k_on*C_mat(1,ct1)+k_off)*dt ); 
            if ct1 == x_chip_s_index 
                gamma_store(t_index) = mean(gamma(ct1:ct1+x_chip_f_index-
x_chip_s_index)); 
            end 
        end 
    end 
     
    for ct1 = Ny+1:N-Ny     % Loop through Inner Matrix & set values 
        y_index = mod(ct1,Ny); 
        x_index = floor(ct1/Ny); 
         
        % Set Boundary Conditon for the surface containing the BIOCHIP 
        if y_index == 1 && (x_index >= x_chip_s_index) && (x_index <= 
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x_chip_f_index)    
            A(ct1,ct1)   = -D/2/dy - k_on*(gamma0 - gamma(x_index)); 
            A(ct1,ct1+1) =  D/2/dy; 
            B(ct1,ct1)   =  D/2/dy; 
            B(ct1,ct1+1) = -D/2/dy; 
            d(ct1)       = -k_off*gamma(x_index); 
        end 
    end 
     
    C_mat = reshape(c,Ny,Nx); 
    CNEW = A\(B*c+d);         % Solve for Cj+1 
    c = CNEW;                 % Store Cj+1 as Cj for next time step 
     
    % Plot Solution 
    C_mat = flipud(C_mat); 
    imagesc(x,y,C_mat); 
    colorbar; 
    title(strrep(strcat('Simulation is running at t 
=:',num2str(t_index*dt,'%10.1f'),':s'),':',' ')); 
    if make_video == 1 && mod(t_index*dt,1) == 0 
        frame(t_index) = getframe;    % Generate a movie clip 
    end 
end 
  
figure; 
plot(t_array,gamma_store/gamma0);     % Plot the Kinetic Curves   
xlabel('Time (s)');                   % Set x label of the figure 
ylabel('Gamma/Gamma0');               % Set y label of the figure   
title('Kinetics Curve');              % Set title of the figure 
  
if make_video == 1 
    movie(frame);                     % Play video clip 
    movie2avi(frame,'demo');          % Save the video clip 
%  
%     writerObj = VideoWriter('Demo.mp4','MPEG-4'); 
%     open(writerObj); 
%     f = im2frame(frame); 
%     writeVideo(writerObj,f); 
end 
  
 	
